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Existing methods of treating glioma are not effective for eradicating the disease. 
Therefore, new and innovative methods of treatment alone or in combination with 
existing therapies are necessary. Delivery of therapeutic agents through delivery carriers 
such as liposomes diminishes the harmful effects of the agent in healthy tissues and 
allows increased accumulation in the tumor. In addition, targeted chemotherapy using 
liposomes provides the opportunity for further increase in drug accumulation in tumor. 
However, the current targeting strategies suffer accelerated plasma clearance and are not 
advantageous in improving efficacy. The search for new tumor targets, novel ligands, 
new strategies for targeting, and particle stabilization will advance our ability to improve 
delivery at the tumor level while decreasing toxicity to normal tissues.  
The global objective of this thesis was to improve the status of current liposomal 
therapy to achieve higher efficacy in tumors. Here, we show a novel mechanism to 
increase targeting to tumor while uncompromising on the long circulation of stealth 
liposomes. Long circulation is essential for passive accumulation of the nanocarriers due 
to EPR effect, in order to see benefits of targeting. Using phage display technique, a 
variety of tumor specific peptides were identified for use as targeting moieties. One 
potential advantage of the approach proposed here is the rapid identification of patient 
tumor specific peptide that evades the RES. This could lead to the development of a 
nanocarrier system with high avidity and selectivity for tumors. Therefore, tumor 
accumulation of the targeted formulations will be higher than that of 
non‐targeted liposomes due to increased drug retention at the tumor site and 
uncompromised blood residence time. 
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In addition, it has been shown that the distribution of nanocarriers, spatially 
within the tumor, is limited that might further hinder the distribution of the encapsulated 
drug, thereby limiting efficacy. It is necessary to release the drug from within the 
nanocarrier to promote increased efficacy. Here, we were able to address the problem of 
drug diffusion within the tumor interstitium using a combination therapy employing a 
remotely triggered thermosensitive liposomal chemotherapeutic. We fabricated a 
thermosensitive liposomal nanocarrier that maintained its stability at physiological 
temperature to minimize toxicity to healthy cells. We, then, showed a remote triggering 
mechanism mediated by gold nanorods heated via NIR can help in achieving precise 
control over the desired site for drug release. These strategies enabled increased drug 
availability at the tumor site and contributed to tumor retardation. Additionally, we show 
that the synergistic therapy employing gold nanorods and thermosensitive liposomes may 
have great potential to be translated to the clinic. 
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CHAPTER 1  
INTRODUCTION  
1.1 Statement of the problem 
Malignant tumors of the central nervous system like meningiomas, astrocytomas, 
glioblastoma multiforme (GBM) are the leading cause of death from solid tumors in 
children and third leading cause of death in adolescents and adults. Brain tumor incidence 
is about 14.8 per 100,000 person-years. About 12,760 patients of benign and malignant 
tumors die each year [1]. An inability to control the local growth of these solid tumors 
leads to significant morbidity and mortality. About 60% of the therapies fail eventually 
with local recurrence in the United States alone [2]. Clinical use of most conventional 
chemotherapeutics is often limited due to inadequate delivery of therapeutic drug 
concentrations to the tumor target tissue or severe and harmful toxic effects on normal 
organs.  
It is important to develop novel technologies that can be used for targeted drug 
delivery to tumors thereby improving the therapeutic index of cytotoxic, anti-tumor 
drugs. After their discovery in 1965, liposomes became a promising tool for drug 
delivery. Much research has been conducted on stabilizing liposomes and increasing their 
plasma half life. Polyethylene glycol coated long circulating liposomes [3-4] accumulate 
significantly in tumors due to a leaky vasculature and the lack of an effective lymphatic 
drainage system [5]. This effect is often referred to as the enhanced permeability and 
retention effect (EPR) [6-7]. The pore sizes in solid tumor vasculature vary from 100 to 
780 nm, and are generally much larger than in normal vasculature where the gaps 
between endothelial cells are usually less than 6 nm [5]. This results in selective passive 
2 
 
targeting of liposomes in tumors through passive diffusion while sparing healthy tissue. It 
was demonstrated in patients with brain glioblastomas and metastatic brain tumors that 
long circulating liposomal nanocarriers overcome the blood brain barrier (BBB) in the 
tumor lesions resulting in 13-19 times higher accumulation in the glioblastoma as 
compared to the normal brain [8].  
Liposomal anthracyclines were the first nanotherapeutics to be approved for 
clinical use as the first line for treatment of AIDS- el ted K po i‘     com   nd  el p ed 
ovarian cancer and are under numerous clinical trials (128 active studies) for treatment of 
other types of cancer. However, in the past 20 years even after significant development 
and improvement in nanoparticle drug delivery only 2 nanoparticle loaded drugs have 
been approved till date for clinical use (Doxil and Abraxane) [5, 9]. When tested in vitro, 
nanoparticle loaded drugs show excellent cytotoxicity and specificity. The question that 
emerged then, is why these drugs, ostensibly carried by a particle that should, by the EPR 
effect localize itself with high specificity in solid tumors, not show an immediate and 
significant improvement in efficacy. Failure in efficacy could be attributed to sequential 
barriers following the systemic administration of a nanoparticle drug that can be outlined 
as follows: 1) Organ distribution and clearance. 2) Inability to diffuse uniformly in the 
tumor due to nanocarrier size. 3) Resistance to release of drug from the nanoparticles 
localized into tumors, effectively neutralizing the drug. 
1.2 Hypothesis 
We have hypotheses to increase the efficacy and specificity. Currently, liposomal 
nanocarriers can potentially be tagged with high affinity targeting ligands that bind to 
tumor cells. However, the principal shortcoming of existing targeting ligands, such as 
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folate and antibodies, is that they significantly compromise circulation time when 
presented on nanocarriers [10-13]. Long circulation is critical for increasing passive 
accumulation of liposomal nanocarriers in the tumors to reap the benefits of targeted 
nanocarriers. We hypothesize that improving the specificity by identification of small 
peptide ligands that afford selective tumor targeting without compromising circulation 
time would be greatly advantageous. To overcome the non-uniform distribution of the 
encapsulated drug and resistance to release of drug from nanoparticles, we believe the use 
of stably circulating thermosensitive liposomes that can be triggered remotely using 
nano-antennas to release its contents. Therefore, due to its small size, the drug will have a 
greater opportunity to diffuse further into the tumor lesion away from the blood 
vasculature. 
1.3 Objectives 
The goal of this thesis is to achieve enhanced tumor efficacy with liposomal 
nanocarriers in comparison to existing drug encapsulating nanocarriers. To achieve this 
goal, we employed active and passive targeting, and destabilization of nanocarriers at 
target site while preventing normal tissue uptake.  
The objectives to achieve these goals were: 
1)  Identify new targeting moieties and design a targeted nanocarrier that has 
comparable blood plasma half life to non-targeted nanocarriers, and 
characterize nanocarrier in vivo performance in a glioma animal model. 
2) Fabricate a stable, long circulating, thermo-sensitive nanocarrier that can be 
triggered remotely using gold nanorods and near-infrared radiation to release 
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its contents and demonstrate the success of such a system in increasing 
efficacy in vivo. 
a. Fabricate a liposome and evaluate the stability of such a liposomes in 
retaining the drug at physiological temperature 
b. Determine the effectiveness of gold nanorods in triggering the drug 
release and evaluate the efficacy of this system, thereby, in increasing 
tumor cytotoxicity. 
The search for tumor targets, novel ligands, new strategies for targeting, and 
particle stabilization will advance our ability to improve delivery at the tumor level while 
decreasing toxicity to normal tissues. Here, we propose a novel mechanism to increase 
tumor targeting while uncompromising on the long circulation of stealth liposomes. Long 
circulation is essential for passive accumulation of the nanocarriers due to EPR effect, in 
order to see benefits of targeting. Identifying several non-immunogenic motifs specific to 
the tumor type can greatly enhance nanocarrier accumulation at the tumor site. To 
address the problem of drug diffusion within the tumor interstitium, it is necessary to 
release the drug from within the nanocarrier. It is important to fabricate such nanocarriers 
without compromising their stability in circulation to minimize toxicity to healthy cells. 
Using a remote triggering mechanism can help in achieving precise control over the 
desired site for drug release. Eventually, these strategies should enable increased drug 
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CHAPTER 2  
BACKGROUND AND RELEVANT LITERATURE REVIEW 
2.1 Brain Tumor Prevalence 
Brain tumors continue to be a challenge to treat because they are inherently 
diffuse, highly invasive, and non-localized. Instead of completely and permanently 
eliminating a malignant brain tumor, current treatments have been shown to merely 
prolong patient survival [1-3]. Radiation therapy and surgical resection are often 
incapable of completely removing deeply penetrated and diffuse brain tumors. The 
penetration of radiation therapy is limited by the energy of the incident photons, and 
increasing the energy to allow for deeper penetration invariably results in irradiation of 
healthy tissue. Recurrence of tumors is common following surgical resection since it is 
often difficult to completely eradicate both the tumor and the invading tumor front 
without harming any adjacent healthy brain tissue. As a result, median survival duration 
is merely 12 months following the combination of surgical resection and focal 
radiotherapy [1].  
Currently, chemotherapy is not the primary treatment of choice for malignant 
brain tumors due to the exposure of non-target organs to chemotherapeutic resulting from 
systemic administration as well as due to the presence of the highly impermeable BBB, 
which limits transport to lipophilic or low molecular weight, uncharged compounds. In an 
effort to prevent exposure of healthy organs to the toxic side effects of 
chemotherapeutics, implantable biodegradable drug depots within a brain tumor are 
currently being used in clinical practice to localize a chemotherapeutic and allow for 
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prolonged and controlled drug delivery [4]. Gliadel

 is an intracranial implantable 
polyanhydride polymer loaded with BCNU. BCNU and carmustine have been widely 
used as systemic agents due to their lipophilicity but effectiveness is restricted by the 
dose-limited side effects [5-6]. On the other hand, Gliadel

 has produced better results 
for patients with grade IV glioma extending the median survival by 13.4 weeks compared 
to placebo [7-8]. However, this method relies on drug diffusion from a central core. As a 
result, drug usually cannot reach the tumor periphery where the most aggressive cells 
persist. Chemothe  py vi   y temic int  v  cul    dmini t  tion utilize  the tumo ‘  own 
blood supply for transport allowing for drug delivery throughout the tumor and is 
minimally non-invasive. Therefore, new strategies to improve systemic delivery of 
chemotherapeutics will be an additional beneficial tool for treatment of gliomas. 
2.2 Nanocarriers in Drug Delivery to Solid Tumors 
Nanoparticles are systems that are constructed to be in nanometer (nm) size and 
range from a few nm to several hundred nm depending on their intended use. The particle 
size is purposely constructed for the nanoparticle to pass through the fenestrations of the 
leaky cancer endothelium. In addition, lack of tumor lymphatics enables the preferential 
accumulation of nanoparticulate drug at tumor site. This phenomenon is called the 
enhanced permeation and retention effect (EPR). The result of the EPR effect is an 
altered biodistribution for the nanocarrier-associated drug, with a notably higher 
concentration of the drug accumulating at the site of disease, and a lower concentration 
accumulating in healthy tissues. 
Particle size also determines if the circulating nanoparticle is opsonized and 
rapidly cleared by the reticulo-endothelial system (RES), which is predominantly 
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distributed in liver, lungs, spleen, and bone marrow. The surface of the nanoparticle must 
be modified to escape the RES. One such approach has been the alteration of the 
polymeric composition of the particle. An example is the addition of polyethylene glycol 
(PEG) over the surface of the nanoparticle. Pegylating enables shielding of the 
n nop  ticle  f om m c oph ge   nd imp  t  it to be ―STEALTH‖ p  ticle. Hyd ophilic 
polymers like PEG coating the nanoparticle surface repel plasma proteins and escape 
op oniz tion  nd cle   nce. Thi  h   been de c ibed      ―cloud‖ effect [9-10]. 
A variety of materials are used to construct nanoparticles including ceramic, 
polymers, lipids, and metals. Nanoparticle structures may contain predominantly organic 
molecules or have inorganic elements usually incorporating a metal as a core. 
Nanoparticles have a variety of sizes and shapes, which include spheres, branched 
structures, shells, tubes, fullerenes, emulsions, and liposomes. Therapeutic drugs can be 
incorporated into the nanoparticle by entrapment, surface attachment, or encapsulation. 
The characteristics of each particle differ in terms of drug loading capacity, particle and 
drug stability, drug release rates, and targeted delivery ability. Each class of nanoparticles 
encompasses different characteristics; however, the following essential conditions are 
universal [11]: biodegradability, biocompatibility, non-immunogenicity, physical stability 





Table 2.1. Nanocarrier based drugs on the market 
2.2.1 Dendrimers 
A dendrimer is characterized by its highly branched 3D structure that provides a 
high degree of surface functionality and versatility. Due to their multivalent and 
monodisperse character, dendrimers have stimulated wide interest in the field of 
chemistry and biology, especially in applications like drug delivery, gene therapy and 









































Relapsed or refractory, low-








Relapsed or refractory, low-
grade, follicular, or transformed 
non-Hodgkin's lymphoma 
Daunorubicin DaunoXome Liposomes Kaposi's sarcoma 
Doxorubicin Myocet Liposomes 
Combinational therapy of 
recurrent breast cancer, ovarian 
cancer, Kaposi's sarcoma 
Doxorubicin Doxil/Caelyx Peg-liposomes 
Refractory Kaposi's sarcoma, 
recurrent breast cancer, ovarian 
cancer 
Vincristine Onco TCS Liposomes 
Relapsed aggressive non-





Metastatic breast cancer 
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chemotherapy. Dendrimers‘ well defined three-dimensional structure, the availability of 
many functional surface groups, their low polydispersity and their ability to mimic make 
them attractive drug delivery vehicles. Drug molecules can be loaded both in the interior 
of the dendrimers as well as attached to the surface groups. Dendrimers can function as 
drug carriers either by encapsulating drugs within the dendritic structure, or by inter-
acting with drugs at their terminal functional groups via electrostatic or covalent bonds 
(prodrug). 
The versatile nature of dendrimers allows them to deliver either hydrophobic or 
hydrophilic agents to a target site.  Drugs may be covalently attached to functional groups 
on the dendrimer or simply associated with the internal core of the sphere by electrostatic 
interactions, hydrogen bonding, or hydrophobic interactions [12]. The anticancer drug 
doxorubicin was covalently bound to this carrier via an acid-labile hydrazone linkage. 
The cytotoxicity of doxorubicin was significantly reduced (80–98%), and the drug was 
successfully taken up by several cancer cell lines. The encapsulation behavior of these 
compounds for the anticancer drugs adriamycin and methotrexate was studied. The 
highest encapsulation efficiency, with on average 6.5 adriamycin molecules and 26 
methotrexate molecules per dendrimer, was found for the generation number = 4 (G, the 
number of focal points when going from the core towards the dendrimer surface) 
Polyamidoamines (PAMAM) polymer terminated with PEG2000 chains. The anticancer 
drug 5-fluorouracil encapsulated into G = 4 PAMAM dendrimers with PEG5000 surface 
chains revealed reasonable drug loading, and reduced release rate and hemolytic toxicity 
compared to the non-PEGylated dendrimer [13]. In contrast, up to 24 drug molecules 
were encapsulated into the hyper branched polyol. The drug was successfully transported 
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into lung epithelial carcinoma cells by the dendrimers. Dendrimers are promising in 
various pharmaceutical applications in the coming years as they possess unique 
properties, such as high degree of branching, multivalency, globular architecture and 
well-defined molecular weight, thereby offering new scaffolds for drug delivery. 
2.2.2 Polymeric Micelles 
Polymeric micelles are nano-sized particles, made up of polymer chains, and are 
usually spontaneously formed by self-assembly in a liquid as a result of hydrophobic or 
ion pair interactions between polymer segments. Micelles are useful for delivery of water 
insoluble drugs carried in the hydrophobic central core [14-15]. The core of the micelles, 
which is either the hydrophobic part or the ionic part of the nanoparticles, can contain 
molecules such as therapeutic drugs, while the shell provides interactions with the solvent 
and make the nanoparticles stable in the liquid.  
Polymeric micelles are composed of block or graft copolymers. Block copolymers 
are generally linear polymers that are composed of a sequence of at least two polymer 
segments that differ in physico-chemical properties, e.g. charge and/or polarity. In graft 
copolymers, side chain segments are grafted to a main polymer chain. Fully hydrophilic 
block or graft copolymers in which one of the segments carry a charge may form stable 
complexes in water together with oppositely charged (macro) molecules, resulting in 
polyion complex micelles or polyelectrolyte micelles. On the other hand, amphiphilic 
block copolymers are capable to self-assemble, when placed in a solvent that is selective 
for one of the polymeric segments, to form micelles. Many important characteristics of a 
micelle (critical micelle concentration CMC, association number Z, core radius Rc, shell 
thickness L, hydrodynamic radius Rh) are determined by the copolymer characteristics, 
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e.g. its molecular weight and composition. Micellization of amphiphilic block 
copolymers in water is an entropy-driven process as a consequence of hydrophobic 
interactions and changes of the water structure in vicinity of the polymer chains. 
Intravenous injection of a polymeric micellar drug formulation prevents the 
breakdown of the micelles due to biological barriers encountered, for example, by oral 
administration. The biggest challenge, although, is the prevention of a-specific 
interactions of the drug-containing micelles with blood components (e.g. with proteins, 
which can eventually cause premature excretion by the body) and non-target cells or 
tissues. Another problem is the stable retention of the drug by the micelles during 
circulation. Micelles are also prone to dilution. Micelles maintain a dynamic equilibrium 
with free unimers that can be absorbed by blood proteins, which will cause an adverse 
shift of this equilibrium. If diluted below the CMC, however, individual copolymers are 
rapidly removed by the kidneys [16]. Also, the drug molecules may gradually diffuse out 
of the micelles and bind to proteins or cells before they reach the target site. In the case of 
polyion complex micelles, the relatively high physiological salt concentration or 
exchange with charged biomolecules may cause premature dissociation of the polymer-
drug complexes. There are several efforts to overcome the above mentioned problems are 
ongoing. 
2.2.3 Polymeric Nanoparticles 
These nanoparticles are composed of a matrix system in which drug is distributed 
by entrapment, attachment, or encapsulation or vesicular systems with a central cavity or 
core to which a drug is confined. The surface of the nanoparticle may be modified by the 
14 
 
addition of polymers and biological materials like ligands or antibodies may also be 
attached for targeting purposes.  
Polymers are the most commonly explored materials for constructing 
nanoparticle-based drug carriers. One of the earliest reports of their use for cancer 
therapy dates back to 1979 [17] when adsorption of anticancer drugs to 
polyalkylcyanoacrylate nanoparticles was described. Couvreur et al. revealed the release 
mechanism of the drugs from the polymer in calf serum, followed by tissue distribution 
and efficacy studies in a tumor model [18]. Polymeric nanoparticles can be made from 
synthetic polymers, including poly(lactic acid) (PLA) and poly(lactic co-glycolic acid), or 
from natural polymers such as chitosan [19] and collagen [20] and may be used to 
encapsulate drugs without chemical modification. The drugs can be released in a 
controlled manner through surface or bulk erosion, diffusion through the polymer matrix, 
swelling followed by diffusion, or in response to the local environment. Several 
multifunctional polymeric nanoparticles are now in various stages of pre-clinical and 
clinical development [21-23]. Concerns arising from the use of polymer-based 
nanocarriers include the inherent structural heterogeneity of polymers, reflected, for 
example, in a high polydispersity index (the ratio of the weight-and-number-average 
molecular weight (Mw/Mn)). There are, however, a few examples of polymeric 
nanoparticles that show near-homogenous size distribution [24]. 
At least 12 polymer–drug conjugates have entered Phase I and II clinical trials 
and are especially useful for targeting blood vessels in tumors. Examples include anti-
endothelial immunoconjugates, fusion proteins [25-27], and caplostatin, the first 
polymer-angiogenesis inhibitor conjugates [28]. Polymers that are chemically conjugated 
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with drugs are often considered new chemical entities (NCEs) owing to a distinct 
pharmacokinetic profile from that of the parent drug. Despite the variety of novel drug 
targets and sophisticated chemistries available, only four drugs (doxorubicin, 
camptothecin, paclitaxel, and platinate) and four polymers (N-(2-hydroxylpropyl) 
methacrylamide (HPMA) copolymer, poly-L-glutamic acid, PEG, and dextran) have been 
repeatedly used to develop polymer–drug conjugates [29-30]. 
2.2.4 Carbon Nanotubes 
Carbon nanotubes are a family of fullerenes composed of carbon in the form of a 
hollow ellipsoid tube. Nanotubes self assemble as either single- or multi-walled with a 
hollow cage like architecture. One popular form of nanotubes is the soluble derivatives of 
fullerene such as C60 which has promise as a pharmaceutical. The C60 variant resembles 
a black and white soccer ball. Atoms may be trapped inside fullerenes and tubes and 
antibodies or ligands bound to the surface for targeting [15]. Tolerability is largely 
unknown. 
Carbon nanotubes (CNT) range from 1 to 10s of nanometers in diameter, and their 
length can range from several to hundreds of microns. Drugs can be covalently attached 
to functional groups on the external surface of the nanotubes [31]. Soluble derivatives of 
fullerenes have good biocompatibility and low toxicity and are under investigation as 
antiviral agents [32], antibacterial agents [33], anticancer therapies [34], antioxidants and 
anti-apoptosis agents for potentially treating amyotrophic lateral sclerosis and 
P  kin on‘  di e  e [35].  
The ability of functionalized CNT (f-CNT) to penetrate into the cells offers the 
potential of using f-CNT as vehicles for the delivery of small drug molecules [36-37]The 
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development of delivery systems able to carry one or more therapeutic agents with 
recognition capacity, optical signals for imaging and/or specific targeting is of 
fundamental advantage, for example in the treatment of cancer and different types of 
infectious diseases [38]. Water-soluble CNT functionalized with substituted carborane 
cages was developed as a delivery system for an efficient boron neutron capture therapy 
[39] aimed at the treatment of cancer cells. These studies showed that some specific 
tissues contained carborane following intravenous administration of the CNT conjugate 
and carborane was concentrated mainly at the tumour site. Another class of carbon 
nanomaterial similar to CNT, Single-walled carbon nanohorns (nanostructured spherical 
aggregates of graphitic tubes), has also been used for drug delivery [40]. Murakami et al. 
loaded these tubes with dexamethasone and found that dexamethasone could be adsorbed 
in large amounts onto oxidized nanohorns and maintains its biological integrity after 
being liberated. This was confirmed by activation of glucocorticoid response in mouse 
bone marrow cells and induction of alkaline phosphatase in mouse osteoblasts. In view of 
these results, f-CNT represents a new, emerging class of delivery systems for the 
transport and translocation of drug molecules into different types of mammalian cells. 
Although these CNT conjugates displayed no cytotoxicity in vitro, for further 
development, it will be important to assess their metabolism, biodistribution and 
clearance from the body. 
2.2.5 Liposomes are Ideal Candidates for Chemotherapy 
Liposomes constitute a class of nanoparticulate drug carriers generally 
characterized by the presence of one or more amphiphile bilayers enclosing an interior 
aqueous space. Liposomes have been used to increase the therapeutic index of a wide 
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range of antineoplastic agents. This has primarily been accomplished by improving the 
pharmacokinetic profile or allowing for site-specific drug delivery to solid tumors. 
Liposomes are self-assembled colloidal particles resembling tiny cells that occur 
naturally and can be prepared artificially [41]. Phospholipids can self-organize and form 
ordered structures in solvents due to hydrophilic and lipophilic interactions. The 
orientation of these self-assembled lipid structures  is such that the polar portion of the 
molecule is in contact with the polar media and shields the nonpolar part, and vice versa. 
When they are at high concentrations, liquid-crystalline phases are formed with the most 
common being lamellar and lesser common being hexagonal and cubic phases. Upon 
suspension in water, they disperse into colloidal suspensions such as liposomes, and 
hexasomes. The shape of the phospholipid is of great importance for the symmetry of 
lipid self-assembly and liquid- crystalline-phase formation (see fig 2.1). Based on the 
cross-sectional area of the hydrophilic part (Shydro) relative to the one of the lipophilic part 
(Slipo), micelles (high surface curvature) are formed when Shydro>Slipo while inverse 
micelles (negative surface curvature) are formed Shydro<Slipo. In the case that the two areas 
are similar, a bilayered configuration (liposome) is the most stable form. The high surface 
ten ion fo ce    fl t l mell    heet to bend  e ulting in   dec e  e of the ―edge‖ ene gy    
well as an increase of the energy for the induced curvature. In order to further minimize 
the ene gy, the bending i  complete fo ming    phe e which  e ult  in ze o ―edge‖ 
energy. At low temperatures, the bilayer is in a gel state in which the lipid chains have a 
close packing. At high temperatures or in the presence of unsaturated acyl chains, the 
bilayer is in a liquid-crystalline state. The temperature (Tm) where the gel-to-liquid 
crystalline transition occurs depends on the acyl chains. Unsaturated lipids have lower Tm 
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since double bonds introduce kinks prohibiting close packing. Therefore, liposomes are 
lipid vesicular sacs with a thin lipid bilayer membrane separating the internal aqueous 
compartment from the external aqueous media. Since Shydro and Slipo depend on 
temperature or ionization (pH), phase transitions between various phases can be induced. 
Steric stabilization tackled the problems associated with colloidal and biological 
instability of liposomes. Coating of liposomes with the inert hydrophilic polymers 
methoxypolyethylene glycol (mPEG) allowed prolonged liposome circulation in blood 
and stability by reducing interactions with blood proteins. For example, pegylated 
liposomal doxorubicin (Doxil®, Alza/Johnson & Johnson, Mountain View, CA), a stable 
and long-circulating liposome formulation of doxorubicin, has become a widely used 
 
Figure 2.1. Three typical lipid shapes: cylindrical leading to lamellar arrangement, cone leading to 
micellar structures (positive membrane curvature) and inverted cone leading to inverted phases 
(negative membrane curvature). The association between cone and inverted cone shaped molecules 









anticancer agent. Doxil has been approved for the treatment of Kaposi's sarcoma, ovarian 
cancer, metastatic breast cancer, and has shown activity in other tumor types as well [15].  
Drugs retained in long circulating liposomes benefit from site-specific 
accumulation in the pathological areas such as tumors due to a discontinuous or 
otherwise more permeable microvasculature and nonfunctioning lymphatics [15, 42]. 
Liposomes of approximately 100 nm in size readily distribute into solid tumors with an 
efficiency that depends partially on the anatomical location. Long circulating liposomal 
accumulation maximizes around 48-65 h at the tumor [15]. The liver and spleen, two 
major organs of the reticulo-endothelial system (RES) are major sites of liposome 
clearance due to the presence of macrophages that efficiently phagocytose liposomes.  
Achieving site specific drug targeting is the key to increased therapeutic efficacy 
and reduced side-effects. Strategies that enable intracellular delivery of drugs that exert 
their effects in cytoplasmic compartments are hallmarks in the development of successful 
drug delivery vehicles. Many physical and chemical properties of various phospholipids 
can be employed to gain site-specific drug delivery from liposomes.  
Liposomes can also act as rapid release formulations of the active drug, providing 
rapid exposure of the targeted tissue to the drug thereby increasing toxicity. When 
optimally designed with appropriate lipids, liposomes can remain impermeable at body 
temperature and allow rapid release of their aqueous content to occur following their 
accumulation in the tumor. Various studies have explored the use of pH, temperature, and 
light to trigger drug release at the targeted site. The lipids comprising the bilayer can be 
sensitive to temperature or pH changes. These studies have suggested that pH, 
temperature, and light can be used to cause phase transition of the phospholipids 
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(lamellar-to-hexagonal or gel-to-liquid crystalline transition) that in turn, enables the 
release of drugs from liposomal bilayers. The combination of prolonged circulation, drug 
encapsulation, and their susceptibility to triggered release of the drug at tumor 
site makes liposomes ideal candidates for drug delivery to tumors. 
2.2.5.1 Use of Targeting Ligands on Liposomes can Increase Tumor 
Specificity and Drug Availability  
Receptor-mediated molecular targeting is one approach to promote specific 
localization. Targeting of chemotherapeutic drugs to receptors over-expressed by gliomas 
cells decrease the side effects associate with traditional chemotherapy and enable the 
administration of lower drug dosages to achieve the same therapeutic effect. 
Incorporating targeting ligands over-expressed by tumor cells, not only facilitates 
targeting to the tumor cell but also drug retention at the target site by preventing 
retrograde movement of liposomes into the bloodstream. Targeting ligands can be chosen 
to bind receptors that undergo receptor-mediated endocytosis to facilitate drug uptake by 
cells [43-44]. High affinity tumor targeting ligands can be readily coupled covalently to 
the distal ends of nanocarrier PEG chains. In fact, one or more ligands may be coupled to 
the same nanocarrier, potentially conferring added selectivity. A number of the ligand-
presenting liposomal systems targeting differentially expressed receptors on tumor cells 
(relative to normal tissue) have been reported and shown to promote increased drug 
uptake [43, 45].  
The folate receptor (FR) is one of the numerous transmembrane receptors known 
to be over-expressed by gliomas [46]. Several in vitro liposomal studies utilizing FR as a 
target have demonstrated significantly higher cytotoxicities from FR-targeted 
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formulations compared to non-targeted formulations resulting from increased uptake of 
drug by target cells [47-51]. Survival studies, however, have demonstrated mixed results. 
No therapeutic advantage was observed between non-targeted and FR-targeted 
formulations administered to mice bearing subcutaneous carcinomas. Highly specific 
antibodies that bind target antigens with high affinities have also been used to target 
tumor. However, attachment of antibodies to liposomes has been shown to stimulate 
uptake by the RES. More recent studies have focused on preventing premature clearance 
by Fc-receptor mediated uptake by the RES by the use of antibody fragments as an 
alternative [52-53].  Liposomes targeting with antibodies or antibody fragments has been 
examined previously for HER2 [44, 54-55], disialoganglioside (GD2) [56], CD19 [57-
58], prostate-specific membrane antigen (PSMA) [59-60], transferrin receptor [61-63], 
and epidermal growth factor receptor (EGFR) [64-65]. The incorporation of small 
peptides into liposomes has been investigated to target aminopeptidase N [66-67], matrix 
metalloproteinase (MMP) [68], and integrin [69-70] on or around tumor cells. 
Numerous studies have also shown that targeting ligand attachment to PEG chains 
anchored in liposomal membranes results in accelerated plasma clearance [63, 66, 71-75]. 
Decreased plasma concentrations of targeted formulations have been reported regardless 
of the targeting moiety to be an antibody [63] or a receptor ligand [76]. It is believed that 
targeting moieties anchored with similar length or longer PEG on the liposome surface 
retains the ability to interact with plasma proteins responsible for RES clearance. 
Prolonged circulation is critical to passive accumulation of the targeted nanocarrier. 
Accelerated plasma clearance could be responsible for the inability of targeted 
nanocarriers to increase survival in vivo. Therefore, the major design goal of this project 
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was to identify small peptide-based targeting ligands for nanocarriers that are selective to 
gliomas and do not compromise circulation time. 
2.2.5.2 Triggered Release of Drugs from Liposomes can Increase Drug 
Distribution and Cellular Toxicity 
The use of site-specific targeting has not yet been sufficient to obtain a 
significantly increased efficacy in the treatment of cancer when compared to passively 
accumulating liposomes. This can very well be due to destructive uptake of the liposomes 
by the target cells, possibly due to lysosomal degradation [77]. Liposomes, therefore, 
have to be designed either to escape the endosomes after cell internalization or to release 
the drugs outside the cell, which may be in conflict with site-specific targeting. Several 
strategies have been proposed to accomplish site-specific triggered drug release in tumor 
tissue. Liposomes triggered by acid [78-83], enzymes [84-85], small changes in 
temperature [86-90] and light [91-92] have all been shown to be useful concepts for 
releasing encapsulated drugs. However, liposomes designed with these specific trigger 
mechanisms have not yet reached the pharmaceutical market.  
 
Acid triggered release 
The original strategy of using the acidic microenvironment characterizing tumors 
for triggered release [78] has not been very successful as the highest acidity in tumors is 
distant from the tumor vasculature. As a result, liposomes often fail to reach this tissue 
[93-94]. In addition, the pH of the tumor interstitium rarely declines below pH 6.5, 
making it technically difficult to design liposomes that are stable in the blood but become 
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disrupted in the tumor tissue [82]. A more viable strategy has been to exploit the very 
acidic environment in endosomes and lysosomes where the pH is below 5.0 [95-96]. 
Triggered release of pH-sensitive liposomes is the most biocompatible method for 
releasing drugs directly in the cytoplasm of cells. Research in acid triggered drug delivery 
has resulted in the use of fusogenic liposomes [97-98]. After cell internalization, the pH 
change triggers a liposome morphology change where a lipid bilayer, Lα, to hexagonal, 
HII, phase transition occurs [77]. The main lipid diacylphosphatidylethanolamine (DOPE) 
when mixed with that with micellar forming lipids such as PEG-coated lipids can form 
stable liposomes. After acid catalyzed cleavage or removal of the PEG-lipids from the 
liposomes, they become fusogenic and are expected to fuse with the endosome membrane 
leading to drug release into the cytoplasm of the cell. 
Several groups have presented the idea of using mildly acidic amphiphiles that 
become protonated when entering an acidic environment. This leads to a decrease in 
hydration of the headgroup followed by destabilization of the liposome as non-bilayer 
fusogenic structures are formed [99]. Diacylsuccinylglycerols have been shown to 
stabilize DOPE, are pH-sensitive and effective drug carriers in vitro [81]. Cholesterol 
hemisuccinate (CHEMS) has been shown as an attractive constituent in pH-triggered 
liposomes. Oleic acid (OA) lipids are used in OA: PE liposomes and they are 
considerably more sensitive to pH than the former two, releasing their content below pH 
6.5 [83, 101]. The use of acid sensitive liposomes has been one of the most extensively 
studied active triggering strategies. Since Yatvin et al. [78] reported this strategy in 1980 
there have been many new ideas and reports of new chemical entities in the literature, yet 
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the liposome drug delivery field has still not been able to provide convincing clinical 
results. 
 
Light triggered release 
The employment of lipids that either isomerize, fragment or polymerize upon 
photoexcitation [77, 102] give rise to the principle of light triggered release liposomes. 
Bondurant et al. [91, 103] reported a PEG-liposome formulation containing 1,2-bis[10-
(2′,4′-hexadienoyloxy)-decanoyl]-sn-glycero-3-phosphocholine (bis-SorbPC), a 
photosensitive lipid that forms a cross-linked lipid network upon exposure to UV-light. 
The polymerization causes leakage during the polymerization process due to the 
formation of defects in the bilayer. However, the use of UV-light is not very suitable for 
biological applications due to the potential damage to healthy tissue and it is therefore 
desirable to use light with a longer wavelength. The incorporation of a cyanine dye into 
the PEG-liposomes made them sensitive to visible light [102]. Thompson and co-workers 
[92, 104-106] have reported the use of plasmalogen photooxidation for triggered release. 
Many sensitizing agents like zinc phthalocyanine, tin octabutoxyphthalocyanine and 
bacteriochlorophyll a have been investigated. Bacteriochlorophyll a that has an 
absorption maximum at 820 nm was found to produce the fastest release [104]. An 
extension of the concept was made by encapsulating Ca
2+
 in diplasmalogen liposomes 
that upon photooxidative release activated phospholipase A2 (PLA2), which is a calcium 
dependent enzyme [105]. PLA2 then contributes to the drug release by hydrolyzing acyl-
phospholipids in the liposome. Thompson and co-workers [106] have also showed that 
calcium-dependent transglutaminase can be activated by this principle. Another example 
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of photofragmentation was reported by Zhang and Smith [107]. They used a lipid called 
NVOC-DOPE, which could be fragmented upon excitation at 345 nm to produce DOPE 
resulting in destabilization of the liposomes. Liposomes containing photoisomerizable 
lipids can also be used for light triggered drug release. The well-known trans–cis 
isomerization of azobenzenes was exploited by Bisby et al. [108-109]. An azobenzene-
glycero-phosphocholine isomerization was shown to result in fast release from liposomes 
in the gel phase upon UV-light activation. It is however important to underline that the 
principle of light triggered activation has not yet been proven to be a viable method for 
obtaining drug release from liposomes in vivo. 
 
Enzyme triggered release 
The uses of enzymes that are upregulated in tumor tissue have been used for site-
specific drug release. Cell associated proteases have been suggested as possible 
candidates for enzymatically triggered drug release from liposomes [84]. Davis and 
Szoka [110] have designed liposomes that are sensitive to alkaline phosphatase and upon 
cleavage of the lipid conjugate results in the generation of fusogenic lipids that 
destabilize the liposome. They showed that liposomes consisting of cholesterol phosphate 
derivatives and DOPE could be induced to collapse upon phosphatase-catalyzed removal 
of the phosphate group. Thompson and co-workers have also employed enzymes as part 
of a trigger mechanism. They proposed the use of phospholipase A2 (PLA2) [105] and 
transglutaminase [106] for site-specific drug release. Alonso and co-workers [111-112] 
have used sphingomyelinase and phospholipase C as enzymatic triggers of liposome 
mixtures of sphingomyelin, phosphatidylcholine, phosphatidylethanolamine and 
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cholesterol to create fusogenic liposomes. Villar et al. [113-114] have furthermore 
suggested that phosphatidylinositol-specific phospholipase C can be employed for 
triggered drug release by promoting the site-specific formation of fusogenic liposomes. 
 
Heat triggered release 
In 1978, Yatvin et al. [86] proposed the use of mild local hyperthermia for tumor-
specific drug release. Their basic strategy was to design liposomes with the main phase 
transition just above physiological temperature. The objective of this principle is to 
design liposomes with a narrow phase transition region with respect to temperature, as 
this will result in selective and controlled drug release due to a narrow temperature range 
with lipid membrane heterogeneity and leaky interfacial membrane regions [90, 115]. 
Yatvin and co-workers [86-87] used DPPC as the main lipid component and added small 
amounts of DSPC to adjust the main phase transition temperature. Several other 
formulations based on this composition have been designed [116-117], including long 
circulating thermosensitive liposomes that released more than 60% of their contents when 
heated at 42 °C for 30 min in vitro [88, 118]. The use of hyperthermia allows for 
increased liposome tumor accumulation as a consequence of increased tumor blood flow 
[119] and increased microvascular permeability [118, 120], and therefore, has a 
significant advantage over other triggering concepts. In addition, hyperthermia itself has 
been shown to be cytotoxic [121].  
The strategy of using microenvironment-sensitive polymers as described for pH-
sensitive liposomes has also been employed for temperature-sensitive liposomes. Many 
synthetic and natural polymers are known to become water insoluble above a lower 
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critical solution temperature (LCST) while being soluble below this temperature [89]. 
The physical behavior of temperature-sensitive polymers can be exploited as a trigger in 
liposomal drug delivery because of the significant difference in polymer hydration below 
and above the LCST. Among thermosensitive polymers, poly(N-isopropylacrylamide) is 
the most extensively studied [89, 122]. Many others have been synthesized to adjust the 
LCST to a desired temperature which can be achieved by copolymerization [123-124]. 
The anchoring of the polymers to the liposome has been performed in a variety of ways 
and appeared to be important for the destabilization of the liposomes [89, 125-126]. 
A new liposome formulation that was optimized for doxorubicin release at 39–
40°C was introduced by Needham, Dewhirst and co-workers [90, 127]. They designed 
liposomes incorporated with lyso-phospholipids that were kinetically trapped in the 
liposomal membrane in the gel phase. When the liposomes were heated above the main 
phase transition, the lyso-phospholipids were shown to leave the bilayer, which 
drastically enhanced the permeability of the liposomal membrane at temperatures close to 
the gel-to-fluid phase transition [127]. 
The main shortcoming of the current state of the use of hyperthermia and 
liposomes is that it requires the location of the tumor is known and the tumor site is 
accessible to local hyperthermia [120]. However, this provides an exciting opportunity 
for remote triggering mechanism and will be discussed later in detail. 
2.3 Limited Efficacy due to Inhomogeneous Liposome Distribution  
The success of passive (and subsequent active) targeting of nanoscale 
chemotherapeutic agent therapy for intracranial tumors is critically dependent on the 
access that these agents have to tumors via the leaky vasculature across the BBB [42, 
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128-129]. Unfortunately, it is well-known that the degree of tumor vascular leakiness 
differs not only among similar type tumors but also spatially within the same tumor [130-
132]. For instance, previous studies in our laboratory showed that the standard deviation 
of the intratumoral accumulation of liposomal doxorubicin in a rat brain tumor was 150% 
of the mean value [133]. Due to non-uniform distribution of tumor blood vessels, the 
distribution of nanocarrier drug is patchy and inhomogeneous. As the size of the 
nanocarrier further limits the diffusion of the drug deeper into the tumor tissue, the drug 
distribution is limited to the periphery of the tumor where most vascularization is seen 
[134]. A study evaluating localization of liposomal doxorubicin in solid lung tumors 
showed that 98% of the tumor-associated drug was not tumor-cell associated and a small 
proportion of the drug co-localized with the tumor-associated macrophages [135]. 
Therefore, bioavailability of the liposomal encapsulated drug may be required to promote 
increased tumor-cell drug uptake. Dewhirst et al. have shown that triggered release of the 
drug from thermosensitive liposomes can greatly enhance efficacy at the tumor site [90, 
127, 136-138].  
2.4 Gold Nanorods for Remote Thermal Destabilization of Liposomes 
Triggered contents release from nanosized particulates has interesting potential 
applications in drug targeting and diagnostics. Heat sensitive liposome technology is a 
potential method to produce triggered systems for controlled contents delivery. The 
temperature required for gel-to-liquid crystalline phase transition in the liposomes can be 
adjusted by lipid composition. This property has been used in the cancer treatments, 
where a slightly higher temperature in the tumor triggers the drug release from the 
liposomes with a phase transition below 41 °C [90, 139].  
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Many external remote triggers have been explored to induce contents release from 
liposomes. For example, Huang and MacDonald studied ultrasound-triggered release 
from acoustically active liposomes [140]. Peyman et al. used laser light to release drugs 
from the liposomes [141], whereas Mueller et al. reported destabilization of liposomes 
using visible and ultraviolet light [142], although these methods are known to disturb cell 
membranes. 
In recent years, tremendous development of nanotechnology has provided a 
variety of nanostructures with unique optical properties that are useful in biology and 
biomedical applications. Noble metal nanoparticles, like gold, absorb light strongly in the 
visible region due to the coherent oscillations of the metal conduction band electrons in 
strong resonance with visible frequencies of light. This phenomenon is called surface 
plasmon resonance (SPR). Gold nanoparticles, for this reason, are ideal in cancer 
diagnostics and therapy. SPR frequency is dependent upon the size and shape of the gold 
nanoparticles. Changing the shape of the gold nanoparticles from a sphere to a rod 
significantly redshifts the SPR absorption wavelength into the NIR region. NIR region of 
the light spectrum is optically transparent and minimally absorbed by tissue 
chromophores and water making it optimal for clinical applications. Therefore, NIR-
resonant gold nanostructures are extremely useful for clinical therapy applications 
involving tumors that are located deep within bodily tissue [143-150]. 
In tumors of the brain, water bath mediated heat therapy poses several risks. 
Hyperthermia to a local region in the brain using a water bath is unattainable. Further, 
water bath mediated hyperthermia in the brain can trigger brain death. Gold nanorods can 
provide an opportunity to locally disrupt the liposomes in specific areas of the brain with 
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the help of NIR. By modulating the NIR power and gold nanorod dose, intratumoral 
temperature can be tightly controlled. Co-injecting gold nanorods and thermosensitive 
liposomes of similar sizes may cause co-accumulation at the tumor site due to EPR effect 
while sparing healthy brain tissue. In addition, tagging thermosensitive liposomes with 
gold nanorods can be further explored to this effect.  
2.5 Conclusions  
Existing methods of treating glioma are not effective for eradicating the disease. 
Therefore, new and innovative methods of treatment alone or in combination with 
existing therapies are necessary. Ideal glioma therapy requires minimally invasive 
administration and can be targeted to tumors thereby sparing non-target organs. 
Liposomes are ideal candidates for such delivery because they can be administered 
intravascularly. Delivery of therapeutic agents through delivery carriers such as 
liposomes diminishes the harmful effects of the agent in healthy tissues and allows 
increased accumulation in the tumor. In addition, targeted chemotherapy using liposomes 
provides the opportunity for further increase in drug accumulation in tumor. The use of 
antigens over-expressed by tumors as targeting ligands is an effective means of targeting. 
However, such unique antigens are rare and their receptors are usually expressed in small 
quantities on healthy cells causing even lower doses of chemotherapeutics reaching them 
to be toxic. The current targeting strategies, also, suffer accelerated plasma clearance and 
are not advantageous in improving efficacy. The search for new tumor targets, novel 
ligands, new strategies for targeting, and particle stabilization will advance our ability to 
improve delivery at the tumor level while decreasing toxicity to normal tissues. Here, we 
proposed a novel mechanism to increase targeting to tumor while uncompromising on the 
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long circulation of stealth liposomes. Long circulation is essential for passive 
accumulation of the nanocarriers due to EPR effect, in order to see benefits of targeting. 
Identifying several non-immunogenic motifs specific to the tumor type can greatly 
enhance nanocarrier accumulation at the tumor site.  
It has been shown by us and elsewhere that the distribution of nanocarriers, 
spatially within the tumor, is limited that might further hinder the distribution of the 
encapsulated drug, thereby limiting efficacy. To address the problem of drug diffusion 
within the tumor interstitium, it is necessary to release the drug from within the 
nanocarrier. Currently used triggered systems suffer from loss of drug in the circulation 
due to leaky characteristics. It is important to fabricate nanocarriers without 
compromising their stability in circulation to minimize toxicity to healthy cells. Using a 
remote triggering mechanism can help in achieving precise control over the desired site 
for drug release. Eventually, these strategies should enable increased drug retention and 
availability at the tumor site and contribute to tumor retardation. 
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CHAPTER 3  
RATIONAL IDENTIFICATION OF A NOVEL PEPTIDE 
FOR TARGETING NANOCARRIERS TO 9L GLIOMA 
Parts of the following chapter are published in Journal of Biomedical and Material 
Research: Part A, Jan 15, 2008 
3.1 Abstract  
Traditional therapies for high grade gliomas are limited in part by collateral 
damage to normal tissues. Selective delivery of therapies to tumors is, therefore, needed. 
Here, we report that liposomal nanocarriers coated with a novel oligopeptide enhance 
uptake by 9L gliosarcoma. A targeting 9 amino acid peptide sequence (RSI) was 
identified by differential panning of random peptide phage display libraries on 9L cells 
and rat blood cells and plasma. Peptides were coupled to the surface of liposomal 
nanocarriers which were subsequently loaded with doxorubicin. The ability of RSI coated 
liposomes to facilitate drug uptake and cytotoxicity was compared to conventional 
liposomal nanocarriers and controls. In addition, plasma clearance profiles of the RSI 
peptide coupled liposomal nanocarriers were evaluated in adult immuno-competent rats. 
RSI peptide-coupled liposomal nanocarriers enhanced drug uptake by 9L cells by 500% 
compared to conventional liposomal nanocarriers, and significantly increased 
cytotoxicity. The plasma half-lives confirmed that the presence of the RSI peptide on the 
liposomal nanocarriers did not compromise circulation time in the blood in comparison to 
Stealth liposomal nanocarriers. These data suggest that phage-identified oligopeptides 




Brain tumors represent the most common solid tumors in children and adolescents 
and show rising incidence [1-2]. Prognosis remains poor for these therapeutically 
challenging neoplasms [3] where long-term survivors are rare among patients with high 
grade gliomas. The median survival time for patients with high-grade gliomas treated 
with surgery and chemotherapy is a year or less [3]. These highly infiltrative tumors are 
not amenable to surgical cure, and current chemo- and radio-therapies suffer from a lack 
of specificity for the tumor tissue with significant untoward effects on uninvolved tissues 
[4]. Therefore, there is a dire clinical need for alternative approaches that afford selective 
tumor targeting. 
Currently, a primary limiting step in achieving this goal is lack of molecular 
targeting ligands and appropriate carriers for specific and efficacious treatment of brain 
tumors. Liposomal nanocarriers are nanocarrier vehicles that show great promise for 
delivery of therapeutic agents. PEG-coated liposomal nanocarriers (Stealth) [5-6] have 
small size and long circulation time, which are major advantages for drug delivery, and 
when administered systemically, liposomal nanocarriers can passively accumulate in 
tumor tissue, including in high-grade gliomas [7]. Tumors have compromised vasculature 
that is leakier than normal vasculature. Due to longer blood residence time and presence 
of ‗le ky‘ tumo  vasculature, repeated passage of liposomal nanocarriers through the 
tumor microvascular bed results in much higher concentration of liposomal nanocarriers 
within the tumor compared to free drug. This is called the enhanced permeability and 
retention effect [8-11]. Active targeting follows passive accumulation and is achieved by 
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incorporating receptor-mediated molecular targets on the nanocarriers to promote their 
specific localization.  
High affinity tumor targeting ligands can be readily coupled covalently to the 
distal ends of nanocarrier PEG chains through a variety of chemical linkages [12]. In fact, 
one or more ligands may be coupled to the same nanocarrier, potentially conferring added 
selectivity [13]. We have developed techniques to tightly control the number of targeting 
ligands on these nanocarriers, a means to finely tune cell-binding selectivity. The 
principal shortcoming of existing targeting ligands, such as folate and antibodies, is that 
they significantly compromise circulation time when presented on nanocarriers. 
Compromised circulation time results in decreased nanocarrier extravasation into tumors 
[14].  Long circulation is critical for increasing passive accumulation of liposomal 
nanocarriers in the tumors [15-16]. The extent of passive accumulation, in turn, 
determines the maxima in the effects of active targeting. Therefore, identification of 
ligands that afford selective tumor targeting while not compromising circulation time 
would be greatly advantageous. 
Recently, selective cell targeting ligands have been identified using random 
peptide phage display libraries by employing in vitro [17-19] and in vivo [20-22] panning 
approaches. We and others have identified and characterized high avidity cell and tissue-
type selective targeting peptide moieties using random peptide phage display libraries by 
panning in vitro on cells [23-25]. Libraries that contain up to 10
8-9
 unique oligopeptide 
sequences in a small volume afford rapid screening of immense numbers of peptides to 
identify distinctive cell surface signatures without the prior information about such sites. 
In this study, we employed random peptide phage display libraries to rationally identify 
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glioma selective binding peptides that a) permit significantly enhanced nanocarrier 
uptake in 9L glioma and b) demonstrate that liposomal nanocarriers coated with targeting 
oligopeptides manifest prolonged circulation times ensuring uncompromised passive 
accumulation in tumors.  
3.3 Materials and Methods 
3.3.1 Materials 
1,2-distearoyl-sn-glycerophosphoethanolamine poly(ethylene glycol)3400 
maleimide (DSPE-PEG3400-mal) was obtained from NOF Corporation (Tokyo, Japan).  
1,2-distearoyl-sn-glycerophospho-choline (DSPC) and 1,2-distearoyl-sn-
glycerophosphoethanolamine poly(ethylene glycol)2000 (DSPE-PEG2000) were 
purchased from Avanti Polar Lipids (Birmingham, AL). A fluorescent phospholipid β-
DPH was obtained from Invitrogen (Carlsbad, CA). Cholesterol, paraformaldehyde, and 
Triton X-100 were purchased from Sigma (St. Louis, MO).  RSIEWSGLWGPPVESC 
(RSI) and WRWGSELISGPPVESC (scrambled negative control) peptides were 
synthesized by Global Peptide Services (Ft. Collins, CO) using standard fMOC chemistry 
followed by HPLC purification and sequence confirmation with mass spectroscopy.  
Dialysis tubing (10,000 and 100,000 molecular weight cut-off) was purchased from 
Spectra/Por (Dominguez, CA). DC protein assay was obtained from Bio-Rad, (Hercules, 
CA). A 9L glioma cell line was received as a generous donation from the Neurosurgery 
Ti  ue B nk  t UCSF.  Minim l e  enti l medium cont ining E  le‘  b l nced   lt 
solution (MEM/EBSS) was purchased from Hyclone (Logan, UT).  Gentamicin (50 
mg/ml) and fetal bovine serum (FBS) were obtained from Gibco (Carlsbad, CA).  
Trypsin-EDTA (0.05% trypsin, 0.53 mM EDTA) in H nk ‘ b l nced   lt  olution w   
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purchased from Mediatech (Herndon, VA).  FluorMountG was obtained from Southern 
Biotech (Birmingham, AL). Heparin (1000 USP units/ml), isoflurane, and doxorubicin 
(DXR) were purchased from Baxter Healthcare (Deerfield, IL).  Cell Counting Kit-8 
(CCK-8) was obtained from Dojindo (Kumamoto, Japan) and Cytotoxicity Colorimetric 
Assay Kit, (CytoTox 96) was obtained from Promega (Madison, WI). Fisher 344 male 
rats were purchased from Harlan (Indianapolis, IN).  
3.3.2 Cell Culture 
9L glioma cell line was maintained in MEM/EBSS medium supplemented with 
10% fetal bovine serum and 0.05 mg/ml gentamicin.  Cells were passaged by 
trypsinization and washed with growth medium. 
3.3.3 9L glioma-based panning experiments 
The linear nonapeptide (LL9) and constrained hexapeptide (CL6) random peptide 
phage display libraries were prepared as described [23].  Panning was performed on sub 
confluent (<95%) 9L adherent cells in 162 cm
2
 culture flasks for 6 rounds using a 
modification of a previously described protocol [23, 25]. Briefly, cell layers were washed 
twice with 10 ml H nk ‘ b l nced   lt  olution (HBSS), cont ining 1 mM C Cl2, 1 mM 
MgCl2 , 10 mM HEPES, and 0.5% BSA, pH 7.4  (HBSS(+)). Phage libraries (30 µL 
containing 3 x 10
11
 pfu) were added to 6 ml HBSS+, supplemented with 5 mM CaCl2 and 
10% rat plasma as adsorbent (Cocalico Biologicals, Reamstown, PA) and incubated with 
gentle rotation for 4 hours. Supernatants were removed and cell layers washed 10 times 
with HBSS+. Bound and internalized phage particles were recovered by adding 3 ml lysis 
buffer [25] for 10 minutes. Phage were collected and amplified in K91 E. coli overnight 
and purified, concentrated, re-suspended in buffer, and quantified to generate sub-
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libraries for use in the next round of panning [23].  Before the second and each 
subsequent round of panning, phage sub-libraries were pre-adsorbed on rat blood cells 
(Cocalico Biologicals). Sub- libraries (30 µL containing 3 x 10
11
 pfu) were incubated 
with 2 ml washed, packed blood cells from a buffy-coat preparation suspended in 2 ml 
HBSS+ for 3 hours. Cells were pelleted to remove adsorbed phage. Cell-free supernatants 
containing non-adsorbed phage were applied to 9L cells as above. After the fourth and 
fifth panning rounds, 15 randomly selected phage clones were propagated and 
concentrated  for each library [25].  The amino acid sequences of the displayed peptides 
were deduced for specific phage clones by sequencing the coding nucleotides in the viral 
DNA [25]. 
3.3.4 Phage Binding Assays 
Phage binding assays were performed with minor modification [23]. In brief, 9L 
cells were grown to approximately 95% confluence in 96 well plates and washed. 100 µl 
individual phage clones were added at 10
10
/ ml in HBSS+ in quadruplicate for 1 hour at 
37 C. After washing, bound phage were fixed to cells with 3.7% paraformaldehyde, 
washed with HBSS+, and detected with horseradish-peroxidase conjugated anti-phage 
antibody (Amersham) and peroxidase substrate for quantification using a microtiter plate 
reader. Synthetic peptide inhibition experiments were performed as described [26]. Cells 
were incubated with primary phage conjugates or unlabeled phage clones in the presence 
or absence of 1 mM specific or control synthetic peptide and binding to cells assayed as 
above.   
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3.3.5 Flow Cytometry 
Flow cytometry (FACS) studies with phage clones and blood cells were 
performed as described [25-26]. 
3.3.6 Liposome Preparation 
Liposomal nanocarriers were formed as described earlier [13, 27]. Briefly, a ratio 
of 59:40:0 and 57.5:40:1.5 of DSPC: cholesterol: DSPE-PEG2000 was dissolved in 1mL 
of ethanol at 60
o
C.  1.5% of DSPE-PEG2000 was used to evade the RES in the plasma 
cle   nce  tudie . 0.01 (mol %) of fluo e cent pho pholipid (β-DPH) was used to 
dete mine pho pholipid content  nd   0.1 (mol %) of β-DPH for fluorescent microscopy 
studies. Liposome size was determined by dynamic light scattering (Particle Size 
Analyzer, Brookhaven Instruments, Holtsville, NY).  Liposomal nanocarriers were 
dialyzed against a phosphate-buffered saline solution to establish an ammonium sulfate 
gradient for DXR loading. 
3.3.7 Lipid-Peptide Conjugate Synthesis 
A lipid-PEG-peptide conjugate was synthesized such that it can later be 
incorporated into liposomal nanocarriers to facilitate targeting.  The N-terminal of the 
peptide was determined to be the active binding site.  Therefore, a cysteine residue was 
attached to the carboxyl terminal of the peptide for conjugation to the lipid-PEG tether. 
RSI peptide was coupled to DSPE-PEG3400-mal via the sulfide on the cysteine. DSPE-
PEG3400-mal was dissolved in water to form a 1mM micellar solution. 1.5 mmoles of 
the RSI peptides were slowly dissolved in the micellar solution maintaining the pH 
between 6.7 and 7.2. The solution was stirred for 3hours at room temperature. Unreacted 
peptides were removed by dialyzing against deionized water in a 10,000 MWCO 
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membrane overnight. The solution was lyophilized. The final product was analyzed by 
MALDI-TOFMS acquired on Applied Biosystems 4700 proteomics analyzer. A 
conjugate was constructed using a scrambled version of the RSI peptide (control) for use 
as a control. 
The amount of reacted peptide was determined by a modified Lowry method (DC 
protein assay). Peptide content measured by DC protein assay was verified by Beer-
Lamberts law by measuring absorbance at 280 nm in a Synergy microplate reader (Bio-
Tek, Winooski, VT).  
3.3.8 Lipid-Peptide Conjugate Incorporation into Liposomal Nanocarriers 
Peptide presenting liposomal nanocarriers were prepared by post-inserting DSPE-
PEG3400-peptide micelles to pre-formed liposomal nanocarriers at 60
o
C.  Micelles were 
formed by dissolving the DSPE-PEG3400-peptide conjugate in deionized water. 
Unincorporated micelles were removed by dialysis as described previously [13].  The 
amount of peptide inserted into liposomal nanocarriers was determined by DC protein 
assay after lysis of liposomal nanocarriers with 20% SDS.   
3.3.9 Active Loading of Doxorubicin 
Following ligand incorporation, liposomal nanocarriers were loaded with DXR 
via the ammonium sulfate gradient as described before [28].  Briefly, liposomal 
nanocarriers and 2 mg/ml DXR solution in 0.9% saline were mixed at a ratio of 0.1 mg 
DXR per 1 mg of DSPC in the liposomal nanocarriers for all in vitro studies. For plasma 
clearance studies, a 15 mg/ml DXR solution was mixed with liposomal nanocarriers at a 
ratio of 0.3 mg DXR per 1 mg of DSPC in the liposomal nanocarriers. The 
liposome/DXR suspension was heated at 60 °C for 1 h. The liposomal nanocarriers were 
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then cooled immediately on ice and dialyzed in 100 000 MWCO membrane against PBS 
to remove un-encapsulated DXR. The formulations were sterilized by passing through a 
0.2 m filter. The final DXR concentration after dialysis was determined by lysis of the 
liposomal nanocarriers with 5% Triton X-100 and measurement of absorbance at 480 nm. 
3.3.10 Cellular Liposomal Drug Uptake Experiments 
Cellular uptake experiments were conducted using strategies published earlier 
[13, 29]. The targeting efficiency as a function of peptide ligand number per liposome 
was determined by in vitro incubation of cells with DXR-loaded peptide-liposome 
formulations. Cells were seeded at a density of 1.5x10
5
 cells per well in a 12 well plate. 
After 48 hours in culture, cells were utilized for DXR uptake experiments. After 
 emoving the cultu e medium, cell  we e w  hed once with PBS. DXR (200 μM) in 
either free form (free DXR) or liposomally encapsulated form was mixed with culture 
medium and immediately added to cells. Cells were then incubated for 6 h with the DXR 
mixture at 37 °C in a 5% CO2, high humidity environment. Following incubation, cells 
were placed on ice, washed three times with PBS containing calcium and magnesium to 
remove ext  cellul   DXR. Cell  we e then ly ed with 500μl of 5% T iton X-100 and the 
fluorescence intensity of DXR was measured on a fluorescence spectrometer at an 
excitation/emission of 485/590 nm.  
Competitive binding experiments were performed simultaneously to determine if 
the RSI peptide specifically mediated the cellular uptake of liposomal-DXR. In these 
expe iment , 200 μM of DXR-peptide-liposomal nanocarriers bearing 500 RSI peptides 
were co-incubated with an excess of free peptide at 4 mM concentration. An amount of 4 
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mM free peptide is a 100-fold excess over the number of RSI peptides present due to the 
500 peptide motifs per liposome level. 
3.3.11 Cytotoxicity of RSI-targeted liposomal nanocarriers 
9L glioma cells were seeded at a density of 2x10
4
 cells per well of a 24-well plate 
and incubated for 48 hours prior to incubation with liposomal nanocarriers.  48 hours 
l te , lipo om l fo mul tion  we e mixed with MEM/EBSS medium to   100μM 
doxorubicin concentration and added immediately to cells.   
Cells were incubated with free DXR or liposomal DXR for 30 minutes at 37
o
C 
and 5% CO2 in a humidified environment.  Cells were then washed three times with fresh 
medium and re-incubated for 72 hours.  The number of viable cells was determined with 
a water soluble formazan-based assay (CCK-8). The number of dead cells was quantified 
by a lactate dehydrogenase based assay (CytoTox 96).   
3.3.12 Liposome Cellular Localization Imaging 
To visualize the cellular localization of peptide-presenting liposomal nanocarriers, 
cells were seeded at a density of 3x10
3
 cells per well of an eight-well chamber slide for 
24 hou  . 2 mM lipo om l fo mul tion  th t inco po  ted 0.1% of   fluo e cent lipid β-
DPH were incubated with the cells for 10 minutes at 37
o
C and 5% CO2 in a humidified 
environment. Cells were then placed on ice, washed three times with PBS to remove 
unbound liposomal nanocarriers, and fixed with 4% paraformaldehyde for 30 minutes. 
The chambers were removed and slides were coversliped with Fluoromount G. Cells 
were imaged on a Nikon Eclipse 80i microscope using an Optotronics Microfire camera.  
59 
 
3.3.13 Plasma Clearance 
All animal work was done according to an approved animal protocol and in strict 
compliance with NIH Clinical Center Animal Care and Use Committee guidelines and 
regulations. 10-11 weeks old male Fisher rats weighing 250g were anesthetized under 
isoflurane and administered DXR-Stealth liposomal nanocarriers (n=4) or DXR-RSI 
peptide-presenting liposomal nanocarriers (n=4) via tail vein at a dose of 10 mg/kg DXR.  
500 µl of blood was collected from the orbital sinus before IV injection and at 0.5, 2, 8, 
24, 48, and 72 hours after injection in heparinized gel tubes.  Tubes were centrifuged at 
3000 rpm for 20 minutes to separate the plasma.  Liposomal nanocarriers were lysed as 
described elsewhere [30]. Briefly, a mixture of 0.75N acidified isopropanol, 10% Triton 
X100, water, and plasma was prepared to analyze the DXR content.  To quantify total 
DXR content, fluorescent readings were obtained using a fluorescence spectrometer at 
excitation/emission of 485/590 nm. Plasma samples obtained prior to injection were used 
to correct for background fluorescence.   
3.3.14 Survival Studies 
All animal studies were conducted under a protocol approved by the Institutional 
Animal Care and Use Committee (IACUC) at Georgia Institute of Technology.  A rat 
glioma model was established by surgically implanting 1x10
6 
9L glioma cells into the 
frontal lobe of 10-11 week old male Fisher 344 rats.  During surgery, anesthesia was 
maintained through the administration of 2-3% inhalant isoflurane.  The incision site was 
shaved and the animal mounted in a stereotaxic frame.  The scalp was opened to expose 
the skull, and a burr hole was drilled 2 mm anterior and 2 mm lateral to the bregma.  9L 
gliom  cell  in 10 μl of Leibovitz‘  L-15 medium were slowly injected into the frontal 
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lobe through a 21-gauge needle at a depth of 3 mm.  The burr hole was then sealed with 
bone wax, and the scalp was sutured. 
Four days after tumor inoculation, animals were treated with a saline sham, 0 
peptide-t  geted ‗Ste lth‘, o  500 peptide-targeted liposomal DXR i.v. injections (10 
mg/kg doxorubicin) via tail vein. Equivalent volumes of 0.9% sterile saline solution were 
administered to animals receiving sham injections.  To a second set of animals, another 
liposomal dose of 10 mg/kg of doxorubicin was administered 5 days after the first dose 
(cumulative 20 mg/kg doxorubicin). Tumor growth was allowed to progress until the 
animal showed signs of morbidity, at which point, interventional euthanasia was 
administered. Time of death was determined to be the following day. 
3.4 Results 
3.4.1 Identification of 9L Glioma Selective Binding Peptides 
Panning experiments were performed to identify phage clones bearing peptides 
that selectively bind to the 9L model rat glioma cell line while displaying minimal 
binding to normal rat blood cells, a potentially major source for nonspecific uptake of 
injected nanocarriers. Sequences of the displayed random peptides were determined for 
15 phage clones per library each after panning rounds 4 and 5 for 60 total sequences. Of 
these, specific motifs were identified for a subset. As shown in Table 1, three remarkable 
motif groups were apparent, labeled groups 1-3. In group 1, 9 amino acid long peptides 
display the WxGxW consensus (bold) with [R/K][T/S]xEWxGxW and 
[R/K][T/S]xxWDGxW motif , whe e ―x‖ i   ny AA. G oup 2 clone   ll di pl yed the 
same the RGDN motif in a cyclic 6 AA peptide constrained by N and C terminal Cys 
residues. A similarly constrained 10 AA peptide consensus was DVFxxWMxRx. A set 
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of clone  devoid of con en u  motif  i  l beled ―None‖ in T ble 3.1. Based on searches 
of public databases, no significant identities to known peptide/protein sequences were 
found for the other displayed peptides shown. Finding such clear-cut motifs is consistent 
with high affinity of the sequences for discrete receptors on the 9L cell surface.  
Screening experiments were then performed to assess the relative binding 
selectivity and avidity of the phage clones with the goal of identifying high 9L glioma 
binding and low blood cell binding. Results of phage binding assays and FACS analyses 
using adherent 9L glioma and suspension rat blood cells, respectively, are displayed in 
Table 1. Consistent with their similar peptide motif, group 1 clones clustered as the top 
12 binders to 9L cells. By contrast, they ranked in the lower middle to lower half for 
binding to rat blood cells. Control clones (CTLs group, Table 3.1) included those 
previously selected for binding blood cells (e.g. FGPNLTGRW-bearing phage (FGP)) 
[23] and performed as expected in FACS analysis 4. The best differential binding profile 
was observed for the displayed peptide of the 2nd clone in group 1, RSIEWSGLW (RSI). 




Table 3.1. Summary of the glioma selective binding peptides.  
 
Motifs Displayed peptide  
Freq 
ELISA FACS 
Groups Sequence 9L Glioma cells Blood Cells 
Group 1 
WSYSWDGFW  6 1 11 
RS IEWSGLW  1 2 16 
KSYEWPGTW  2 3 15 
MRTEWTGVW  2 4 17 
KSASWDGLW  1 5 24 
SHLT WDGTW  6 6 19 
VVIQ WDGAW  1 7 12 
YTVAWDGTW  3 8 8 
LTT EWSGTW  2 9 14 
GRLQWDGAW  2 10 13 
RTVEWSGNW  1 11 7 
AKTVWDGRW  1 12 9 
Group 2 C RGDNFQ C 9 13 4 
Group 3 
C DVFEVWMGRV C 4 17 20 
C DVFTYWMRRD C 9 18 18 
None 
KSLLTTMAS 1 19 21 
GWGMEALGA 1 21 23 
RSPN 1 22 22 
CRGTQNTMRARC 1 24 10 
CTLs 
DLDVSPWDL   14 3 
FGPNLTGRW   15 2 
CVWHPVTGAAVC   16 6 
Wild type   20 1 






Figure 3.1. RSI phage and peptide selectively bind 9L cells. ELISA was performed with a synthetic 
version of the RSI peptide to confirm specificity of binding. The RSI Φ displayed significantly higher 
(*** p<0.001) binding to 9L cells compared to control DLV Φ (DLV= DLVTSKINI) and FGP Φ 
(FGP = FGPNLTGRW). RSI Φ binding was selectively diminished by the 0.1 mM synthetic RSI 
peptide but not by 0.1 mM control FGPNLTGRW peptide confirming specific binding via the 





To confirm specificity of binding of RSI at the molecular level, a synthetic 
peptide version was used in phage binding assay to test whether peptide selectively 
abrogates binding of RSI phage to adherent 9L glioma cells. As shown in fig. 3.1, the RSI 
ph ge (Φ = ph ge) di pl yed  ignific ntly highe  (p<0.001) binding to 9L cell  comp  ed 
to control phage bearing peptide DLVTSKINI (DLV) or FGP. DLV and FGP phage 
displayed peptides that were not related to the RSI primary AA sequence and were 
therefore chosen as controls. RSI phage binding was selectively abrogated by the 0.1 mM 
synthetic RSI peptide (p<0.001) but not by 0.1 mM control FGP peptide, confirming 
specific binding via the displayed RSI peptide. Moreover, dose-dependent binding of a 
biotinylated version of the RSI peptide (0.1 μM to 1 mM) w   demon t  ble (not  hown). 
In aggregate, these data confirm binding of the RSI peptide to 9L glioma cells. 
3.4.2 Targeting Peptide Conjugate and Liposome production 
We next produced liposomal nanocarriers bearing the RSI peptide to test in vitro 
binding capability. RSI peptides were conjugated to DSPE-PEG3400 via a maleimide 
functional group. The final product yield of DSPE-PEG3400-peptide conjugate was 65% 
as determined by DC protein assay and Beer-L mbe t‘  inte pol tion method. MALDI-
TOFMS and thin layer chromatography (TLC) were used to analyze the product. 
MALDI-TOFMS confirmed the mass of the conjugate. The mass spectrum had a bell-
shaped distribution of 44 Da-spaced lines indicating a singly charged PEG conjugate. The 
distribution had its mode at 6109 Da, similar to the theoretical molecular mass of 6141 
Da (fig. 3.2). 
The final product was characterized by TLC showing no unreacted peptide 
(absence of ninhydrin staining). Cupric sulfate spray indicated complete consumption of 
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the DSPE-PEG3400-mal (disappearance of the parent spot, Rf=0.36 in CHCl3: 
MeOH=85:15) into the desired DSPE-PEG3400-peptide conjugate (appearance of a new 




Figure 3.2. MALDI-TOFMS of the DSPE-PEG3400-peptide conjugate.  
 
The liposome size, as determined by DLS, was 98 ± 20 nm. To achieve different 
number of peptides per liposome, different micellar concentrations were added. The 
insertion efficiency for the number of conjugated peptides inserted into the liposomal 
nanocarriers was 80% as determined from the DC protein assay. Therefore, the amount of 
 
Agarwal AA-DSPE-PEG(3400)-Mal-NP
14-Apr-2005   12:05:40GT Mass Spectrometry Laboratory











































Figure 3.3. Post insertion efficiency of the conjugate DSPE-PEG3400-peptide conjugate onto 
liposomes with increasing number of peptide conjugate onto the liposomes. Post insertion was 80% 
efficient up till ~800 peptides per liposomes. 
 
3.4.3 Peptide targeting enhances in vitro delivery of DXR by liposomal nanocarriers 
The ability of RSI liposomal nanocarriers to deliver DXR to 9L glioma cells was 
compared to non-targeting stealth liposomal nanocarriers as a function of number of 
targeting ligands per liposome. DXR uptake into cells was quantified after 6 h incubation 
utilizing the fluorescent properties of DXR. As shown in fig. 3.4a, the DXR uptake 
increased as a function of the number of RSI peptides per liposome. Although data 
suggest that cell uptake mechanisms were not saturated even at 750 peptides/liposome, 
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higher peptide content was not assessed because conjugate insertion became inefficient at 
numbers >1000 (fig 3.3). The uptake of the RSI peptide presenting liposomal 
nanocarriers was compared with the uptake of the control peptide-presenting liposomal 
nanocarriers to test the specificity of the RSI peptide to 9L cells. Unlike RSI peptide 
liposomes the drug payload due to control peptide liposomes did not increase with higher 
number of peptides on the liposomal surface.  
As seen in fig. 3.4b, at 500 peptides of either control or RSI the RSI peptide-
presenting liposomal nanocarriers were taken up significantly better than the control 
peptide-presenting liposomal nanocarriers (p<0.05) and conventional non-targeting 
liposomal nanocarriers  (increased by 500%; p<0.002). In competition with 100-fold 
excess of free RSI peptide (4 mM), RSI presenting liposome uptake was reduced 
approximately 50%. By contrast, RSI peptide had no effect on other liposome 
preparations. 
To establish if the enhanced DXR uptake via the RSI peptide presenting 
liposomal nanocarriers yields increased cytotoxicity, live and dead 9L cells were counted 
72 hours after 30 minute incubation with liposomal nanocarriers. 72 hours is sufficient 
time for 3-4 cell divisions [31]. 9L cells were seeded at 20,000 cells per well in 24 well 
plates. DXR at 0 or 100µM in free or liposomal form (conventional non-targeted 
liposomal nanocarriers, 500 RSI peptide presenting liposomal nanocarriers, and 500 










































































Figure 3.4. Specific and dose dependent uptake of DXR loaded liposomes mediated by targeting RSI 
peptide. (a) Effect of increasing number of RSI peptides/liposome on the cellular levels of DXR was 
measured as DXR fluorescence. Fluorescence of the RSI peptide liposomes were normalized to that 
of the conventional liposomes for comparison purposes. As shown, increasing number of RSI 
peptides/liposome also increased the drug uptake by 9L cells and the uptake was significantly better 
than conventional non targeted liposomes (* p<0.05). All RSI peptide liposomes were taken up 
significantly better than the conventional liposomes (** p<0.01). (b)  Comparing uptake of 
conventional, RSI peptide presenting, and control peptide presenting liposomes. Liposomes with 0 
peptides, 500 RSI peptides/liposome, or 500 control peptides/liposome were prepared. 9L cells were 
incubated with either DXR loaded liposomes or DXR loaded liposomes + 4mM free RSI peptide 
(~100 fold excess compared to liposomally bound peptide). Cellular DXR fluorescence was measured. 
Liposomes with 500 RSI peptides/liposome were taken up significantly better than conventional 
liposomes (**p<0.002), 500 control peptide presenting liposomes (* p<0.05), and RSI peptide 
presenting liposomes co incubated with excess of free RSI peptide (** p<0.01). Data represents the 




Figure 3.5. Cytotoxic effects of various liposomal formulations on 9L cells. Cells were incubated with 
various liposomal formulations for 30 minutes. Cells were washed with fresh media and post 
incubated for another 72 hours. Live cells and dead cells were enumerated. The kill percentage 
represents the ratio of the number of dead cells to the total number of cells (dead + viable) per well. 
Similarly, % viability is the ratio of the viable cells to the total number of cells per well. Data 
represents the mean ± SEM. **p<0.01 compared to untreated cells and cells treated with 









Initial microscope examination of treated and untreated 9L glioma showed no 
differences in cell density and morphology. After 72 hours, percentages of live cells (a 
measure of metabolically active cells) and dead cells (measured by the content of lactate 
dehydrogenase released from dead cells) were determined as a ratio of number of dead 
cells or live cells to the total number of cells (live + dead) in a given well and are 
displayed in fig. 3.5. As shown, 76% of cells treated with RSI liposomal nanocarriers 
were dead in contrast to 35% by control scrambled peptide liposomal nanocarriers and 
15% by conventional non-targeted liposomal nanocarriers.  Less than 1% of cells were 
dead in untreated wells.  The RSI peptide-presenting liposome treated wells were 
statistically (p<0.05) different from the other treatments. In aggregate, these studies 
suggest selectively enhanced delivery of liposomal nanocarriers mediated by RSI 
targeting 
To determine the early intracellular localization and selectivity of liposomal 
uptake, the distribution of fluorescently tagged liposomal nanocarriers with β-DPH was 
studied by fluorescence microscopy.  Fig. 3.6 shows the sub cellular localization of 
different liposomal formulations after 10 minutes incubation at 37°C followed by cell 
fixation. In comparison to background cellular fluorescence (fig. 3.6A), non-targeted (fig. 
3.6B) and control peptide (fig. 3.6C) liposomal nanocarriers yield minimal to no increase 
in signal. By contrast, RSI liposomal nanocarriers yield clear and selective increase in 













Figure 3.6. Selective uptake of RSI liposomal nanocarriers by 9L cells. Cells were incubated with 
either conventional, RSI peptide presenting, or control peptide presenting liposomes for 10 minutes 
and then fixed followed by epifluorescence microscopy using identical gain, exposure time, and target 
intensities. Cells were treated with (A) no liposomes (B) conventional liposomes (C) control peptide 
liposomes (D) RSI peptide presenting liposomes (500 peptides/liposome). 
 
 
3.4.4 Presentation of RSI on liposomal nanocarriers does not diminish plasma half-
life 
With favorable in vitro targeting established for RSI liposomal nanocarriers, we 
next addressed whether peptide coated liposomal nanocarriers would show extended 
plasma half-life required for in vivo efficacy. Liposomal nanocarriers were formulated 
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with 1.5% DSPE-PEG2000 to provide Stealth characteristics. RSI peptides were post-
inserted onto the liposomal nanocarriers via a longer lipid-PEG tether, as described 
earlier, in different numbers to examine the effect of increasing peptides/liposome on 
plasma clearance. The area under the curves (AUCs) were computed and compared for 
statistical significance. As shown in fig. 3.7, AUC of the liposomal nanocarriers with as 
many as 500 RSI peptides was statistically the same as the AUC of Stealth liposomal 
nanocarriers with no peptides. Increasing the number of RSI peptides/liposome greater 
than 800 accelerated plasma clearance and the AUC decreased by 40% in comparison to 
Stealth nanocarriers with no peptides.  
In addition, the 500 RSI peptides/liposome formulation was compared to 3% 
Stealth liposomal nanocarriers with no peptides. The plasma clearance half life of 3% 
Stealth liposomal nanocarriers was statistically the same as that of 500 RSI 
peptides/liposome formulation (data not shown). These data rule out the effect of 
increasing PEG concentration on plasma clearance half life. PEG at 1.5% was chosen 
over 3% PEG to facilitate the post insertion process of lipid-PEG-peptide conjugate. The 
lipid dose administered (30mg/kg) for the pharmacokinetic study was kept significantly 






Figure 3.7. Plasma clearance profiles. Stealth liposomes (1.5% PEG2000) were compared to Stealth 
RSI peptide presenting liposomes. 4 animals each were injected via the tail vein with 10 mg/kg of 
DXR. Blood was collected through the orbital’s sinus at 0.5, 2, 8, 24, 48, and 72 hours. Blood was 
collected at 3, 10, 20, 27, 46, and 70 hours for the case of 850 RSI peptide/liposome formulation. DXR 
concentrations in the blood were compared, plasma half lives, and the areas under the curves (AUCs) 
were evaluated. The AUCs of Stealth non-targeted versus Stealth 500 RSI peptide liposome 
formulations were not statistically different from each other. However, the clearance profile of the 
Stealth 850 RSI peptide liposomes were statistically different from the other two formulations 
(p<0.05). Data represents the mean ± SEM. 
  




Stealth Liposomes (500 RSI)
Stealth Liposomes (0 RSI)








AUC 3142 2839 1916  
T1/2 25.43  23.32 10.2  
T1/2(fast)  0.9408333 0.877 0.458152 
T1/2(slow)  75.83667 45.180 21.28333 

















Figure 3.8. Use of RSI peptide to target liposomal DXR does not prolong survival of tumor-bearing 
rats.  Animals received saline sham, non-targeted, or 500 RSI peptide-targeted liposomal DXR i.v. 4 
days after tumor inoculation. A different set of animals received 2 doses at 4 days and 9 days after 
tumor inoculation. Both liposomal treatments were able to prolong survival of tumor-bearing rats 
compared to saline-treated controls. 2 doses were better at increasing survival than a single dose. 
However, there was no effect of RSI peptide on liposomes in prolonging survival when compared to 


















Non-targeted 2 doses RSI-peptide tagteted Single Dose
RSI-peptide targeted 2 doses
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3.4.5 RSI peptide targeted liposomes did not improve survival 
All animals received first treatment 4 days after tumor inoculation. As seen in fig 
3.8 survival times of liposomal DXR treated animals were improved compared to saline-
treated controls, however, there was no significant difference in survival between the 
groups receiving either non-targeted or 500 RSI peptide-targeted liposomal doxorubicin 
(p<0.05). To investigate the impact of multiple treatment administration on therapeutic 
efficacy, additional survival studies were conducted on tumor bearing rats receiving 
either non-targeted or 500 RSI peptide-targeted liposomal DXR. Animals received 
treatments 4 days after tumor inoculation, and a subsequent treatment 9 days after tumor 
inoculation. Survival was monitored, and the results of this study are exhibited in fig. 3.8. 
No improvement in survival resulted upon increasing the number of doses between 
animals receiving non-targeted liposomal DXR compared to those receiving 500 RSI 
peptide-targeted liposomal DXR. However, there was a significant increase in survival 
times of animals when comparing single treatment to animals receiving 2 treatments. 
3.5 Discussion 
The major shortcomings of the current generation of actively targeted 
nanocarriers are either lack of specificity or reduced efficacy due to ineffective tumor 
dosing stemming from decreased circulation time.  
Recent studies have indicated successful targeting of liposomal nanocarriers to 
solid tumors by use of monoclonal antibodies and antibody fragments [33-34]. In these 
studies, the removal of the Fc portion of the IgG helped reduce antigenicity and increase 
efficacy [35]. However, the mass scale production and use of monoclonal antibodies and 
fragments is time and cost inefficient. Antibody therapy has been more beneficial in the 
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case of lymphoma or leukemia than solid tumors because of their enhanced accessibility 
to monoclonal antibodies [36]. In fact, one antibody or antibody fragment for targeted 
nanocarriers is insufficient in treating solid cancer which may be due to the incidence of 
multiple parallel or compensatory oncogenic pathways that allow tumor cells to escape 
and survive [37]. Therefore, use of combination of targeting ligands may help increase 
specificity to tumors and in turn, increase efficacy [27]. 
Phage panning of random peptide libraries features rapid screening of immense 
numbers of peptides to identify distinctive cell surface signatures without the benefit of 
prior information about such sites or knowledge about target cell biology. Unlike 
antibody technology, phage display offers the advantages of facilitating the identification 
of immunogenic as well as non-immunogenic structures, without bias as to which may be 
of therapeutic importance. Isolated phage clones bearing cell targeting peptides can be 
rapidly prepared for detailed analyses, including DNA sequencing to determine displayed 
peptide amino acid sequences. Peptides that target breast, prostate, and nasopharyngeal 
cancer have been identified as well by others [38-40]. Interestingly, a phage-derived 
small peptide was identified and used to guide an MRI contrast agent to image 
atherosclerotic plaques [41]. Thus, random-peptide phage display libraries represent a 
powerful combinatorial technology to help identify selective molecular targeting 
moieties. 
One major problem associated with the use of targeting moieties on liposome 
surface is the loss of circulation time in the plasma. Folate targeted liposomal 
nanocarriers are a good example of ineffective targeting due to loss of plasma half-life 
[15-16]. In other studies, we have shown that folate targeted liposomes are cleared 3 
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times faster than Stealth liposomes from the blood circulation. Enhanced plasma 
clearance of folate targeted liposomes, in turn, decreases the passive accumulation at the 
tumor site. P   ive  ccumul tion,  e ulting f om ‗le ky‘ tumo  v  cul tu e, i  di ectly 
proportional to the AUC for plasma drug clearance when operating below lipid RES 
saturation limits. The benefits of active targeting of liposomal nanocarriers can only be 
 e ped by not comp omi ing the p   ive  ccumul tion component due to ―le ky‖ 
vasculature [42-43] at the tumor sites. We have made the important observation here that 
the use of a small peptide as targeting moiety on liposomal nanocarriers at sizeable 
number per carrier does not compromise passive accumulation necessary to achieve 
increased drug efficacy by active targeting. 
This study suggests that the use of peptides, identified through phage display, on 
the surface of liposomal nanocarriers can result in enhanced specificity and uptake of 
chemotherapeutics by tumors. The peptide (RSI) used here was rationally selected for 
maximal binding to 9L glioma cells and minimal binding to blood cells. Initial FACS 
analysis demonstrated relatively reduced binding of the RSI peptide to blood cells with 
more rigorous in vivo confirmation through plasma clearance studies that confirmed no 
compromised in plasma half life for RSI liposomal nanocarriers. In fact, the strength of 
our peptide selection techniques lies in our ability to screen peptides that minimally bind 
to blood cells, which can thus evade the RES in vivo and have high selectivity towards 
the desired cell type.  
Liposomal nanocarriers are good candidates for their use as therapeutics 
nanocarriers in vivo for several reasons. They are easy to formulate and acquiescent to 
surface modification with targeting moieties. They can stably carry a variety of 
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therapeutics. Importantly, the presence of PEG chains provide for long circulation times 
in the blood. In the present study, PEG was used to sterically stabilize liposomal 
nanocarriers for in vivo application. However, as PEG promotes steric hindrance [44-45] 
for interaction of targeting moieties with the cell surface, the RSI peptide was conjugated 
to the end of a long spacer lipid-PEG molecule (DSPE-PEG3400-mal) that could be 
easily inserted into the liposome. DXR was the chosen as the preferred drug due to its 
fluorescent properties that enable both its detection intracellularly, and its ability to 
remotely load in the liposome [28, 46] with high efficiency >95% [47]. DXR is also non 
leaky due to the formation of stable precipitates inside the liposomal vesicle, and it is 
FDA approved for use in liposomal nanocarriers (DOXIL).  
The RSI peptide liposomal nanocarriers were successful in delivering high 
payload (up to a six fold increase compared to the conventional non-targeted liposomes) 
of the drug DXR to the 9L cells, in a fashion that increased with higher number of 
peptides on the surface of the liposomal nanocarriers (fig. 3.4a). The number of peptides 
that could be tethered on the liposomal nanocarriers was limited as the method of post-
insertion of lipid-peptide conjugates in numbers >1200 per liposome became highly 
inefficient. In addition, plasma half life was reduced when more than 500 peptides were 
used per nanocarrier. Nevertheless, as seen from the DXR uptake study, when 500 RSI 
peptides were presented on the liposomal nanocarriers, significantly increased cellular 
DXR levels were observed as compared to liposomal nanocarriers with no peptides. The 
requirement for the specific RSI peptide sequence is evident suggested by the significant 
reduction in DXR delivery when a scrambled version of the RSI peptide was used. 
Although, it can be argued that the effect of the scrambled peptide is larger than the non-
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targeted liposomes.  This effect can be attributed to the preservation of the phage 
sequence (GPPVESC) on the scrambled peptide. Therefore, one may conclude that the 
phage part of the peptide may have had a significant role in binding to the cells. In a 
competitive environment where RSI liposomes were presented to the cells in the presence 
of excess of free RSI peptides, RSI liposome-mediated DXR delivery was significantly 
reduced indicating increased uptake specifically due to the RSI peptide. 
From the cytotoxicity experiments, it was observed 72 hours after treatment with 
DXR-RSI-liposomal nanocarriers that a large number of cells died. These data confirm 
that DXR payload was cellular uptake and not merely surface binding. DXR primarily 
kills cells by binding to topoisomerase II and disrupting the DNA base pairs during the 
cell cycle; the efo e, it i  impo t nt th t DXR  e che  the cell‘  inte io . Howeve , the 
mechanism by which RSI peptide facilitates cellular uptake is not known. The 
fluorescence micrograph images of 9L cells treated with DXR free liposomal 
nanocarriers presenting RSI peptide also confirm that the liposomal nanocarriers, indeed, 
reach the cytoplasm. 9L cells were also treated with free RSI peptide to rule out any 
cytotoxic effects of the peptide (data not shown). There were no differences found in the 
viability of the untreated cells and the cells treated with free RSI peptide. This result 
argues that cytotoxicity was medicated by DXR and RSI peptides.  
In the survival studies, we failed to observe an improvement in survival of tumor 
bearing animals compared to non targeted formulations. We followed these animals with 
a second dose. There was overall improvement in survival due to multiple doses. 
However, the presence of the 9L tumor binding peptide (RSI) did not have any effect on 
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the survival of tumor bearing mice receiving liposomal doxorubicin. Such outcome could 
be attributed to a number of factors.  
It is likely that the 9L tumor cells may have changed in vivo compared to their 
phenotype in vitro. Therefore, the binding of the RSI peptide to the tumors would be 
affected and the peptide presenting liposomes would be then similar to non-targeted 
liposomes in their outcome. In vivo environment is significantly different than what can 
be replicated in vitro. The RSI peptide could have been competed out by other peptides 
and proteins in the microenvironment of the tumor cells, in turn, leading to less liposomal 
uptake of the RSI targeted liposomes.  In comparison to folate targeting liposomes that 
binds 9L cells about 18 times more than non-targeted liposomes, RSI-peptide presenting 
liposomes were about 3.5 times better than non-targeted liposomes in vitro. The gain seen 
in vitro may have been in significant in vivo, and several doses needed to be administered 
before a therapeutic difference could be registered. Alternatively, it is likely that once 
extravasated, the liposomes do not penetrate far into the tumor tissue.  Liposomes are big 
particles and interstitial diffusion is limited. Presence of targeting moieties, therefore, 
may not be useful in solid tumors due to limited diffusion of liposomal particle.  
3.6 Conclusions 
One potential advantage of the approach employed here is in rapid identification 
of    pecific peptide fo    p tient‘  tumor. The phage identified RSI peptide for 9L 
gliomas in this study is an example of a technique that can be extended to tumor lines of 
any kind. The rationale for using a rat glioma line was to enable us to test nanocarrier 
targeting in an immune-competent animal where the RES is capable of detecting and 
eliminating drugs from the body. The non-improvement in survival of tumor bearing 
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animals should not necessarily discredit the strength of the technique, reported here, in 
being able to personalize treatment for solid tumors.  
Using the phage display technique, a variety of peptides could be identified at the 
same time for use as targeting moieties. This could lead to the development of a 
nanocarrier system with high avidity and selectivity for tumors without compromising 
tumor dosing due to decreased passive accumulation. 
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CHAPTER 4  
SYNERGISTIC APPLICATION OF GOLD NANORODS 
AND THERMALLY SENSITIVE LIPOSOMES FOR SOLID 
TUMORS 
4.1 Introduction 
Nanocarriers have become popular in delivering therapeutics primarily due to 
their ability to shield the drug and prevent unwanted tissue exposure. Nanochemotherapy 
benefits from effectively evading the reticulo-endothelial system (RES) and delivering 
high payloads of the drug at the tumor site compared to healthy tissue [1-2]. Liposomes 
are long circulating [3] and are the only nanochemotherapeutics approved for clinical use 
by FDA. Their long circulation enables increased passive accumulation in the tumor due 
to enhanced permeation and retention effect. However, once extravasated, nanocarriers 
accumulate close to the blood vessels and further tissue diffusion is limited [4]. In 
addition, the release of the drug from these nanocarriers, once extravasated, is very slow 
[5]. Since their discovery, much research has been conducted to improve liposomal 
nanocarrier delivery for higher drug payloads by incorporating targeting ligands or 
triggering content release at the specific site. Targeted systems require tumor specific 
ligand identification. In addition, such liposomes, after extravasation, are trapped by the 
cells close to the endothelium and suffer deeper tissue penetration [6]. Several triggered 
release systems have been fabricated including triggers like pH, light, enzymes, and heat. 
However, the stability of such systems in the blood circulation remains a challenge [7]. In 
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turn, the intrinsic characteristics of liposomal nanocarriers for protecting the drug and 
reducing systemic toxicity are lost.  
Much effort has been made to optimize the composition of triggerable 
nanoparticle systems without much success. Thermosensitive liposomes have been 
investigated for controlled drug delivery [8]. However, the traditional methods used to 
trigger the release of the drug from the liposomes lead to exposure of healthy tissue to 
chemotherapeutics. In addition, these methods also expose healthy tissue to hyperthermic 
temperatures and can only be used effectively for peripherally located tumors. 
Development of a remote triggering mechanism can help control the release of the drug 
from the liposomes. Recently, there has been advancement in the field of photothermal 
hyperthermia mediated by laser light, particularly near infrared (NIR). To this effect, 
noble metal nanoparticles are very useful for photothermal therapy due to their enhanced 
absorption and non-bleaching characteristic. Plasmonic nanoparticles exhibit strong 
absorption in visible as well as NIR due to surface plasmon resonance oscillations [9-12]. 
Gold nanorods (GNRs) are particularly attractive as they can be tuned to absorb in the 
NIR region that enables their use in biological tissue. NIR light has been reported to have 
a penetration depth of up to 10 cm [13]. As described earlier, GNRs can accumulate 
specifically in tumor tissue due to EPR effect [14]. Use of GNRs, therefore, enables 
noninvasive and spatially controlled heating of desired tissue. By optimizing the shape 
and amount of the GNRs administered and the power of the laser, one can achieve precise 
and controlled temperature increase.  
In this study, we explored the possibility of formulating a relatively plasma stable 
thermosensitive liposomal formulation to reduce systemic toxicity. We employed GNRs 
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to noninvasively and spatially trigger the release of the chemotherapeutic drug from the 
thermosensitive liposomes after their passive accumulation in the tumor. In doing so, we 
were able to achieve control over drug release at the desired site. The synergistic 
application of GNRs with thermosensitive liposomes led to increased therapeutic 
efficacy. 
4.2 Materials and Methods 
4.2.1 Materials 
1,2-distearoyl-sn-glycerophospho-choline (DSPC), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) and 1,2-distearoyl-sn-glycerophosphoethanolamine 
poly(ethylene glycol)2000 (DSPE-PEG2000) were purchased from Genzyme 
Pharmaceuticals (Cambridge, MA). Cholesterol, paraformaldehyde, and Triton X-100 
were purchased from Sigma (St. Louis, MO).  Dialysis tubing (10,000 and 100,000 
molecular weight cut-off) was purchased from Spectra/Por (Dominguez, CA). U87-MG 
human glioma cell line was purchased from American Type Culture Collection 
(Manassas, VA).  DMEM and trypsin-EDTA (0.05% trypsin, 0.53 mM EDTA) in H nk ‘ 
balanced salt solution was purchased from Mediatech (Manassas, VA).  Doxorubicin 
(DXR) was purchased from Bedford Labratories (Bedford, OH).  Cell Counting Kit-8 
(CCK-8) was obtained from Dojindo (Kumamoto, Japan). Nu/nu mice were purchased 
from Charles River Laboratories International, Inc. (Wilmington, MA).  
4.2.2 Cell Culture 




4.2.3 Liposome Preparation 
Liposomal nanocarriers were formed as described earlier [15-16]. Briefly, x: 97-
x:3 DPPC/DSPC/PEG or a ratio of 57-x:40-x:3 of DPPC:Cholesterol:DSPE-PEG2000 or 
57:3:30:3 DPPC:DMPC:Cholesterol:DSPE-PEG2000 was used to identify a 
thermosensitive formulation. A non-thermosensitive stealth liposomal formulation of 
DPPC:Cholesterol:DSPE-PEG2000 in the ratio 57:40:3 respectively (NTSL) was used as 
control in all in vivo studies. The lipid mixture was dissolved in 1ml of ethanol at 60
o
C.  
Liposome size was determined by dynamic light scattering (Particle Size Analyzer, 
Brookhaven Instruments, Holtsville, NY).  Liposomal nanocarriers were dialyzed against 
a phosphate-buffered saline solution to establish an ammonium sulfate gradient for DXR 
loading. 
4.2.4 Active Loading of Doxorubicin 
Following ligand incorporation, liposomal nanocarriers were loaded with DXR 
via the ammonium sulfate gradient as described before [17].  Briefly, liposomal 
nanocarriers and 5 mg/ml DXR solution in 0.9% saline were mixed at a ratio of 0.1 mg 
DXR per 1 mg of phospholipid in the liposomal nanocarriers. The liposome/DXR 
suspension was heated at 45 °C for 30 minutes. The liposomal nanocarriers were then 
cooled immediately on ice and dialyzed in 100 000 MWCO membrane against PBS to 
remove un-encapsulated DXR. The formulations were sterilized by passing through a 0.2 
m filter. The final DXR concentration after dialysis was determined by lyses of the 
liposomal nanocarriers with 5% Triton X-100 and measurement of absorbance at 480 nm. 
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4.2.5 Liposomal Leak Studies 
Liposomal DXR was diluted to a final concentration of 1 µg/ml in 50% FBS 
solution and heated in circulating water bath at 37°C for 24 hours. The samples were 
placed in water bath at 43°C for 10 minutes in order to quantify drug release and then 
transferred back to the water bath at 37°C. 24 hours later all samples were analyzed for 
the amount of drug released. 100% release was the intensity after the addition of 
detergent Triton X-100, while 0% (no release) was the intensity measured for 50% FBS 
solution [18]. DXR intensity was measured at 485/590 excitation and emission 
wavelength in a spectrophotometer. 
         
                                          
                                           
 
where T = time 
4.2.6 In vitro Cell Cytotoxicity Studies 
U87-MG glioma cells were seeded at a density of 2x10
4
 cells per well of a 24-
well plate and incubated for 48 hours prior to incubation with liposomal nanocarriers. 48 
hours later, liposomal formulations were mixed with cell media to a different doxorubicin 
concentration and added immediately to cells.  





C and 5% CO2 in a humidified environment. All wells were then incubated at 37
o
C for 
additional 4 hours. Cells were then washed three times with fresh medium and re-
incubated for 72 hours. The numbers of viable cells were determined with a water soluble 
formazan-based assay (CCK-8). 
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4.2.7 In vivo Therapeutic Studies 
All animal studies were conducted under a protocol approved by the Institutional 
Animal Care and Use Committee (IACUC) at Georgia Institute of Technology.  For the 
tumor model, the U87-MG human glioma cell line was used. A 100 µL aliquot 
containing 2x10
6 
cells was subcutaneously injected using a 26-gauge needle into the right 
shoulder of 6-8 weeks old female nude mice. Caliper measurements were used to 
estimate tumor size and the tumor volume was calculated as:  
       
     
 
 
where a and b are the maximum and minimum diameters respectively [19-20]  
When tumors were about ~45-75 mm
3
, animals were treated with a saline sham, 
TSL, NTSL liposomal DXR i.v. injections (10, 5, and 2.5 mg/kg doxorubicin) via tail 
vein with or without GNRs. Equivalent volumes of 0.9% sterile saline solution were 
administered to animals receiving sham injections. Tumor growth was allowed to 
progress until the tumors were 1.5 cm or showed signs of ulceration, at which point, 
interventional euthanasia was administered. Time of death was determined to be the day 
of euthanasia. 
4.2.8 In vivo Apoptotic Imaging 
All animals used for in vivo fluorescence imaging were fed Teklad 2916 
chlorophyll free diet for 10 days prior to imaging to reduce autofluorescence [21]. Tumor 
bearing mice, received 100 µl of Annexin-Vivo 72 hours after treatment administration. 
All animals were imaged using IVIS Lumina (Caliper Life Sciences, Hopkinton, MA). 
Images were acquired using the appropriate filter set at 2, 4, and 48 hours after 
administering the imaging agent.  
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For analysis, images were loaded together to normalize all images to one color 
scale. A region of interest (ROI) around the tumor was drawn and the fluorescence 
intensity was quantified for each time point. For comparison between groups, each 
 nim l‘  tumo  volume w   u ed to no m lize the fluo e cence inten ity pe  cubic 
millimeter of the tissue. Values obtained were then averaged for the respective group for 
statistical analysis.  
4.2.9 Statistical Analysis 
Means were determined for each variable in this study and the resulting values 
from each experiment were subjected to an analysis of variance (ANOVA) with Tukey 
post-hoc pairwise comparisons.  Significance was determined using a 95% confidence 





Figure 4.1. Release of DXR from liposomes. A) Liposomes with varying combinations of 
DSPC/DPPC and without cholesterol were formulated and and amount of DXR released after 24 
hours at 37 °C was quantified. B) Liposomes with varying cholesterol content were formulated and 
amount of DXR released after 24 hours at 37 °C was quantified. C) Liposomes comparable in 
stability to Doxil were selected from B) and C). After 24 hours at 37 °C, liposomes were transferred 
to higher temperature of 43 °C and DXR release was quantified indicated by brown bars () and 
almost all formulations failed to show a burst release. D) Small amount of DMPC was added to 
DPPC liposomes in order to achieve thermosensitivity. DPPC/30%Chol/3%DMPC/3%PEG showed 
comparable stability after a 24 hour period at 37 °C to Doxil and was able to show significant amount 
of DXR release upon heating. After heating at 43 °C, liposomal formulations were transferred back 
to 37 °C water bath and their release was quantified after another 24 hours indicated by white bars 
(□). Doxil still carried DXR very stably. In contrast, DPPC/30%Chol/3%DMPC/3%PEG (TSL) 
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Figure 4.2. TEM image of negatively stained TSLs. Scale bars are 200 nm. 
 
4.3 Results and Discussion 
4.3.1 Controlled Release of Chemotherapeutic Drug from Liposomes 
Thermosensitive liposomes reported in the literature suffer from excessive drug 
loss from the nanocarriers at physiological temperature in contrast to FDA approved 
Doxil composed of HSPC/39%Chol/3.1%PEG. Loss of drug at physiological temperature 
compromises passive drug accumulation in the tumor and increases systemic 
cytotoxicity. Several liposomal formulations were fabricated and tested for drug 
encapsulation stability at physiological temperature and release at 4-5 ˚C elevated 
temperature. Liposomes were diluted at 1 µg/ml in 50:50 mixtures of FBS/PBS [18]. 
Liposome aliquots were heated at various temperatures and times and the fluorescence of 
doxorubicin released from the liposomes was quantified to assess % drug released. It was 
found that DPPC liposomes, devoid of any cholesterol, rendered the liposomes highly 
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unstable and liposomes did not carry the drug stably over extended periods of time at 
physiological temperatures (Fig 4.1B). In 24 hours, DPPC liposomes lost more than 50% 
of the encapsulated DXR. DSPC liposomes, on the other hand, do not release any DXR at 
37 ˚C, which could be attributed to the fact that they have very high transition 
temperature of 55 ˚C preventing leakiness.  Addition of varying amounts of DPPC to 
DSPC liposome did not affect their stability, but DXR was also not released from these 
formulations upon heating at 43 ˚C (fig. 4.1C). These results are in contrast to earlier 
reports where calcein was reported to be released from such liposomes at a temperature 
of 37-45 ˚C [22]. The differences can be attributed to the fact that calcein that is passively 
loaded is easier to release upon heating. However, a remotely loaded drug like DXR is 
more difficult to release. DXR, upon remote loading is trapped inside the liposomes as 
precipitates of the sulfate. The slight increase in release of DXR upon heating to 43 ˚C, in 
the case of DPPC/DSPC liposomes, could be due to increase in DXR solubility in 
comparison to its solubility at 37 ˚C. Increase in DXR solubility may enable its outward 
movement recorded as released DXR. Therefore, it can be concluded that every 
thermosensitive formulation needs to be optimized for the chemotherapeutic drug of 
choice. DPPC liposomes were also fabricated by inclusion of varying amounts of 
cholesterol (fig 4.1B). It was found that 30% cholesterol in DPPC liposomes results in 
very small loss of DXR over a 24 hour period at 37 ˚C. However, these liposomes, also, 
do not exhibit any thermosensitivity at 43 ˚C, which is higher than DPPC phase 
transition. Cholesterol, therefore, has a stabilizing effect on DPPC membrane as shown 
here and in earlier reports [23]. As shown in fig 4.1C, it was found that inclusion of 30% 
cholesterol and small amounts (3%) of very low transition temperature (23 °C) lipid 
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DMPC resulted in a liposome (DPPC/30%Chol/3%DMPC/3%PEG, TSL) that would 
carry its content stably at physiological temperature and released DXR at 43 ˚C when 
heated for 10 minutes. Reduction of cholesterol to 25% in these liposomes reduced their 
stability at 37 ˚C. It was also seen that after heating for 10 minutes and placing TSLs 
back in 37 ˚C for another 24 hours resulted in complete loss of DXR from these 
liposomes (fig 4.1D). Such a characteristic could be very useful in causing the liposomes 
to lose their contents quickly after reaching the tumor instead over a period of time. TSLs 
were also heated for 10 minutes at various temperatures from 37 °C to 45 °C to determine 
the maximum release temperature. For all further release studies, TSLs were heated at 43 
°C. Fast release of the chemotherapeutic can result in better bioavailability of the drug 
and higher apoptosis rate as is explained later in this report. For further therapeutic 
studies, DPPC/30%Chol/3%DMPC/3%PEG was chosen as the thermosensitive liposomal 
formulation for its better stability over other formulations and ability to release drug at 
elevated temperatures. 
4.3.2 In vitro Cytotoxicity Studies 
Cytotoxicity of TSL formulation was determined by evaluating cell viability to 
ensure that the extent of DXR release at 43 ˚C was cytotoxic in comparison to NTSL (fig. 
4.3). Untreated cells remained unaffected by temperature change with the viability of 
cells being at 100%. Cells exposed to empty liposomes (NTSLs or TSLs) also did not 
show change in viability at either temperature. Cell viability, also, remained unaffected 
upon treatments with NTSLs, did not depict any significant change due to change in 
temperature and exhibited approximately 70-90% viability under all conditions (fig. 4.3). 
TSLs, however, demonstrated a significant increase in cytotoxicity over NTSLs at 43 ˚C 
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(p < 0.001) at all DXR concentrations confirming the release of DXR from TSLs, and 
thereby, the cytotoxic effect at higher temperature. Free DXR depicted an LC50 at 10 
µg/ml DXR concentration. TSLs did not show an increase in cytotoxicity at 37 ˚C and the 
results were comparable to cells treated with NTSLs. However, at 43 ˚C TSLs depicted 
























Figure 4.3. In vitro heat mediated cell cytotoxicity of liposomal formulation. Cells were treated with 
free DXR, non thermosensitive liposomes (NTSL), or thermosensitive liposomes (TSL) with varying 
DXR concentrations at A) 37 ˚C or B) 43 ˚C. Cell cytotoxicity was measured by modified MTT assay 
(CCK8). Cells treated with TSL showed significant increase in cytotoxicity at 43 ˚C in comparison to 
NTSL (**p < 0.01, or ***p < 0.001) at all DXR concentrations. TSL were significantly cytotoxic at 43 





































































Figure 4.4. Therapeutic efficacy. Nude mice were injected with 2x10
6
 U87-MG. A) Schematic of 
treatment administration and in vivo imaging. B) Relative tumor volume after treatment 
administration in different groups (n = ~6-9) was measured everyday for the first 10 days and every 
other day after day 10. Mice received either liposomal DXR (2.5 mg/kg) or saline in combination with 
GNRs at 5 pmol/kg of rods. 48 hours later, mice received NIR irradiation with a laser (808 nm, 0.5 
W/cm
2
) for 10 minutes. TSL + GNR + NIR were significantly different from the saline groups (day 6-
17, p <0.001). Animals that were treated with TSL + GNR + NIR were significantly different from all 
other liposomal treatment groups (day 19-26, p < 0.001). Data represented is mean ± S.E.M. C) 
Absolute tumor volumes for various treatments. Data represented is mean ± S.E.M. D) Percent 
survival for different treatments groups (n = ~6-9). Mantel-Cox analysis indicated that TSL + GNR + 
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4.3.3 In vivo Drug Studies 
Further, to assess the cytotoxic effect and therapeutic efficacy of the TSL 
triggered via GNRs in NIR, we used a xenograft mouse model of human glioma U87-
MG. In this study, we co-injected the liposomal drug and GNRs and waited for 48 hours 
to heat the tumors. In doing so, we wanted to assess the capability of the GNRs in 
disrupting the liposomes in vivo, as well as, compare the effect of burst release of the 
drug from the nanaocarriers to drug being released from non-disruptable nanocarriers for 
long periods of time after passive accumulation. Animals received liposomal DXR or 
saline +/- GNR (fig. 4.3A) when the tumor size was ~4-6 mm. The average temperature 
recorded using a thermo-probe in all animal tumors heated via GNRs was 43 ± 1˚C. All 
animal tumors that did not receive GNRs but were irradiated with NIR recorded an 
average of 39 ± 1˚C. The basal temperature of tumors before NIR irradiation was 34-
35˚C primarily due to loss of heat as animals were anesthetized for NIR irradiation. 
We found that GNR mediated heating of TSL was highly effective in suppressing 
tumor progression. As seen in fig. 4.3B, animals that received TSL + GNR + NIR did not 
show increase in the size of tumors up till day 21. All saline treated animals, in contrast, 
showed exponential increase in tumor size. All other liposomal treatments with or 
without GNR/NIR were also able to suppress tumors on an average till day 17. There was 
a significant difference in the ability to suppress tumors overall between TSL + GNR + 
NIR treatment and all other treatments (p <0.001). In addition, TSL + GNR + NIR 
treatment was successful in extending overall survival (median survival = 38 days, fig 
4.3C). In contrast, saline treated animals +/- GNR mediated heating did not show such 
pronounced effects with median survival of 17 days. Animals that received either NTSL 
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+/- GNR mediated heating or TSL +/- NIR, were also, less successful in prolonging 
survival in comparison to TSL + GNR + NIR treatment. All animals receiving liposomal 
DXR at 2.5 mg/kg showed significant tumor suppression in comparison to saline treated 
animals with or without GNRs mediated heating. In our studies, we tested 10 mg/kg and 
5 mg/kg DXR doses as well; however, animals did not tolerate these doses very well and 
were not further investigated. 
Increased animal survival indicates that GNR mediated heating results in 
increased bioavailability of DXR trapped in TSLs. The incapability of NTSL heated via 
GNRs in reducing tumor progression shows that the drug is not able to escape the 
nanocarrier. Therefore, the cytotoxic effects of the drug are also suppressed. It can be 
concluded that GNRs can be effectively used to remotely and locally trigger the release 
of the drug from nanocarriers, thereby, promoting drug distribution and bioavailability. 
To demonstrate the immediate effect of drug release from the nanocarriers on cell 
viability in vivo, we used Annexin-Vivo 750. Annexin injected 18 hours after NIR 
irradiation was able to bind to apoptotic cells and reveal information about immediate 
cell death induced by drug release. 
4.3.4 Apoptosis Imaging 
In vivo fluorescence imaging provides inexpensive and rapid assessment of real-
time biological processes [24-25] in contrast to MRI or histological techniques. To assess 
the short term effect of various drug treatments, we measured and quantified the extent of 
apoptosis at the tumor site using an in vivo fluorescence modality. Apoptotic agent 
Annexin-Vivo (excited at: 740, and emission collected at: 780 nm) was administered 18 
hours after the tumors were heated via NIR (see fig 4.3A). Imaging conducted at 2, 4 and 
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24 hours post annexin administration, fluorescent signal was quantified for each animal, 
and normalized by their respective tumor volume determined via calipers to obtain a per 
cell apoptosis intensity. A signal enhancement was found at all time points for animal 
tumors that received TSLs and were heated via GNRs using NIR. Tables 4.1 and 4.2 
show the average increase in signal quantified per millimeter cube and the related 
statistics respectively. Enhancement in signal intensity can be attributed to increase in 
annexin binding at the tumor site. At 24 hours, when all treatment groups showed 
reduction in annexin intensity, in comparison, TSL + GNR + NIR group showed the 
maximum fluorescent signal per cubic millimeter indicating retention of annexin at the 
tumor after clearance of annexin from the blood pool (fig 4.6A and fig 4.5). Annexin 
clearance could be easily detected through the kidneys as the fluorescence recorded in 
this area was much higher than the tumor. As a result, the CCD was flooded with photons 
from the kidney area and could not detect differences in the tumor apoptosis in uncovered 
animals. Therefore, animals had to be covered with a black paper to cover the kidneys 
and reveal the differences in the annexin accumulation in the tumors. 
Apoptosis imaging can be used as a powerful tool to assess the success of a 
treatment in suppressing the tumor. When comparing the survival of the animals to the 
fluorescent intensity obtained at 24 h, we find that the fluorescence intensity is somewhat 
indicative of the length of survival (fig 4.6B). The graph is segmented into two distinct 
areas with animals surviving less than 30 days showing lower signal intensity and 
animals above 30 day showing much higher signal intensity. The correlation is somewhat 
independent of the type of treatment. All saline animals, although, showed much lower 
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signal intensity. The correlation co-efficient was 0.4998, and hence, apoptosis imaging in 
this study cannot be reliably used as a predictor of survival. 
Table 4.1.  Fluorescence intensity per cubic millimeter obtained for 2, 4, and 24h time in vivo 
apoptosis imaging for different treatment groups. 
 
2h 4h 24h 
FI p/s/mm3 Mean S.D. Mean S.D. Mean S.D. 
Saline 3.59E+06 5.11E+05 2.66E+06 6.40E+05 1.27E+06 9.01E+05 
Saline + GNR + NIR 3.07E+06 8.73E+05 3.09E+06 1.58E+06 1.72E+06 7.85E+05 
NTSL 2.01E+06 5.15E+05 4.60E+06 2.79E+06 1.79E+06 1.16E+06 
NTSL + GNR + NIR 2.76E+06 5.35E+05 5.44E+06 3.30E+06 1.50E+06 1.17E+06 
TSL + GNR 2.61E+06 5.20E+05 4.49E+06 3.05E+06 2.09E+06 1.55E+06 
TSL + NIR 2.17E+06 4.73E+05 4.00E+06 3.00E+06 1.96E+06 1.56E+06 
TSL + GNR + NIR 8.35E+06 3.59E+06 9.13E+06 4.08E+06 5.49E+06 2.12E+06 
 
Table 4.2. Bonferroni statistical comparison between TSL + GNR + NIR and different treatment 
groups for 2, 4, and 24h time in vivo apoptosis imaging. 
 
Saline 
Saline + GNR + 
NIR NTSL 
NTSL + GNR + 
NIR TSL + GNR TSL + NIR 
2h p < 0.05 p <0.01 p <0.001 p <0.01 p <0.001 p <0.001 
4h p <0.001 p <0.001 p <0.001 p <0.01 p <0.001 p <0.001 












































































Figure 4.6. In vivo apoptosis imaging shows higher accumulation and retention of apoptosis marker 
Annexin-Vivo 750. A) Different groups of tumor bearing animals, 18 h post NIR irradiation, were 
administered Annexin-vivo 750 i.v. and were imaged at 2, 4, and 24 hours. Fluorescence intensity 
(FL) acquired in photons/s was quantified by drawing a region of interest around the tumor. The 
resulting flux was then normalized by each animal’s tumor volume measured using calipers. Animals 
treated with TSL+GNR+NIR were significantly different from all other groups at all time points (2h 
*p <0.05, 4h & 24h **p <0.01, at the least for all groups). B) Correlation of apoptosis quantification 
obtained from imaging to animal survival at 24h (n = ~4-6). The survival time is somewhat correlated 
to the apoptosis seen from in vivo imaging.  







Saline + GNR + NIR
TSL + GNR
TSL + NIR
NTSL + GNR + NIR
NTSL



































Saline + GNR + NIR
NTSL
NTSL + GNR + NIR TSL + NIR




























In this report we identified a thermosensitive liposomal formulation that can 
stably carry DXR in the plasma over a period of 24 hours and release its contents when 
heated at 43 °C. We used GNRs to heat this TSL formulation remotely in an in vivo 
xenograft model. The GNRs were highly effective in releasing the DXR from TSLs as 
was seen from increased survival of animals receiving TSLs heated via GNRs. The 
synergistic effect of GNRs and TSL in this study proves the principle that liposomes can 
be disrupted remotely and can be, especially, useful in treating tumors without the toxic 
exposure of the chemotherapeutic to surrounding normal tissue. The combination can 
provide a strong tool in increasing the effects of a chemotherapeutic. As demonstrated 
earlier, such a combination can also be used to increase the accumulation of the 
chemotherapeutic in the tumor region [14, 26]. In this study, we demonstrated that when 
same amount of liposomal drug accumulates passively in a tumor, the effect of release of 
the chemotherapeutic from a nanocarrier is much more beneficial than the drug being 
slowly released from the nanocarrier over time. Using GNRs to cause higher drug 
accumulation at the tumor site and then using a second NIR pulse to disrupt the 
liposomes may significantly enhance the effects of chemotherapy and reduce the overall 
drug administered systemically.  
The major drawback of thermally induced triggered release therapy is that it 
requires the localization of the tumor. In case of metastatic tumors, this can be a 
disadvantage to using thermally triggered liposomes for chemotherapy. Using GNRs may 
allow for non invasive tracking of tumor using optical coherence tomography and 
photoacoustic tomography [27]. Using the approach, described here, for remote 
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disruption of liposomes with GNRs can allow for tracking of tumor in vivo and following 
up with thermally destabilizable liposomal chemotherapy. The study presented here is a 
proof of principle that remote triggering of thermosensitive liposomes is achievable and 
allows for point specific treatment.  
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CHAPTER 5  
REMOTE TRIGGERED RELEASE OF LIPOSOMES IN A 
RODENT BRAIN TUMOR MODEL 
 
5.1 Introduction 
Passively accumulated long circulating liposomes, after extravasation, exhibit 
very slow release, hence, not enough therapeutic efficacies [1]. In addition, delivery of 
liposomes to solid tumors is limited by elevated interstitial pressures and inability to 
diffuse beyond the perivascular space [2]. The ideal chemotherapeutic liposome should 
be able to retain the drug, evade the RES, target the tumor, and release the drug within 
the tumor [3]. Many efforts have been directed towards triggered release in response to a 
specific stimulus at target site. To obtain controlled release, the carrier/drug relationship 
must change from the stable state for carrying drugs in the circulation, to rapid instability 
to release the drug at the tumor site. In the late 1970s, Yatvin et al. proposed the use of 
pH sensitive and thermosensitive liposomes to trigger this change. However, when 
fabricating triggerable liposomes, the ability of such liposomes to carry their payload 
stably in the circulation is compromised.  
In chapter 4, we fabricated stable thermosensitive liposomes that would enable 
rapid drug release at the tumor site. In addition, we administered gold nanorods to a 
xenograft model of human U87-MG gliomas to achieve point specific heating. In this 
chapter, we substitute the chemotherapeutic with a water soluble dye ADS645WS in the 
thermosensitive liposomes and co-administer it with the gold nanorods in an orthotopic 
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brain tumor model. We show that the gold nanorod mediated disruption of the liposomes 
enables enhanced distribution of the dye in the tumor. Therefore, disruption of liposomes 
with GNRs is achievable and beneficial for rapid drug distribution. 
5.2 Materials and Methods 
5.2.1 Materials 
1,2-distearoyl-sn-glycerophospho-choline (DSPC), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) and 1,2-distearoyl-sn-glycerophosphoethanolamine 
poly(ethylene glycol)2000 (DSPE-PEG2000) were purchased from Genzyme 
Pharmaceuticals (Cambridge, MA). Cholesterol, paraformaldehyde, and Triton X-100 
were purchased from Sigma (St. Louis, MO).  Dialysis tubing (10,000 and 100,000 
molecular weight cut-off) was purchased from Spectra/Por (Dominguez, CA). A 9L 
glioma cell line was received as a generous donation from the Neurosurgery Tissue Bank 
at UCSF.  U87-MG human glioma cell line was purchased from American Type Culture 
Collection (Manassas, VA). Minim l e  enti l medium cont ining E  le‘  b l nced   lt 
solution (MEM/EBSS) was purchased from Hyclone (Logan, UT). ( Gentamicin (50 
mg/ml) and fetal bovine serum (FBS) were obtained from Gibco (Carlsbad, CA).  
DMEM and trypsin-EDTA (0.05% trypsin, 0.53 mM EDTA) in H nk ‘ b l nced   lt 
solution was purchased from Mediatech (Manassas, VA).  Heparin (1000 USP units/ml), 
isoflurane, and doxorubicin (DXR) were purchased from Baxter Healthcare (Deerfield, 
IL).  Fisher 344 male rats were purchased from Harlan (Indianapolis, IN) and nu/nu mice 
were purchased from Charles River Laboratories International, Inc. (Wilmington, MA).  
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5.2.2 Cell Culture 
9L glioma cell line was maintained in MEM/EBSS medium supplemented with 
10% fetal bovine serum and 0.05 mg/ml gentamicin.  Cells were passaged by 
trypsinization and washed with growth medium.  
A 9L gliom  cell line t  n fected with the b cte i l β-galactosidase encoding 
gene, LacZ, was maintained in MEM/EBSS medium supplemented with 10% fetal 
bovine serum and 0.05 mg/mL gentamicin. 
5.2.3 Liposome Preparation 
Liposomal nanocarriers were formed as described earlier [4-5]. Briefly, a ratio of 
54:3:30:3 of and DPPC:DMPC:Cholesterol:DSPE-PEG2000 to fabricate thermosensitive 
stealth liposomes (TSL). A non-thermosensitive stealth liposomal formulation (NTSL) of 
DPPC: cholesterol: DSPE-PEG2000 in the ratio 57:40:3 respectively was also formulated 
for plasma clearance studies. The lipid mixture was dissolved in 1mL of ethanol at 60
o
C.  
Liposome size was determined by dynamic light scattering (Particle Size Analyzer, 
Brookhaven Instruments, Holtsville, NY).  For dye loaded liposomes, a 12 mg/ml 
solution of ADSWS645 in 0.9% saline was used to hydrate the liposomes after 
dissolution in ethanol. Following extrusion, extra dye was removed from the external 
phase by dialysis. Liposomal nanocarriers were dialyzed against a phosphate-buffered 
saline (PBS) solution to establish an ammonium sulfate gradient for DXR loading for 
plasma clearance studies. 
Liposomal nanocarriers were actively loaded with DXR via the ammonium 
sulfate gradient published previously [6].  Briefly, liposomal nanocarriers and 5 mg/ml 
DXR solution in 0.9% saline were mixed at a ratio of 0.1 mg DXR per 1 mg of 
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phospholipid in the liposomal nanocarriers. The liposome/DXR suspension was heated at 
45 °C for 30 minutes. The liposomal nanocarriers were then cooled immediately on ice 
and dialyzed in 100 000 MWCO membrane against PBS to remove un-encapsulated 
DXR. The formulations were sterilized by passing through a 0.2 m filter. The final DXR 
concentration after dialysis was determined by lysing liposomal nanocarriers with 5% 
Triton X-100 and measurement of absorbance at 480 nm. 
5.2.4 Liposomal Leak Studies 
Liposomal dye ADS645WS was diluted to a final concentration of 1 µg/ml in 
50% FBS solution and heated in circulating water bath. Samples were analyzed for the 
amount of dye released. 100% release was the intensity after the addition of detergent 
Triton X-100, while 0% (no release) was the intensity measured for 50% FBS solution. 
ADS645WS intensity was measured at 645/670 excitation and emission wavelength in a 
spectrophotometer. For stability and triggered release studies, samples were heated in 
circulating water bath at 37°C for 24 hours. Samples were then placed in water bath at 
43°C for 10 minutes in order to quantify drug release and then transferred back to the 
water bath at 37°C. 24 hours later all samples were analyzed for the amount of drug 
released. 
         
                                       
                                        
 
where t = time 
5.2.5 Plasma Clearance 
All animal work was done according to an approved animal protocol and in strict 
compliance with NIH Clinical Center Animal Care and Use Committee guidelines and 
117 
 
regulations. 10-11 weeks old female Fisher rats weighing ~200g were anesthetized and 
maintained using isoflurane and administered DXR-NTSL nanocarriers (n=4) or DXR-
TSL nanocarriers (n=4) via tail vein at a dose of 8 mg/kg DXR.  500 µl of blood was 
collected from the orbital sinus before IV injection and at 0.5, 2, 9, 24, 48, and 72 hours 
after injection in heparinized gel tubes.  Tubes were centrifuged at 3000 rpm for 20 
minutes to separate the plasma.  Liposomal nanocarriers were lysed according to an 
established protocol [7]. Briefly, a mixture of 0.75N acidified isopropanol, 10% Triton-
X100, water, and plasma was prepared to analyze the DXR content.  To quantify total 
DXR content, fluorescent readings were obtained using a fluorescence spectrometer at 
excitation/emission of 485/590 nm. Plasma samples obtained prior to injection were used 
to correct for background fluorescence.  
5.2.6 Tumor Inoculation 
 A rat glioma model was established by orthotopic inoculation of 1 x 10
6
 9L/LacZ 
glioma cells following modified version of established methods [8]. Briefly, a dental drill 
was used to create a 2 mm hole at a position 1mm lateral and 1mm anterior to the 
bregma, with a custom trephine. The bone plug was carefully removed. A 26 gauge 
needle w   in e ted into the f ont l lobe  t   depth of 3mm to inject 10μl of the gliom  
cell suspension (1 x 10
6
 cells). The cells were slowly injected over a period of 
approximately 30 seconds. Following injection of the cell suspension, the needle was 
slowly retracted over a period of approximately one minute to prevent backflow. The 
wound was, then, closed with suture (4.0). Animals were administered buprenorphine 
0.03 mg/kg SC to alleviate pain as needed.  
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5.2.7 Heating via Gold Nanorods 
At day 7 after tumor implantation, animals were intravenously injected with gold 
nanorods (courtesy of Dr. El-Sayed) through the tail vein. At this time the tumors were 
large enough to be seen visually. 48 hours after the injection, the animals were 
anesthetized with 50, 10 and 1.67 mg/kg respectively of ketamine/ xylazine/ 
acepromazine. A 33 gauge hypodermic thermocouple (Omega) 10 mm long was inserted 
into the tumor to measure the temperature rise at the tumor. Animals were then irradiated 
with NIR radiation and the power of the laser was varied till desired heating was 
obtained. The concentration of GNRs injected was varied, in order to determine the 
optimal heating. A temperature profile was obtained as a function of time. 
5.2.8 Flow Cytometric Studies 
Animals were allowed to recover from surgery, and 10 days later, saline sham, 
Stealth non-thermosensitive, or thermosensitive liposomal ADS645WS (2 mg/kg 
ADS645WS; ~70 mg/kg lipid) treatments were administered with or without 2.25 
pmol/kg GNR i.v.  After 48 hours, animals were subjected to NIR for 10 minutes each as 
described above.  Animals were anesthetized with 5% isoflurane 24 hours later and 
decapitated immediately.  Tumors were dissected from explanted brains, mechanically 
fragmented, and treated for 60 minutes at 37C with a solution of collagenase (0.1 U/ml 
PBS) and dispase (0.8 U/ml PBS) to dissociate cells.  The cell solution was re-suspended 
in 4% fetal bovine serum in PBS and treated with a FluoReporter
®
 lacZ flow cytometry 
kit.  Tumor cells expressing the lacZ reporter gene product, beta-galactosidase, 
hydrolyzed the fluorogenic beta-galactosidase substrate allowing fluorescent detection of 
expression to distinguish tumor cells from non-tumor cells. Flow cytometry was 
119 
 
conducted using a Becton-Dickinson DLSR digital flow cytometer equipped with a 488 
nm excitation laser using the APC channel for detection of liposomal ADS645WS and 
the FITC channel for tumor cell (lacZ) detection.  Liposome uptake by lacZ+ (tumor) 
cells and lacZ- (non-tumor) cells were then quantified.  Tumor cells obtained from saline 
treated animals served as a negative control for ADS645WS while untransfected 9L 
glioma cells stained with the FluoReporter
®
 lacZ flow cytometry kit were utilized as a 
negative control for lacZ staining.   
5.2.9 Statistical Analysis 
Means were determined for each variable in this study and the resulting values 
from each experiment were subjected to a one way analysis of variance (ANOVA) with 
Tukey post-hoc pairwise comparisons.  Significance was determined using a 95% 
confidence level. For plasma clearance, a biphasic curve was fitted to the experimental 
data and groups were compared by a two way ANOVA. Half lives were determined from 






Figure 5.1. Characterization of liposomes and GNRs. A) ADS645WS dye release in 50:50 FBS:PBS. 
TSL and NTSL liposomes were diluted to 1 μg/ml of dye and incubated in a 37 °C circulating water 
bath. Samples were measured for released dye from the liposomes at indicated time points. At 24 
hours, one sample for each liposomal formulation was transferred to a 43 °C water bath and 
incubated for 10 minutes. The liposomal dye released was measured and the sample was transferred 
back to the 37 °C water bath for another 24 hours, and dye released at this point was quantified. The 
release of the dye from TSL at 37 °C after 24 hours was slightly higher than NTSL. However, the 
release of the dye from TSL upon heating was significantly higher and continued to increase over the 
next 24 hours. B) Spectrum of GNRs used in this study. Peak wavelength was 818 nm. C) TEM image 
of PEG coated GNRs. Scale bars are 200 nm. 
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5.3 Results and Discussions 
5.3.1 ADS645WS Release from Liposomes 
TSL and NTSL were loaded with ADS645WS and compared for dye release at 37 
°C and 43 °C. Liposomes were diluted at 1 µg/ml in 50:50 mixtures of FBS: PBS. 
Liposome aliquots were heated at various times and the fluorescence of ADS645WS 
released from the liposomes was quantified to assess % dye released. As shown in fig. 
5.1, TSL exhibit similar stability to NTSL at 37 °C. However, when heated for 10 
minutes at 43 °C, TSLs were able to release significantly higher amount of dye in 
comparison to NTSL. In addition, further incubation for another 24 hours at 37 °C of 
liposomes heated at 43 °C, resulted in almost complete loss of dye from TSLs. In 
contrast, NTSLs retained about 50% of the dye.  
5.3.2 Controlled Heating of Tumors via Gold Nanorods 
Orthotopic tumor bearing Fisher rats were administered different concentrations 
of GNRs via the tail vein (2.25 pmol/kg-11.25 pmol/kg). 2 days later, animals were 
irradiated with NIR-light (~0.5 W/cm
2
, 808 nm) for a period of 10 minutes. Temperatures 
were recorded via a thermo-couple [9]. All animals receiving a dose of over 5 pmol/kg 
reached temperatures over 50 ˚C in less than 5 minutes of heating. The goal of this study 
was to determine a GNR dose that would limit the temperature rise to a maximum of 45 
˚C. We determined (fig 5.2B) that at a dose of 2.25 pmol/kg, desired temperature was 
attained and remained steady for 10 minutes of heating. 2.25 pmol/kg GNR dose was 





Figure 5.2. GNR mediated heating of brain tumors. A) Schematic representing the location of brain 
tumor implantation and the setup used for laser irradiation. B) Brain tumor bearing animals were 
either administered varying GNR concentrations and irradiated 48 hours later, as shown in A), with 
NIR. Animals that received 2.25 pmol/kg of GNR indicated a controlled and desired increase in 
temperature to 43 ± 1 °C. Control animals also showed slight increase in tumor temperature to 39 ± 1 
°C. After NIR removal, tumor temperature quickly returned to normal. 
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5.3.3 In vivo ADS645WS Dye Distribution 
To determine the ability to promote increased bioavailability and uptake of 
encapsulated contents delivered by TSL nanocarriers to tumor cells in vivo, we performed 
studies on brain tumor-bearing rats (9L/LacZ glioma model) receiving TSL encapsulating 
a fluorescent dye (ADS645WS) in combination with GNRs with or without NIR. Animal 
tumo   we e di  oci ted  nd  t ined fo  β-gal production, and analyzed through flow 
cytometry.  Cultured 9L/LacZ cells and nontransfected 9L glioma cells were stained and 
served as positive and negative controls, respectively, fo  β-gal production.  Cytometric 
detection of β-g l in the 9L/L cZ gliom  tumo   deline ted two popul tion  of cell , β-
g l+ (tumo  cell )  nd β-gal- (nontumo ) cell .  The β-gal- populations exhibited minimal 
ADS645WS staining intensity as percentage of the total population (TSL + GNR + NIR: 
1.0984 ± 0.573%, TSL + NIR: 1.016 ± 0.852%, TSL + GNR: 0.67125 ± 0.3433%) 
indicating that the uptake of liposomes by non-tumor cells was nominal.  The tumor 
population of cells obtained from animals receiving TSL + GNR followed up by NIR 
irradiation, demonstrated a significant increase in ADS645WS signal detected in the APC 
channel (Figure 5.3B).  In contrast, tumor cells obtained from the other treatment groups 
(TSL + GNR, TSL + NIR) showed comparably low uptake of the dye.  Frequency 
p ofile  of β-gal and dye signal intensity on two-dimensional graphs demonstrated an 
increase as well as a shift in the tumor cell population obtained from animals treated with 
TSL + GNR + NIR into the APC channel (Figure 5.4).  The percentage of tumor cells 
from these animals that demonstrated dye uptake (APC+/FITC+) was significantly 
(p<0.01) greater than that of other treatment groups. Specific increased uptake of dye 
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ADS645WS in vivo delivered by TSLs heated via GNRs is indicative of increased release 
of the dye from the liposomes as a result of point specific heating.   
Cytometric data allowed for quantitative analysis of the results obtained from 
treated animals (Table 5.1).  The shift in fluorescent intensity representing liposomal 
uptake per cell observed in the group TSL + GNR + NIR was significant compared to the 
remaining treatment groups.  Median ADS645WS fluorescence in tumor cells obtained 
from TSL + GNR + NIR was 1.9 times greater than that from other treatment groups.   
 
Table 5.1. Tumor associated median fluorescence intensity for ADS645WS released from liposomes. 
Data represented is Mean ±S.D. 
Treatment 
Tumor ADS645WS 
Median Signal Intensity 
TSL + GNR 1.245 ± 0.056 
TSL + NIR 1.268 ± 0.053 
TSL + GNR + NIR 1.912 ± 0.215 *** 
 ***p <0.0001 
 
The above results verify that GNRs are successful in disrupting the tumor 
accumulated thermosensitive liposomes in vivo.  The liberation of the dye from the 
liposomal nanocarriers significantly increased the number of cells stained by the dye as 
well as the intensity measured per tumor cells of the dye. The increase in dye uptake 
could be attributed to increased diffusion due to small size of the dye in contrast to the 
liposome. The relatively low level of dye uptake by host cells also shows that GNRs can 
be effectively heated remotely by NIR, and can successfully be used locally to disrupt the 





Figure 5.3. In vivo dye distribution quantified by flow cytometry. A) Representative image showing 
the distribution of tumor cells (β-gal positive) in the APC channel indicative of ADS645WS dye 
staining. In contrast to TSL + GNR and TSL + NIR, TSL + GNR + NIR showed shift towards 
ADS645WS staining. Controls were β-gal positive tumors explanted from animals that did not 
receive any ADS645WS dye. B) ADS645WS stained cells normalized again unstained control cells 
were quantified for each group. For each animal, % of tumor cells that were positive for ADS645WS 
was determined (n = 6, for all groups). Animals that were treated with TSL + GNR + NIR showed 
significantly better staining of the tumor cells (**p <0.01) between all groups. Data represented in 








































Figure 5.4. Flow cytometric distribution of cells in the APC (ADS645WS) versus the FITC (β-gal 
stained tumor cells) channel for different treatments. 




Figure 5.5. Plasma clearance profiles. TSLs were compared to NTSLs. 4 animals each were injected 
via the tail vein with 8 mg/kg of DXR. Blood was collected through the orbital’s sinus at 0.5, 2, 9, 24, 
48, and 72 hours. A) DXR concentrations in the blood were compared, plasma half lives, and the 
areas under the curves (AUCs) were evaluated. The AUCs of TSL and NTSL formulations were 
statistically different from each other (p <0.001). B) Lipid concentration in the plasma remaining in 
comparison to the initial injected dose was determined. Lipid clearance from the blood of TSL was 
similar to the DXR clearance. The AUC for lipid clearance in the case of TSL was also statistically 
different than NTSL (p <0.001). 
5.3.4 Plasma Clearance of TSL 
With favorable in vitro targeting established for RSI liposomal nanocarriers, we 
next addressed whether peptide coated liposomal nanocarriers demonstrated extended 
plasma half-life required for in vivo efficacy. Liposomal nanocarriers were formulated 
with 3% DSPE-PEG2000 to provide Stealth characteristics. The % initial dose of DXR, 
as well as the % initial dose of lipid administered was quantified for different time points. 
The area under the curves (AUCs) were computed and compared for statistical 
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significance. As shown in fig. 5.5, the AUC of TSL for the circulation of DXR was 
statistically significant from the NTSL nanocarriers. The half life of DXR and liposomes, 
in the case of TSL, were computed to be 4 hours. The lipid dose administered (80 mg/kg) 
for the pharmacokinetic study was kept significantly below the RES saturation dose of 
280 mg/kg[10]. The reduction in the TSL content in plasma may significantly affect their 
passive accumulation in the tumor. In spite of 30% reduction in the total circulating 
levels of TSL compared to NTSL, if 20% of the encapsulated contents are being released 
upon heating (as seen from release studies), up to a 10 fold increase in tumor bioavailable 
drug levels can be expected. Further studies will need to be conducted to evaluate the 
effect of reduced plasma circulations on TSL accumulation in tumor.  
In the present study, we show the differences between the distributions of a 
liposomally encapsulated particle upon, externally mediated, burst release from the 
liposomes versus slow self release in the tumor. In addition, the use of GNRs alongside 
liposomes allowed for remote and point specific tumor tissue heating. Animals treated 
with TSL + GNR + NIR demonstrated a significant increase in uptake of ADS645WS by 
tumor cells. The increase in uptake of ADS645WS is, therefore, a result of thermal 
disruption of liposomes mediated by GNRs. In addition, the percentage of tumor cells 
positive for ADS645WS was significantly greater in tumors explanted from animals 
treated with TSL + GNR + NIR compared to either TSL + GNR or TSL + NIR alone. 
Our outcomes indicate that a small molecule like ADS645WS upon release from the 
liposome has a higher opportunity to diffuse farther and reach more tumor cells. Since 
this was a short preliminary study with the objective to demonstrate the difference 
between triggered versus non-triggered release, non-thermosensitive liposomes controls 
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were not evaluated for tumor dye distribution. Further studies, with these controls 
included, will help us validate the outcomes of this study. Such efforts are currently 
underway. 
The circulation half life of TSL was 4 times less than that of NTSL. However, as 
discussed in chapter 4, TSLs were effective in increasing the survival of xenograft model 
of U87-MG in mice over NTSLs. These results may indicate that the effect of fast release 
of the chemotherapeutic from the nanocarriers has significant benefits in spite of 
compromised circulation.  
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CHAPTER 6  
SUMMARY OF FINDINGS 
The overall objective of the work presented in this thesis was to explore the 
possibility of increasing the therapeutic efficacy of existing long circulating liposomal 
nanocarriers. To further achieve this goal, the study was divided into two parts. To 
address the problem of increased plasma clearance of targeted liposomes, we identified 
small peptide ligands that would not suffer RES uptake and, thereby, would show 
benefits of active targeting. In addition, we explored the possibility of fabricating plasma 
stable thermosensitive liposomes that would enable rapid drug release at the tumor site, 
and hence, increase drug availability and therapeutic efficacy. 
6.1 Rational Identification of Small Peptides for Targeting Liposomal 
Nanocarriers 
We conducted a study to identify novel peptide sequences through phage display 
that bind to tumor cells but do not bind to blood cells. It has been shown that a negative 
impact on targeting ligand inclusion through demonstrated reductions in circulating levels 
of actively targeted formulations in the bloodstream [1-6]. Since passive accumulation to 
tumor is directly related to circulating levels in the bloodstream, accelerated clearance of 
actively targeted liposomal formulations reduces passive targeting to tumor. Decrease in 
passive targeting effectively offsets the benefits of active targeting to tumor. Therefore, 
we wanted ensure that the peptide carrying liposomes were able to evade the RES in vivo. 
One peptide sequence was chosen out of the 9 that were identified using phage display 
due to its maximal binding to 9L glioma cells and minimal binding to blood cells. 
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Consequentially, the RSI peptide, when presented on the surface of liposomal 
nanocarriers, enhanced specificity and uptake of chemotherapeutics by tumor cells. Initial 
FACS analysis demonstrated relatively reduced binding of the RSI peptide to blood cells 
with more rigorous in vivo confirmation through plasma clearance studies that confirmed 
the plasma half life for RSI liposomal nanocarriers was not compromised. In fact, the 
strength of this peptide selection technique was the ability to screen peptides that 
minimally bound to blood cells, which can thus evade the RES in vivo and have high 
selectivity towards the desired cell type.  
RSI peptide was bound to liposomal nanocarriers by conjugating the peptide to 
the end of a long spacer lipid-PEG molecule (DSPE-PEG3400-mal). PEG is known to 
promote steric hindrance [7-8] for interaction of targeting moieties with the cell surface. 
Therefore, smaller PEG chains (2000) were used to impart stealth characteristic to the 
liposomes in vivo. DXR was the chosen as the preferred drug due to its fluorescent 
properties that enable both its detection intracellularly, and its ability to remotely load in 
the liposome [9-10] with high efficiency >95% [11].  
The RSI peptide liposomal nanocarriers were successful in delivering high 
payload (up to a six fold increase compared to the conventional non-targeted liposomes) 
of the drug DXR to the 9L cells, in a fashion that increased with higher number of 
peptides on the surface of the liposomal nanocarriers. The number of peptides that could 
be tethered on the liposomal nanocarriers was limited as the method of post-insertion of 
lipid-peptide conjugates in numbers >1000 per liposome became highly inefficient. In 
addition, plasma half life was reduced when more than 500 peptides were used per 
nanocarrier. Nevertheless, as seen from the DXR uptake study, when 500 RSI peptides 
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were presented on the liposomal nanocarriers, significantly increased cellular DXR levels 
were observed as compared to liposomal nanocarriers with no peptides. It is likely that 
increased exposure of the RSI peptide to immune system is able to elicit a response 
against the peptide; however, 500 or less RSI peptides do not sensitize the immune 
system. 
The requirement for the specific RSI peptide sequence is evident suggested by the 
significant reduction in DXR delivery when a scrambled version of the RSI peptide was 
used. Although, it can be argued that the effect of the scrambled peptide is larger than the 
non-targeted liposomes.  This effect can be attributed to the preservation of the phage 
sequence (GPPVESC) on the RSI and the scrambled peptide. Therefore, one may 
conclude that the phage part of the peptide may have had a significant role in binding to 
the cells. In a competitive environment where RSI liposomes were presented to the cells 
in the presence of excess of free RSI peptides, RSI liposome-mediated DXR delivery was 
significantly reduced indicating increased uptake specifically due to the RSI peptide.  
From the cytotoxicity experiments, it was observed 72 hours after treatment with 
DXR-RSI-liposomal nanocarriers that a large number of cells died. These data confirmed 
that DXR payload was cellular uptake and not merely surface binding. 9L cells were also 
treated with free RSI peptide to rule out any cytotoxic effects of the peptide. There were 
no differences found in the viability of the untreated cells and the cells treated with free 
RSI peptide. This result argues that cytotoxicity was medicated by DXR and RSI 
peptides.  
In the survival studies, we failed to observe an improvement in survival of tumor 
bearing animals compared to non targeted formulations. We followed these animals with 
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a second dose. There was overall improvement in survival due to multiple doses. 
However, the presence of the 9L tumor binding peptide (RSI) did not have any effect on 
the survival of tumor bearing mice receiving liposomal doxorubicin. Such outcome could 
be attributed to a number of factors. It is likely that the 9L tumor cells may have changed 
in vivo compared to their phenotype in vitro. Therefore, the binding of the RSI peptide to 
the tumors would be affected and the peptide presenting liposomes would be then similar 
to non-targeted liposomes in their outcome. In vivo environment is significantly different 
than what can be replicated in vitro. Although, a BLAST search did not reveal any known 
or similar sequences, RSI peptide could have been competed out by other peptides and 
proteins in the microenvironment of the tumor cells, in turn, leading to less liposomal 
uptake of the RSI targeted liposomes. 
In comparison to folate targeting liposomes that binds 9L cells about 18 times 
more than non-targeted liposomes, RSI-peptide presenting liposomes were about 3.5 
times better than non-targeted liposomes in vitro. The gain seen in vitro may have been 
insignificant in vivo, and several doses needed to be administered before a therapeutic 
difference could be registered.  
It is, also, likely that once extravasated, the liposomes do not penetrate far into the 
tumor tissue.  Liposomes are big particles and interstitial diffusion is limited. In addition, 
it is known that long circulating liposomal particles that extravasate into the tumor 
interstitium exhibits very slow release of the encapsulated drug. Presence of targeting 
moieties, therefore, may not be useful in solid tumors due to limited diffusion of 
liposomal particle.  
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6.2 Remotely Triggerable Liposomes for Therapeutic Efficacy  
In this study, we designed a thermally triggered synergistic system that stably 
carried its payload at physiological temperature and released the payload in the tumor 
interstitium upon heating with gold nanorods via near infrared laser. In vivo studies in 
chapter 3 and other recent studies in the lab have indicated that targeting alone may not 
be sufficient for therapeutic efficacy. Designing a liposome that is capable of delivering 
its payload to the tumor tissue, may present a more promising opportunity for improving 
chemotherapeutic efficacy. As described earlier, passively accumulating liposomes 
release the drug from their inner compartment very slowly and over time. The release rate 
of the drug has to be faster than the division cycle of the tumor cells and sufficient to 
overcome the cell multiplication. Traditional long circulating liposomes have failed to 
achieve therapeutic levels in systemically non-toxic levels. Rapid drug release, in this 
study, and elsewhere enables overcoming the tumor growth rate and hence was able to 
significantly improve therapeutic efficacy. The triggered release of liposomes was first 
proposed by Yatvin et al. The shortcoming of a triggered liposomal system is that when 
designing cannot stably hold its contents in circulation. In addition, the triggers that cause 
the liposomes to lose its contents are not specific and sophisticated, and cause systemic 
toxicity or injury to neighboring healthy tissue.  
In this study we compared several liposomal formulations reported in literature 
for stability over a 24 hour period at physiological conditions. Most thermosensitive 
formulations lost over 50% of their doxorubicin content in contrast to long circulating 
FDA approved formulation composed of HSPC/39%Chol/3.1%PEG. One criterion for 
increased efficacy is passive accumulation due to the EPR effect. Loss of drug at 
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physiological temperature not only compromises passive drug accumulation in the tumor, 
but also increases systemic cytotoxicity.  
To this end, we fabricated and tested several liposomal formulations for drug 
encapsulation stability at physiological temperature and release at 4-5 ˚C elevated 
temperature. We found that that DPPC liposomes that have exhibit gel-liquid state at 41 
˚C, lost ~50% of the encapsulated DXR. DSPC liposomes, on the other hand, do not 
release any DXR at 37 ˚C, which could be attributed to the fact that they have very high 
transition temperature of 55 ˚C preventing leakiness.  Addition of varying amounts of 
DPPC to DSPC liposome did not affect their stability, but DXR was also not released 
from these formulations upon heating at 43 ˚C. In earlier reports, such liposomes were 
shown to release ~100% calcein  a temperature of 37-45 ˚C [12]. These differences, in 
comparison, with our studies can be explained by the fact that upon heating, the 
liposomal bilayer is not closely packed and calcein, that is passively loaded, moves 
outwards driven by concentration gradient. Contrastingly, DXR loaded remotely and is 
trapped inside the liposomes as precipitates of the sulfate. This leads to extinction of 
concentration gradient from inside to outside of the liposomes. In addition, the slight 
increase in release of DXR upon heating to 43 ˚C, in the case of DPPC/DSPC liposomes, 
could be due to increase in DXR solubility in comparison to its solubility at 37 ˚C.  
DPPC liposomes fabricated by inclusion of varying amounts of cholesterol 
showed found that 30% cholesterol in DPPC liposomes results in very small loss of DXR 
over a 24 hour period at 37 ˚C. However, these liposomes, also, do not exhibit any 
thermosensitivity at 43 ˚C [13]. We incorporated small amounts of very low transition 
temperature (23 °C) lipid DMPC to DPPC/30%cholesterol liposomes. The rationale 
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behind this approach was that DMPC being in liquid state at >23 °C will render the 
membrane permeable and allow some movement of DXR at increased temperature. In 
addition, cholesterol will help stabilize the membrane at physiological temperature. 
DPPC/30%Chol/3%DMPC/3%PEG (thermosensitive liposomes, TSL) had comparable 
stability to HSPC/39%Chol/3.1%PEG at physiological temperature and released DXR at 
43 ˚C when heated for 10 minutes. The increase in DXR release at 43 ˚C can be attributed 
to increased DXR solubility that drove the chemical gradient of DXR to the outside of the 
liposomes.  
Additionally, we found that after heating for 10 minutes and placing TSLs back in 
37 ˚C for another 24 hours resulted in complete loss of DXR from these liposomes. Since 
this temperature is higher than the transition temperature of both DPPC and DMPC 
lipids, the additional loss of DXR could be a result of rearrangement of liposomal bilayer 
when heated at 43 ˚C. Increase to liquid state may have resulted in a loss of cholesterol 
from these lipid bilayers resulting in pure lipid liposomes. In such a case, the extended 
and complete release of DXR observed over the next 24 hours is expected. Further 
studies can be conducted to determine the molecular phenomenon of the complete release 
of DXR when incubated over an additional 24 hour period. The thermosensitive 
formulation developed here is specific to DXR. Extension of this formulation to other 
chemotherapeutic will require further investigation and testing. The mechanism of 
loading, the solubility of the drug, and the chemical structure of the drug are all important 
in determining the right thermosensitive formulation. 
Next, we explored a remote trigger for TSLs. Traditional triggers for 
thermosensitive liposomes, like a water bath, can be inconvenient, require patient 
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compliance, and can be destructive to surrounding healthy tissue. To this effect, we used 
gold nanorods to heat the TSLs. GNRs can be effectively heated using NIR [14-19]. 
Sterically stabilized gold nanorods have a circulation half life of 17 hours and accumulate 
in the tumors due to EPR [20]. Light in the near infrared range (NIR 650–900 nm) can 
traverse tissue very efficiently as the absorption by water and hemoglobin is relatively 
low in this spectrum [21]. The low absorption coefficients (μa) prevent excessive tissue 
heating and allow for use of GNRs for heating.  
We co-administered and used GNRs with TSL formulation and remotely heated 
them via NIR in an in vivo xenograft model. We waited for 48 hours to heat the TSLs to 
allow for passive accumulation. We recorded an average temperature increase of 43 ± 
1˚C using a thermo-probe in all animal tumors heated via GNRs. All other animals 
recorded an average of 39 ± 1˚C showing that increase in tissue temperature was an effect 
of GNR heating and not the laser alone. 
We found that GNR mediated heating of TSL was highly effective in suppressing 
tumor progression. All saline treated animals showed exponential increase in tumor size. 
Although, other liposomal treatments were able to suppress tumors to a degree, there was 
a significant difference in the ability to suppress tumors between TSL + GNR + NIR 
treatment and all other liposomal treatments. In addition, TSL + GNR + NIR treatment 
was successful in extending overall survival over all other treatments. These results 
indicate that GNRs were highly effective in releasing the DXR from TSLs. All 
liposomally treated animals received DXR at 2.5 mg/kg. In our studies, we tested 10 
mg/kg and 5 mg/kg DXR doses as well; however, animals did not tolerate these doses 
very well and were not further investigated. 
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Increased animal survival, in this study, is suggestive of increased bioavailability 
of DXR trapped in TSLs due to GNR mediated heating. The incapability of NTSL heated 
via GNRs in reducing tumor progression shows that the drug is not able to escape the 
nanocarrier. Therefore, the cytotoxic effects of the drug are also suppressed. It can be 
concluded that GNRs can be effectively used to remotely and locally trigger the release 
of the drug from nanocarriers, thereby, promoting drug distribution and bioavailability. 
We further demonstrated the immediate effect of drug release from the 
nanocarriers on cell viability in vivo by using Annexin-Vivo 750 and whole body 
fluorescence reflectance imaging. Annexin, injected 18 hours after NIR irradiation, was 
able to bind to apoptotic cells in vivo. Imaging was conducted at 2, 4 and 24 hours post 
annexin administration. The fluorescent signal from each animal normalized by their 
respective tumor volume determined via calipers indicated a signal enhancement for all 
time points for animal tumors that received TSLs and were heated via GNRs using NIR. 
Enhancement in signal intensity can be attributed to increase in annexin binding per 
apoptotic tumor cell. After blood clearance of annexin at 24 hours, all treatment groups 
showed reduction in annexin intensity. In comparison, TSL + GNR + NIR group showed 
the maximum fluorescent signal per cubic millimeter indicating retention of annexin 
indicative of higher apoptosis due to the combination treatment.  
The synergistic effect of GNRs and TSL in this study proves the principle that 
liposomes can be disrupted remotely and can be, especially, useful in treating tumors 
without the toxic exposure of the chemotherapeutic to surrounding normal tissue. The 
combination can provide a strong tool in increasing the effects of a chemotherapeutic. In 
this study, we demonstrated that when same amount of liposomal drug accumulates 
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passively in a tumor, the effect of release of the chemotherapeutic from a nanocarrier is 
much more beneficial than the drug being slowly released from the nanocarrier over time.  
Successful outcome of the above study encouraged us to perform a short study 
and evaluate the applicability of such a combination in an orthotopic brain tumor model. 
TSLs encapsulating a fluorochrome ADS645WS were fabricated. The release 
characteristics of the dye from TSLs were found to be similar to that of DXR. We 
evaluated and determined a dose of GNRs needed (2.25 pmol/kg rods) to achieve heating 
of brain tumors to 43 ± 1˚C. We did not observe any adverse effects of GNR mediated 
heating of the brain tumors. Tumor bearing animals received TSL +/- GNR/NIR i.v. 
Explanted tumors were dissociated and analyzed for liposomally delivered dye. Flow 
cytometry was utilized to distinguish between non-disrupted and disrupted liposomal 
outcome. Animals treated with TSL + GNR + NIR demonstrated a significant increase in 
uptake of ADS645WS by tumor cells. The increase in uptake of ADS645WS is, 
therefore, a result of thermal disruption of liposomes mediated by GNRs. In addition, the 
percentage of tumor cells positive for ADS645WS was significantly greater in tumors 
explanted from animals treated with TSL + GNR + NIR compared to either TSL + GNR 
or TSL + NIR alone. The increased number of tumor cells uptake indicates that release of 
contents from the liposomes presents an opportunity for higher diffusion of a small 
molecule into the tumor tissue. In this study, non-thermosensitive liposomes were not 
evaluated for tumor dye distribution. In a plasma clearance study for liposomal DXR, 
TSLs showed a significantly lower half life compared to non-thermosensitive liposomes. 
Further studies, with the inclusion of non-thermosensitive liposomes, will help elucidate 
if reduced circulation has imperative effects on passive accumulation of TSLs. 
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Nonetheless, the above study indicates that the combination therapy can be a real 
advantage for orthotopic tumors.  
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CHAPTER 7  
FUTURE DIRECTIONS 
Significant research has been conducted towards the improvement of liposomal 
therapy since their first FDA approval; however, very little has been translated to clinical 
practice. The ideal chemotherapeutic liposome should be able to retain the drug, evade 
the RES, target the tumor, and release the drug within the tumor. In the present work, we 
described a few novel methods to improving liposomal targeting and efficacies and 
enhanced bioavailability of the drug (DXR) as compared to traditional approach like 
Doxil. We demonstrated a novel technique of identifying RES evading targeting ligands 
for improved plasma circulation and active targeting. We, further address the need to 
release the drug from nanocarriers, after tumor extravasation, in order to increase the 
distribution of the drug and overcome heterogeneous nanocarrier distribution. To this 
effect, we described a novel technique using synergistic application of gold nanorods and 
thermosensitive liposomes for increasing therapeutic efficacy.  
While it is important to maintain the integrity, and the longer circulation time of a 
chemotherapeutic loaded nanocarrier, our findings suggest that it is absolutely necessary 
to make the encapsulated chemotherapeutic bioavailable to the surrounding tumor tissue. 
Although, targeting can be used to achieve better tissue accumulation, tissue penetration 
remains a problem. Slow release from the current stearically stabilized nanocarriers is 
clearly not enough to achieve the cytotoxicity required to overcome tumor multiplication. 
In all future studies, while designing a nanocarrier, it would be extremely necessary to 
keep in mind how to make the encapsulated drug bioavailable at doses necessary to cause 
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a cytotoxic effect. In addition, comparison of treatments in an appropriate animal model 
can severely affect the interpretation of the overall outcomes. With respect to the above 
discoveries, this chapter will further shed light on the future directions to optimizing the 
proposed nanocarriers.    
7.1 Tumor model selection and In vivo study evaluation 
7.1.1 Tumor model 
In chapter 3, we used an intracranial tumor model in an immune-competent 
animal model show the differences in survival and evaluate efficacy of a targeted 
liposomal formulation. In chapter 4, we used a xenograft glioma model, where the rate of 
tumor growth could be evaluated as a function of treatment. Evaluation of tumor size 
using an intracranial tumor model can be challenging. Therefore, survival times are 
typically utilized for determination of therapeutic efficacy.  The drawback in doing so is 
that reductions in tumor volume due to treatment may not be realized if the tumor is 
aggressive and growth recovers rapidly resulting in no significant change in survival 
times.  Using survival as the only measure of treatment efficacy, therefore, may not be 
the best method to evaluate treatment efficacy. Although, the intracranial model was 
more relevant for translational purposes, in the xenograft model the infinite amount of 
space available in the subcutaneous space was able to elucidate the differences between 
the treatments in time. In the case of the human brain, the gliomas can grow in the order 
of centimeters. The time frame for vascular recruitment does not change significantly 
from animals to humans. Therefore, it is only appropriate to evaluate treatments in 
similar sized tumors. With the information about relative tumor size and treatment 
efficacy, further studies may be designed with the aid of computational modeling, to 
146 
 
assess and achieve optimal dosing quantity and frequency for enhanced tumor 
retardation.  
7.1.2 Bioavailability of the Chemotherapeutic 
The major outcome of our study is that it is necessary to make the encapsulated 
drug bioavailable for increased therapeutic advantage. Solid tumors exhibit interstitial 
fluid pressure that is higher in the tumor center compared to the periphery and 
surrounding tissue [1-3].  This pressure differential along with heterogeneity in blood 
supply leads to lower fluid extravasation in the tumor core reducing drug delivery to this 
region.  In addition, this condition makes it difficult for macromolecules like liposomes 
delivered to the periphery to diffuse into tumor since they have to overcome the outward 
convection of fluid from regions of high to low pressure [4]. Free drug, however, should 
not suffer from diffusion limitations due to its small size and should be able to penetrate 
more deeply into the tumor resulting in a more uniform intratumoral distribution. It is 
therefore, imperative, to design nanocarriers realizing the method to liberate the contents 
for enhanced spatial distribution. At the same time, studies directed towards 
understanding the effect of such enhanced spatial distribution can be designed to further 
evaluate treatment efficacy. Further studies should be conducted to understand at the 
distribution of the drug (doxorubicin) in the tumor upon nanocarrier destabilization. A 
window chamber in tumor and intravital microscopy could be utilized to monitor the 
release of fluorescent doxorubicin from liposomes. Doxorubicin should be quenched 
inside the liposomes; however, upon thermal destabilization, doxorubicin should be free 
to fluoresce. Tumors, 24h after thermal destabilization of liposomes, can be removed and 
sectioned frozen to analyze the extent of doxorubicin distribution spatially. However, the 
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fluorescence detection sensitivity may be limited and it may be difficult to distinguish the 
drug signal from disrupted versus undisrupted liposomes. An indirect evaluation of cell 
apoptosis may also help understand the spatial increase in drug bioavailability due to 
thermal destabilization. If more amount of the drug is available, it should be able to reach 
or kill more number of cells in contrast to the drug trapped inside the liposomes. 
Therefore, an evaluation of cell death using TUNEL staining may help establish the 
importance of rapid drug bioavailability for enhanced tumor cell death. 
In this thesis, apoptosis imaging using annexin was useful in assessing short term 
advantage of rapid drug release. Fluorescent in vivo imaging, here, was possible due the 
small size and transparent skin of nude mice. In a rat model, however, in vivo fluorescent 
imaging would not be possible. However, MRI can be very useful here. Iron oxide is used 
an MRI contrast agent. Recently, iron oxide tagged annexin V analog has been fabricated 
and used for apoptosis imaging [5]. The high resolution that is available on MRI, 
compared to the low resolution in in vivo fluorescent imaging, can be beneficial in 
elucidating the spatial distribution of the released drug, indirectly, by changes in 
apoptotic areas. In addition, from a translational perspective, it would be beneficial to use 
detection technologies that are available and useful clinically. This would lead to wider 
adaptation. 
7.1.3 Tumor Tracking with MRI  
As discussed earlier in this chapter, therapeutic efficacy could be analyzed 
through evaluation of changes in tumor size at a predetermined time point following 
treatment administration. Future studies with the nanocarriers proposed in this thesis can 
be evaluated in an intracranial model with the use of in vivo imaging modalities like MRI 
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to estimate the changes in tumor size. When designing a study with MRI, it is important 
to delineate the right parameters needed. Since gliomas tend to be more fluidic, often 
times water surrounding the tumor tissue can be falsely interpreted as tumor. Conversely, 
tumor tissue can be assumed as surrounding water. As described in detail in Appendix A, 
using contrast agents can significantly improve our ability to delineate tumors. However, 
frequent contrast agent administration can also lead to a compromised RES by means of 
saturation and severe systemic toxicity. Therefore, time between contrast agent 
administrations would need to be optimized. 
It has recently been shown in our laboratory that tumor vasculature is 
heterogeneous spatially within a tumor type (Appendix A). In addition, the vasculature 
permeability varies significantly from one subject to the other and affects the 
chemotherapeutic outcome [6-7]. With such differences in permeability, the end outcome 
of two treatments can often be similar. In future studies, MRI can also be employed to 
select subjects with similar vascular permeability to nanocarriers. These subjects can, 
then, be followed up with additional nanocarrier based chemotherapy. However, such an 
approach can lead to RES burden. Alternatively, MRI contrast agent and 
chemotherapeutic agents can be co-loaded within the same nanocarrier. The 
chemotherapeutic outcomes can then be grouped based on the extent of vascular 
permeability. Treatment of tumors exhibiting highly permeable vasculature should 
demon t  te g e te   ucce   ove  tumo   with ve  el  th t   e le   ―le ky‖ bec u e it i  
the vascular permeability, in large part, which determines the extent of extravasation. 




7.1.4 Treatment Regimen  
Most studies investigating targeted chemotherapeutics have not demonstrated a 
positive impact on therapeutic efficacy unless an aggressive treatment regimen involving 
multiple administrations of treatment is followed.  As discussed earlier in this chapter, if 
the tumor growth is aggressive, when comparing targeted carriers to non-targeted 
liposomal carriers, the effect of a single dose may not be realized due to sudden recovery 
in tumor size. In a clinical setting, often times multiple chemotherapeutic regimens are 
administered for therapeutic benefit. In essence, at any time, there should be enough 
amount of drug available to achieve the rate of cell destruction greater than the rate of 
cell division in the tumor. Multiple treatments delivered every other day for a week and if 
necessary for two weeks may further help achieve such drug concentrations. In addition, 
by administering multiple and frequent doses, we may be able to restrict the tumor 
growth and elucidate the benefits of gliomas targeted nanocarriers over non-targeted 
nanocarriers. Consequentially, this would enable the development of functionalized 
nanocarriers that can be tailored to individual patients and overall increase in the 
therapeutic efficacy of the drug. 
7.1.5 Combining Targeting and Triggered Release 
The ultimate goal of nanocarrier mediated drug delivery is to achieve higher drug 
accumulation in the tumor and higher bioavailability of this accumulated drug to tumor 
cell for increased cytotoxicity. As described earlier in this thesis, phage display can help 
identify peptides that can bind to tumor tissue in high affinity. Future studies could also 
be directed towards fabricating thermosensitive liposomes with phage identified, tumor 
surface binding, non-internalizing peptides. The selection criteria for such peptides are 
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discussed in further detail below. The potential advantage of a non-internalizing targeting 
ligand would be higher drug accumulation and retention at the tumor site. GNRs could 
then be applied to remotely disrupt such liposomes for increasing drug availability and 
diffusion and increase therapeutic efficacy. Such a multifactorial approach can provide a 
significant advantage over current clinical technologies and has the potential to improve 
survival in tumor patients. 
7.2 Selection and Validation of Targeting Ligands 
7.2.1 Phage Display for Tumor Over-expressed Receptors 
As is discussed in chapter 3, the RSI peptide did enable higher drug uptake in 
vitro, however, the mechanism behind the uptake was unknown since the RSI peptide 
receptor was unknown. Determination of the receptor can enable further modulation of 
the binding strength of the nanocarriers on the cell surfaces. Many factors can govern the 
interaction of nanocarrier presented ligand and receptors on the surface of cell. It has 
been shown that the distance of separation between two curved surfaces (cell and 
liposome) plays a significant role in the binding of ligand on the liposomes to its 
respective receptor on the cell [8]. As the two surfaces approach each other, the overall 
free energy of the system starts decreasing as a result of binding between the receptors 
and ligands. At a certain critical distance the overall free energy of the system reaches a 
minimum, coincident with the onset of spontaneous contact. It was also shown that for a 
ligand–receptor pair having a high association constant, the vast majority of ligand–
receptor bond formation will take place at this critical distance, also defined as the 
binding distance. At a binding distance separation between the nanocarrier and the cell 
surface, the number of bonds that can be formed will therefore depend on 1) number of 
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ligands on the surface of nanocarrier, 2) length of tether, 3) nanocarrier size, and 4) 
receptor density on the surface of cell. Thus, based on a given receptor density and 
distribution, carriers can be tailored (by altering the tether length and number of ligands) 
to achieve optimal binding to the cell [9]. 
In addition, when designing a targeted liposome, the mechanism of targeting can 
help understand whether the delivery is intracellular, mediated by endocytosis, or if the 
targeting ligand merely enhances surface binding on the cells. In the event of a ligand 
binding to the surface of the cell but not being internalized, it would again have the same 
fate as a non-targeted liposome. As the lipids hydrolyse over time, the drug would 
become bioavailable slowly over time, only in this case, will be right on top of a few cells 
close to the vasculature.  However, endocytosing receptor ligand will ensure rapid drug 
availability once inside the cell. A possibility is to conduct future phage panning studies 
using the approach described in this thesis to identify small peptide sequences binding to 
specific endocytosisng receptors over expressed on the specific tumor cell type. In earlier 
studies in our lab, we found that folate ligand can increase liposomal uptake in 9L 
gliomas cell 18 times over non-targeted liposomes.  Hence, identifying peptides capable 
of evading the RES and able to bind with high affinity to receptors that can endocytose 
liposomes carried by the peptides may significantly enhance therapeutic efficacy.  
7.2.2 In vivo Tumor Binding Validation 
As discussed in chapter 3, we were not able to identify the lack of survival 
improvement with peptide liposomes over non-targeted liposomes. In vivo environment is 
significantly different than what can be replicated in vitro. Peptides identified with our 
specific technique if checked for binding in vivo, would enhance our understanding of 
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specific differences between in vivo and in vitro environment. Ex vivo slices could be 
obtained from orthotopically grown tumors and peptide binding to the tumor could be 
determined. In doing so, one can identify if the tumor phenotype changes in vitro to in 
vivo, and whether this change affects the binding of the phage identified peptide in vivo.  
7.2.3 In vivo Phage Display for Peptide Motif Identification  
Recently, there has been advancement in in vivo phage selection techniques for 
bind and accumulate in tumors, synovium, and vascular tissues [10-11]. In fact, a recent 
study has shown the advantages of simultaneously using an in vivo and in vitro phage 
identification for increasing specificity and binding affinity [12]. Combing the in vitro 
phage identification technique we described in chapter 3 and applying it in vivo can help 
identify a sequence that is does not elicit an immune response. In doing so, the number of 
peptides that can be presented on the liposomal nanocarrier may not be limited and higher 
binding affinity can also be achieved. These techniques, however, were not available to 
us at that time. 
Even though some of these technologies are in their infancy, they are powerful 
tools that will impact the development of future tumor drug therapies. The mechanistic 
insight that will be obtained from exploring the interactions between different short 
peptides and tumor cells will further help in development of targeted therapies. 
7.3 Further Evaluation and Validation of Thermosensitive Liposomes 
7.3.1 Biodistribution Studies with Thermosensitive Liposomes and Gold Nanorods 
In chapter 4, we discussed the benefits of a new combination therapy with gold 
nanorods and thermosensitive liposomes. Although we showed increased survival in a 
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xenograft model, further studies will be required for clinical translation. The 
biodistribution of the thermosensitive liposomes and related toxicity to RES organs 
should be evaluated and compared to the gold standard DOXIL. Cardiotoxicity is one of 
the biggest problems with doxorubicin therapies. The altered uptake of TSLs by the heart, 
liver and spleen can verify the extent of systemic cytotoxicity. In addition, histological 
examination and analysis of apoptosis in the tumors 24 hours after NIR treatment can 
help confirm the results of the in vivo imaging study. With the validation of these results, 
in vivo fluorescent imaging can be reliably used as measure apoptosis in future preclinical 
studies. Such efforts are currently underway. 
7.3.2 Gold Nanorod Mediated Heating Effects 
In our studies, we show that gold nanorods can be effectively used for heating 
intracranial tumors. However, in our studies, we used a thermo-couple to measure the 
temperature. The conduction of heat by the thermo-couple and the rate at which it can 
produce a reading can affect the end recordings. If the thermo-couple does not read 
temperature accurately, the end-user interpretation is also affected. It is possible in our 
experiment that we were able to achieve higher temperatures than were recorded due to 
such limitations. Determining the response rate of the thermo-couple, and the 
simultaneous drop in the tissue temperature, will help accurately determine the 
temperature rise achieved due to GNR mediated heating. Further validation with an IR 
thermographic camera may also be useful. 
If higher temperatures were achieved, we would have to re-evaluate dosing. In the 
case of the brain, temperature of 45 °C can trigger hyperthermic brain death. A point 
source of heat, such as the tumor with GNR, at temperatures >50 °C, will heat the 
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surrounding normal brain tissue to hyperthermic levels. In future studies, it would be 
important to examine the effect of local heating and determine any detrimental damage, 
as a consequence, to the surrounding tissue. It would also be important to understand if 
increasing the laser strength to access deeply seated tumors would heat any normal tissue 
en-route. Brain slices of intracranial tumor animal model, after GNR mediated heating, 
should be obtained and stained for histopathological analysis. H/E stain can inform about 
the overall change in the integrity of the surrounding tissue. In addition, TUNEL staining 
can elucidate the extent of apoptosis or necrosis, if any, in the normal tissue. The effects 
of NIR heating would give us valuable insight into the clinical applicability of the 
proposed treatment.  
7.3.3 Therapeutic Studies with Thermosensitive liposomes in an Orthotopic Brain 
Tumor Model  
In chapter 5, we did a preliminary study with dye loaded liposomes to show the 
benefits of triggered release and the possibility of using gold nanorods in an intracranial 
model. To establish the true clinical potential of this combination, the intracranial model 
should be used to evaluate therapeutic efficacy. For evaluating therapeutic efficacy, all 
the controls, as discussed in chapter 4, should be used. In doing so, the advantage of rapid 
drug release and increasing drug bioavailability over the traditional liposomal carrier 
(Doxil) can be established. Since we saw increased clearance of thermosensitive 
liposomes (chapter 5) over non-thermosensitive liposomes, therapeutic studies will help 
elucidate if reduced circulation has imperative effects on passive accumulation of TSLs, 
and thereby efficacy.  
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In addition, NIR has a maximum penetration depth of 10 cm. In theory, if the 
location of the tumor is identified through imaging, the shortest distance from the surface 
of the skull and tumor can be computed and a hole can be drilled to access the tumor. 
However, the human brain is larger than 20 cm and therefore, tumors deep seated (>10 
cm from the skull) may be difficult to treat with the current approach. To address the 
applicability of the GNR mediated thermal destabilization of liposomes in a human 
glioma, further studies should be conducted in larger animal models with comparable 
skull size. In doing so, therapeutic efficacy for deep seated tumors can be evaluated. The 
extent of normal tissue heating resultant of alteration in laser power can also be 
evaluated. For larger animals, the amount of gold nanorods needed to achieve optimal 
heating may need readjustment.  
7.4 Gold Nanorods 
7.4.1 Gold Nanorods for Hyperthermia and Triggered Content Release  
As demonstrated earlier by other groups, a combination of liposomes and GNR 
can also be used to increase the accumulation of the chemotherapeutic in the tumor 
region [13-14]. This approach again manifests the overall objective of increased drug 
accumulation at the tumor site. An addendum to our approach could be using GNRs for 
hyperthermia to cause higher drug accumulation at the tumor site and then using a second 
NIR pulse to disrupt the liposomes. Hyperthermia from GNRs will help more liposomes 
accumulate in the tumor [14]. A second NIR pulse will significantly enhance the 
bioavailability of the drug and the overall effects of chemotherapy. In addition, by 
causing a higher percentage of the nanocarrier transported drug to be bioavailable, we can 
achieve overall reduction in the amount of drug administered systemically.  
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7.4.2 Gold Nanorods for Tumor Imaging and Triggered Content Release  
The combination of gold nanorods and thermosensitive liposomes can also be 
used to treat several other solid tumors. The major drawback of thermally induced 
triggered release therapy is that it requires the localization of the tumor [15]. In case of 
metastatic tumors, such a requirement would make the application of thermally triggered 
liposomal chemotherapy difficult. The advantages of tumor size and treatment 
monitoring through imaging have been stressed upon, and discussed at different times in 
this chapter. GNRs may, also, serve as additional tools for non invasive tracking of 
tumors using optical coherence tomography and photoacoustic tomography as has been 
demonstrated elsewhere [16]. In doing so, the exact location of the tumor can be 
identified. Since gold nanorods can serve both as heating antennas and imaging contrast 
agents, the need for an additional contrast agent administration, for using other modalities 
like MRI, can be eliminated. Further development of this multifaceted combinatorial 
approach of imaging and thermally destablizable liposomal therapy can really be useful 
clinically. 
7.5 Iron oxide as an Alternative to Gold Nanorods  
Another approach to remote triggered release from thermosensitive liposomes can 
be the use of iron oxide particles. Iron oxide nanoparticles have been demonstrated for 
inducing hyperthermia, in earlier reports, by use of low frequency <200k electromagnetic 
waves [17-18]. Iron oxide has also been shown to be a powerful MRI contrast agent for 
tumors [19-21]. For unreachable deep seated solid tumors, where hyperthermia is 
difficult to achieve with the use of traditional tools like a water bath or GNRs, combining 
iron oxide for disruption of thermosensitive liposomes can provide an alternative 
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synergistic tool for imaging and treatment. Since iron oxide particles are also cleared 
from the circulation by the components of the RES, using a whole body coil to achieve 
heating in the desired tissue could significantly heat the liver and kidney as well. 
Therefore, the design of the coil as well as the applicability of this technique will be 
limited by the location of the tumor (brain versus the abdomen). Further investigation is 
warranted to tailor such a setup for any clinical benefit. 
7.6 Conclusions 
Much work has been presented in this thesis to overcome the current challenges to 
nanochemotherapies. In conclusion, any cargo, be it protein, DNA, RNA, or drug, carried 
within the nanocarriers will show benefit if the bioavailability of such contents is ample 
to achieve the desired effect. Remotely triggered liposomes by gold nanorods offer a 
potential platform for advanced drug delivery. The possibility to control the time, place, 
and rate of drug release can provide better therapeutic response and less adverse effects 
by increasing the drug distribution to the target tissue. By selecting the liposomal 
formulation, triggering signal, and the mechanism of action to be suitable for a specific 
application, liposomes could be utilized in numerous medical treatments for enhanced 
efficacy. Future studies, as described in this chapter, can further help improve and 
optimize these approaches for potential translation into the clinic. 
7.7 References 
1. Jain, R.K. and L.T. Baxter, Mechanisms of heterogeneous distribution of 
monoclonal antibodies and other macromolecules in tumors: significance of 
elevated interstitial pressure. Cancer Res, 1988. 48(24 Pt 1): p. 7022-32. 
158 
 
2. Baxter, L.T. and R.K. Jain, Transport of fluid and macromolecules in tumors. I. 
Role of interstitial pressure and convection. Microvasc Res, 1989. 37(1): p. 77-
104. 
3. Boucher, Y., L.T. Baxter, and R.K. Jain, Interstitial pressure gradients in tissue-
isolated and subcutaneous tumors: implications for therapy. Cancer Res, 1990. 
50(15): p. 4478-84. 
4. Jain, R.K., Delivery of molecular and cellular medicine to solid tumors. Adv 
Drug Deliv Rev, 2001. 46(1-3): p. 149-68. 
5. Kenneth T. Cheng, Sam Gambhir, and Z. Cheng., [18F]FB-(Ac-NIe-Asp-His-d-
Phe-Arg-Trp-Gly-Lys-NH2). [18F]FB-NAPamide. . In: Molecular Imaging and 
Contrast Agent Database (MICAD) [database online]. Bethesda (MD): National 
Library of Medicine (US), NCBI;  Available from: http://micad.nih.gov., 2004-
2009. 
6. Karathanasis, E., et al., Tumor vascular permeability to a nanoprobe correlates to 
tumor-specific expression levels of angiogenic markers. PLoS One, 2009. 4(6): p. 
e5843. 
7. Karathanasis E, et al., MRI mediated, non-invasive tracking of intratumoral 
distribution of nanocarriers in rat glioma. Nanotechnology, 2008. 19(31): p. 
315101. 
8. Jeppesen C, et al., Impact of polymer tether length on multiple ligand–receptor 
bond formation. Science, 2003. 2001: p. 465-468. 
9. Ghaghada, K.B., et al., Folate targeting of drug carriers: A mathematical model. 
J Control Release, 2005. 104(1): p. 113-28. 
159 
 
10. Laakkonen, P., et al., Antitumor activity of a homing peptide that targets tumor 
lymphatics and tumor cells. Proc Natl Acad Sci U S A, 2004. 101(25): p. 9381-6. 
11. Mi, Z., et al., Identification of a synovial fibroblast-specific protein transduction 
domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther, 
2003. 8(2): p. 295-305. 
12. Whitney, M., et al., Parallel in vivo and in vitro selection using phage display 
identifies protease-dependent tumor-targeting peptides. J Biol Chem, 2010. 
285(29): p. 22532-41. 
13. Park, J.H., et al., Cooperative nanoparticles for tumor detection and 
photothermally triggered drug delivery. Adv Mater, 2010. 22(8): p. 880-5. 
14. Park, J.H., et al., Cooperative nanomaterial system to sensitize, target, and treat 
tumors. Proc Natl Acad Sci U S A, 2010. 107(3): p. 981-6. 
15. Kong, G. and M.W. Dewhirst, Hyperthermia and liposomes. Int J Hyperthermia, 
1999. 15(5): p. 345-70. 
16. Wei, A., A.P. Leonov, and Q. Wei, Gold nanorods: multifunctional agents for 
cancer imaging and therapy. Methods Mol Biol, 2010. 624: p. 119-30. 
17. Mitsumori, M., et al., Development of intra-arterial hyperthermia using a 
dextran-magnetite complex. Int J Hyperthermia, 1994. 10(6): p. 785-93. 
18. Shinkai, M., et al., Antibody-conjugated magnetoliposomes for targeting cancer 
cells and their application in hyperthermia. Biotechnol Appl Biochem, 1995. 21 ( 
Pt 2): p. 125-37. 
19. Weissleder, R., et al., Superparamagnetic iron oxide: enhanced detection of focal 
splenic tumors with MR imaging. Radiology, 1988. 169(2): p. 399-403. 
160 
 
20. Stark, D.D., et al., Superparamagnetic iron oxide: clinical application as a 
contrast agent for MR imaging of the liver. Radiology, 1988. 168(2): p. 297-301. 
21. Moffat, B.A., et al., A novel polyacrylamide magnetic nanoparticle contrast agent 




APPENDIX A  
MRI MEDIATED, NON-INVASIVE TRACKING OF 
INTRATUMORAL DISTRIBUTION OF NANOCARRIERS IN 
RAT GLIOMA 
As published with Karathanasis E, Park J, Patel V, Zhao F, Hu X, and 
Bellamkonda RV in Nanotechnology, 2008, 19:315101. 
The following text, figures, and tables comprise a manuscript published in 
Nanotechnology related to the non-invasive tracking of contrast agents to tumors using 
liposomes.  The manuscript is included for reference purposes in regards to the 
dissertational work provided in the main text. 
Abstract 
Nanocarrier mediated therapy of gliomas has shown promise. The success of 
systemic nanocarrier-based chemotherapy is critically dependent on the so-called leaky 
vasculature to permit drug extravasation across the blood-brain barrier. Yet, the extent of 
vascular permeability in individual tumors varies widely, resulting in a correspondingly 
wide range of responses to the therapy. However, there exist no tools currently to 
rationally determine whether tumor blood vessels are amenable to nanocarrier mediated 
therapy in an individualized, patient specific manner today. To address this need for brain 
tumor therapy, we have developed a multifunctional 100nm-scale liposomal agent 
encapsulating a gadolinium-based contrast agent for contrast enhanced Magnetic 
Resonance Imaging with prolonged blood circulation.  Using a 9.4 Tesla MRI system, we 
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were able to track the intratumoral distribution of the gadolinium-loaded nanocarrier in 
rat glioma model for a period of three days due to improved magnetic properties of the 
contrast agent being packaged in a nanocarrier. Such a nanocarrier provides a tool to non-
invasively assess the suitability of tumors to nanocarrier mediated therapy and then 
optimize the treatment protocol for each individual tumor.  Additionally, the ability to 
image the tumor in high resolution can potentially constitute a surgical planning tool for 
tumor resection. 
A.1. Introduction 
Current approaches for the treatment of glioma are limited in their effectiveness 
because malignant brain tumors are characteristically diffuse, highly invasive, and non-
localized (Black and Pikul, 1999).  Complete surgical resection of malignant gliomas is a 
rarity, partly due to the inability to clearly map the tumor, and partly because of its 
invasive nature. Therefore, clinical standard of care includes radiation therapy and 
systemic and topical chemotherapy after surgical resection. Unfortunately, radiation and 
topical delivery of chemotherapeutics using polymer wafers have poor results and extend 
the median survival by 2-9 months and systemic chemotherapy has been minimally 
effective (Barker et al., 1998; Fine et al., 1993) .  Given the diffuse and invasive nature of 
gliomas, the success of systemic chemotherapy is critically dependent on the so-called 
leaky vasculature to permit drug extravasation across the blood-brain barrier (BBB).  
Currently, systemic chemotherapy is not the primary treatment of choice for malignant 
brain tumors due to the exposure of non-target organs to chemotherapeutic resulting from 
systemic administration and due to the presence of the highly impermeable BBB, which 
limits transport to lipophilic or low molecular weight, uncharged compounds. Therefore, 
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new strategies improving systemic delivery of chemotherapeutics will be a potent tool for 
treatment of gliomas. 
Nanocarrier mediated therapy of gliomas has shown promise because 
multifunctional nanocarriers can (i) carry large payloads of one or more types of drugs 
for therapy or contrast agents for imaging or combos of drugs and contrast agents, and (ii) 
manipulate pharmacokinetics and biodistribution of systemically administered agents to 
increase accumulation in tumor site. This multifunctionality of nanoscale systems is 
projected to enable personalized cancer therapy by diagnosing, treating, and monitoring 
the progress of treatment for each individual cancer (Service, 2005; van de Wiele et al., 
2002; Koning and Krijger, 2007; Torchilin, 2006; Mitra et al., 2006). Such nanocarriers 
can theoretically be designed not only to carry a range of chemotherapeutic or anti-
invasive agents (not just low molecular weight, uncharged lipophilic drugs), but also to 
both passively and actively target intracranial tumors such as gliomas. Passive targeting 
results from prolonged circulation of nanocarriers allowing for accumulation at sites with 
abnormal, leaky vasculature. In recent rodent studies of glioma, effective passive tumor 
dosing was achieved by intravenous (IV) injections of drug-loaded liposomal 
nanocarriers (R.D. Arnold et al., 2005). It was demonstrated in patients with 
glioblastomas and metastatic brain tumors that long circulating liposomal nanocarriers 
overcome the BBB in the tumor lesions resulting in 13-19 times higher accumulation in 
the glioblastoma as compared to the normal brain (M.I. Koukourakis et al., 2000). In 
addition, active targeting can be achieved by decorating nanocarriers with multiple 
ligands to increase targeting affinity and selectivity by binding to multiple receptors of 
the same or different type on cancer cells (Saul et al., 2006; Hong et al., 2007).  
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The success of passive (and subsequent active) targeting of nanoscale 
chemotherapeutic agent therapy for intracranial tumors is critically dependent on the 
access that these agents have to tumors via the leaky vasculature across the BBB (Jain, 
1994, 2001; Maeda et al., 2000). Unfortunately, it is well-known that the degree of tumor 
vascular leakiness differs not only among same type tumors but even spatially within the 
same tumor (Fukumura and Jain, 2007; Hobbs et al., 1998; Yuan et al., 1996). For 
instance, previous studies in our laboratory showed that the standard deviation of the 
intratumoral accumulation of liposomal doxorubicin in a rat brain tumor was 150% of the 
mean value (McNeeley et al., 2007). However, there exist no tools currently to rationally 
determine whether tumor blood vessels are amenable to nanocarrier mediated therapy in 
an individualized, patient specific manner today.  Such a determination would no doubt 
be of great benefit for the planning and assessment of multiple chemotherapeutic 
strategies. One recent example demonstrating the critical role that tumor vessels play in 
determining therapeutic outcomes comes from the work of Jain et al, where they 
demonstrate the modulation of tumor vessels by normalizing them leads to better 
chemotherapeutic outcomes (Jain, 2005).    
Here, we report the development of a multifunctional long-circulating nanocarrier 
trackable by Magnetic Resonance Imaging (MRI). The nanocarrier consists of a 100nm-
scale Pegylated liposomal carrier encapsulating Gadolinium (Gd) and/or a 
chemotherapeutics. Conventional MR contrast agents, such as Gd chelates, restrict the 
time window for image acquisition due to their rapid elimination from blood. In the 
recent past, we demonstrated that the prolonged blood circulation of the agent allowed 
enhanced signal for long scanning times resulting in high resolution MR images of rat 
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vasculature (Ayyagari et al., 2006). Other groups have also utilized Gd-loaded liposomal 
formulations as a paramagnetic agent for angiography resulting in a positive signal 
enhancement associated with T1-shortening (Ghaghada et al., 2007; Erdogan et al., 2008; 
Erdogan et al., 2006; Torchilin, 1994; Krauze et al., 2006; Weissing et al., 2000). In this 
work, we have validated the utility of the Gd-nanocarrier for non-invasive determination 
of tumor vasculature permeability to nanoparticles in 9L glioma model rat using a 9.4 
Tesla Bruker Biospin MR system. Interestingly, under this strength of the magnetic field, 
the Gd-containing nanocarrier produces negative signal enhancement due to significant 
T2 shortening resulting in a more potent contrast agent. While more intricate nanoparticle 
systems are novel from a materials science perspective, their potential for translation to 
clinical use is limited by the dearth of knowledge about their toxicity, biodistribution and 
in vivo fate, while liposomal nanoparticles are relatively well characterized and thus 
provide the potential for rapid translation to the clinic.  For instance, nanoscale liposomal 
doxorubicin formulations were the first nanotherapeutics to be approved for clinical use 
as the first line for treatment of AIDS- el ted K po i‘  S  com   nd  el p ed ov  i n 
cancer (Lasic and Papahadjopoulos, 1995) and is under numerous clinical trials (128 
active studies) for treatment of many types of cancer (www.ClinicalTrials.gov; accessed 
12/12/2007). Besides liposomal doxorubicin, other liposomal formulations (Ferrari, 
2005), polymeric micelles and polymer-based particles (Heath and Davis, 2007; 




A.2. Materials and Methods 
A.2.1. Materials 
The phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2 
disteroyl-sn-glycero-phosphoethanolamine poly(ethylene glycol)2000 (DSPE-PEG2000) 
were purchased from Genzyme Pharmaceuticals (Cambridge, MA). Cholesterol was 
purchased from Sigma (St. Louis, MO). Gadodiamide (Omniscan) was obtained from GE 
Healthcare (Milwaukee, WI). 1,2-Dipalmitoyl-sn-glycero-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (DPPE-Lissamine-Rhodamine) was purchased from 
Avanti Lipids (Birmingham, AL). Mouse monoclonal anti-rat CD31 antibody was 
obtained from BD Biosciences Pharmingen (San Diego, CA). The mouse anti-rat RECA-
1 monoclonal antibody (IgG1) was purchased from GeneTex (San Antonio, TX). The 
secondary antibodies, Alexa Fluor 594 goat anti-rabbit IgG and Alexa Fluor 488 goat 
anti-mouse, and 2-(3-(diphenylhexatrienyl)propanoyl)-1-hexadecanoyl-sn-glycero-3-
phosphocholine (β-DPH-HPC) were purchased from Invitrogen (Carlsbad, CA). All 
animals were purchased from Harlan (Indianapolis, IN). A 9L glioma cell line was 
received as a generous donation from the Neurosurgery Tissue Bank at UCSF. Minimal 
essential medium containing Ea le‘  b l nced   lt  olution (MEM/EBSS) w   pu ch  ed 
from Hyclone (Logan, UT). Gentamicin (50 mg/ml), fetal bovine serum (FBS), and 
Leibovitz‘  L-15 medium were obtained from Gibco (Carlsbad, CA). Trypsin-EDTA 
(0.05% t yp in, 0.53 mM EDTA) in H nk ‘ b l nced salt solution was purchased from 
Mediatech (Herndon, VA). Heparin and isoflurane were obtained from Baxter Healthcare 
(Deerfield, IL). Ketamine was purchased from Fort Dodge Laboratories (Madison, NJ). 
Marcaine was obtained from Abbott Laboratories (Abbott Park, IL). Flunixin meglumine 
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was purchased from Phoenix Scientific (San Marcos, CA). Xylazine was purchased from 
The Butler Company (Dublin, OH). Acetylpromazine (10 mg/ml) was obtained from 
Boehringer Ingelheim (Ingelheim, Germany). The rest of the reagents were of analytical 
grade (Fisher Scientific, Atlanta, GA). 
A.2.2. Fabrication and Characterization of the Gd-nanocarrier 
A lipid composition of DPPC, cholesterol and DSPE-PEG2000 in the molar ratio of 
55: 40: 5 was used. Fluo e cent pho pholipid (β-DPH-HPC) at 0.01 mol% was used to 
track phospholipid content. The formulations used in the in vivo imaging studies were 
tagged with DPPE-Lissamine-Rhodamine at 1 mol% of the total lipids (for fluorescent 
microscopy of tissue sections as described in section 2.8). The lipids were dissolved in 
ethanol and hydrated with 0.5 M gadodiamide (Gd) solution at 60°C followed by 
sequential extrusion in a Lipex Biomembranes Extruder (Northern Lipids, Vancouver, 
Canada), to size the liposomal nanocarrier to  about 100 nm. Free, un-encapsulated 
gadodiamide was replaced by a saline solution (300 mM NaCl; 596 mOsm/kg water) 
with comparable osmolarity as the internal phase of the nanocarrier using a 2-day dialysis 
with a 100k molecular weight cutoff dialysis tubing. The size of the Gd-nanocarrier was 
determined by dynamic light scattering (90 Plus Particle Size Analyzer, Brookhaven 
Instruments, Holtsville, NY). The osmolality of the nanocarrier was determined using a 
vapor osmometer (Wescor, Logan, UT).  
A.2.3. In vitro T1 and T2 Measurements 
In vitro, the spin-lattice T1 and spin-spin T2 relaxation times of the Gd-nanocarrier 
suspension and gadodiamide solution were determined on a 0.47 T Bruker Minispec 
NMR system at 37°C. The longitudinal and transverse relaxation rates were determined 
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by an inversion recovery pulse sequence and a spin-echo sequence, respectively. To 
determine the effective Gd concentration, the liposomal nanocarrier was lysed with 20% 
SDS (sodium dodecyl sulfate). The effective relaxivity (per unit Gd concentration) in the 





T1Gd (or T2Gd) is the observed T1 (or T2) relaxation time for the Gd-containing 
formulations, T1noGd (or T2noGd) is the observed T1 (or T2) relaxation time for the buffer, 
and r1 (or r2) is the relaxivity of gadodiamide at 37°C. T1 and T2 relaxation times of the 
formulations were measured over a concentration range of 0.5–2.0 mM Gd. The r1 (and 
r2) relaxivity were then determined from the slope of the linear regression fits of 1/T1 
(and 1/T2) against the Gd concentration.  
Comparative T1 and T2 measurement at 9.4 T were performed on a Bruker 
Biospin MR system. A series of fast imaging in steady-state precession (TrueFISP) 
sequences was performed for T1 measurements. The parameters for the TrueFISP were 
TR/TE = 3 msec/1.5msec, delay time = 8 sec. A total of 40 frames were acquired during 
one excitation with inversion time (TI) linearly ranged from 50 msec to 6 sec. The field 
of view (FOV) was 4 × 4 cm
2
 with a matrix of 128 × 128. A series of Multiple Slices 
Multiple Echos (MSME) sequences was performed for T2 measurements. The pulse 
sequence parameters were TR = 4 sec, number of echoes = 8 with TE of 9, 18, 27, 36, 45, 
54, 63, 72 msec; FOV=4 × 4 cm2 with a matrix of 128 × 128. 
A.2.4. Ex vivo T1 and T2 Measurements 
All of the animal experiments were carried out in compliance with the 
institutional animal use and care protocols of the Georgia Institute of Technology and 
Emory University. Under anesthesia with 2-3% inhalant isoflurane, 9–10 week old male 
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Fisher 344 rats were injected with 0.25 mmol Gd/kg body weight of either the Gd-
nanocarrier (n=3) or gadodiamide (n=3) intravenously (IV) in the tail vein using a 24G 
catheter. Blood samples were withdrawn orbitally once before injection and at 5, 35, 60, 
180, 240 and 300 min after injection and transferred to heparinized blood tubes. Plasma 
was collected by centrifugation at 2,000 rpm. The plasma T1 and T2 values were 
measured immediately as described above on the 9.4 Tesla Bruker Biospin MR system. 
A.2.5. 9L glioma Cell Culture 
9L glioma cell line was maintained in MEM/EBSS medium supplemented with 
10% fetal bovine serum and 0.05 mg/mL gentamicin. Cells were passaged by 
trypsinization and washed with growth medium. Prior to implantation, cells were 




A.2.6. Tumor Inoculation 
A rat glioma model was established by surgically implanting 2 × 10
6
 9L glioma 
cells into the frontal lobe of 9–10 week old male Fisher 344 rats. All procedures were 
conducted under a protocol approved by the Institutional Animal Care and Use 
Committee (IACUC) at Georgia Institute of Technology. During surgery, anesthesia was 
maintained through the administration of 2-3% inhalant isoflurane. The incision site was 
shaved and the animal mounted in a stereotaxic frame. The scalp was opened to expose 
the skull, and a burr hole was drilled 2 mm anterior and 2 mm lateral to the bregma. 2 × 
10
6
 9L glioma cells in 10 l of Leibovitz‘  L-15 medium were slowly injected into the 
frontal lobe through a 21-gauge needle at a depth of 3 mm below the brain surface. The 
burr hole was then sealed with bone wax, and the scalp was sutured closed. Animals 
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received 5 ml Lactated Ringe ‘   olution th ough int  pe itone l (IP) injection  nd   
subcutaneous injection of 0.5% marcaine at the wound site. Flunixin meglumine (2.5 
mg/kg) was administered through an intramuscular injection to alleviate pain as needed. 
A.2.7.  In vivo Images 
All MRI image data were acquired on the 9.4 T Bruker system. A volume coil 
(72-mm inner diameter) and an inductively coupled surface coil (20-mm diameter) for 
signal built saddle volume coil was employed. High resolution angiograms of the rat 
brain (n=1) were obtained before and 15 min after IV injection of the Gd-nanocarrier (at 
a dose of 0.25 mmol Gd/kg b.w.) using a T2*-weighted 3D FLASH sequence with the 
following parameters: TR/TE=50/15 msec, flip angle=30°, matrix=512 x 384 x 32, 
FOV=4 x 3 x 0.5 cm
3
, and 8 averages (scan time = 81 min) for high resolution brain 
angiography. This resulted in an in-plane spatial resolution of 78 m and a slice thickness 
of 156 m. 
The intratumoral extravascular accumulation of the nanocarrier was monitored by 
employing a 3D FLASH sequence with shorter scan time (and lower spatial resolution) 
than the high resolution angiograms with the following parameters: TR/TE=50/15 msec, 
flip angle=30°, matrix=256 x 256 x 32, FOV=4 x 3 x 0.75 cm
3
, and 2 averages (scan time 
= 13 min). This resulted in a spatial resolution of 156 x 117 x 234 μm. Two groups of 
animals were monitored for a period of 3 days after injection of 0.25 mmol Gd/kg b.w. of 
the nanocarrier (group A; n=3) and injection of a saline solution at equal volume to the 
nanocarrier (group B; n=3). Imaging was performed pre-injection and 5 min, 1 day and 3 
days post-injection. Care was taken to maintain similar positioning of the animal for pre- 
and post-contrast images. After each 3D imaging session, a T2*-weighted 2D map was 
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obtained using a multi-gradient echo (MGE) sequence with the following parameters: 
TR/TE=500/3 msec, number of echoes = 12, matrix=128 x 128, FOV=3.4 x 3.4 cm
3
, and 
8 averages (scan time = 9 min). At day 3 post-injection, the animals were euthanized 
immediately after completion of the last imaging session and histological analysis was 
performed as described below. 
A.2.8. Immunohistochemistry and Histological Evaluation of Explanted Tumors 
Upon completion of the imaging study, the animals were anesthetized with 
ketamine (1 mg/kg) and xylazine (0.17 mg/kg), transcardially perfused with 4% 
paraformaldehyde, the tumors were retrieved, and stored in 4% paraformaldehyde. The 
tumors were transferred from 4% paraformaldehyde to 30% sucrose and allowed to 
incubate for 48-72 h. Serial coronal cryostat (Leica CM 300, Leica, Bannockburn, IL) 
sections of 16 μm thickness were made and mounted onto glass slides. Care was taken to 
obtain brain sections with the same orientation as that of the MR images. To visualize the 
tumor microvasculature, the tissue slices were immunohistochemically stained with 
RECA-1, a cell surface antigen which is expressed by all rat endothelial cells. After three 
washes in PBS for 10 min each, the sections were incubated in 4% goat serum and 0.5% 
Triton X-100 for 1 hr. Upon adding the primary antibody (1:250 dilution) in 4% goat 
serum and 0.5% Triton X-100, the sections were incubated at 4 C overnight. After 
washing the sections three times with PBS, the secondary antibody (1:220 dilution), 
Alexa Fluor 488 goat anti-mouse IgG, was added and allowed to incubate for 1 hr. The 
sections were washed three times with PBS, incubated with DAPI (nuclear stain) for 15 
min followed by three washes with PBS and covered with glass coverslips. The tumor 
sections were imaged at 20x on the Nikon Eclipse 80i upright microscope using a 
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Microfire CCD camera (Optronics, Golate, CA) that interfaced with the Neurolucida 
software (MicroBrightField Bioscience, Williston, VT) to obtain a 2D montage of the 
entire brain tissue section.  
A.2.9.  Data and Statistical Analysis 
The plasma T1 and T2 values measured ex vivo (Fig. A.2) and the T2* values 
obtained from in vivo 2D mapping (Fig. A.5) are expressed as mean ± standard deviation. 
To determine the significance of the relaxation times among the various animal groups at 
different time points, an unpaired t test analysis was performed. A p-value less than 0.05 
was used to confirm significant differences at the 95% confidence level. The analysis was 
performed using the Minitab software.  
A.3. Results and Discussion 
A.3.1.  In vitro Characterization of the Gd-nanocarrier  
The liposomal Gd-nanocarrier contained 150 mM lipids and 87 mM Gd, 100% of 
Gd being encapsulated within the liposomes. The average diameter of the Gd-nanocarrier 
was 98 nm (standard deviation = 9 nm) as determined by dynamic light scattering, a size 
known to prevent renal clearance while allowing extravasation. The 600 mOsm/kg water 
osmolality of the formulation allowed intravenous injection, since the liposomal walls 
can sustain the osmotic pressures expected to occur in isotonic environments. Indeed, in 
vitro leakage experiment against isotonic phosphate buffered saline exhibited very low 









, respectively (Figure 1). At the high magnetic field of 9.4 T, the r2/r1 ratio 
of the Gd- nanocarrier substantially increased, which is expected since the r2/r1 ratio 
usually increases with increasing resonance frequencies (Strijkers et al., 2005). Previous 




on 0.47 T 
magnets, a value significantly smaller than the one measured on the 9.4 T system. This 
high r2 value allowed us to use the Gd- nanocarrier in the in vivo imaging studies as a T2-
shortening agent. 
 
Figure A.1. In vitro r1 and r2 relaxivities of the Gd-nanocarrier measured on 9.4 T and 25 °C. 
 
A.3.2. Ex vivo Plasma T1 and T2 Measurements 
Figure 2.a shows the changes in plasma T1 relaxation time measured at 9.4 T 
following administration of Gd- nanocarrier and gadodiamide. At t=5 min after 
administration of the nanocarrier, a sharp decrease of the T1 value from the pre-injection 
value of 2500 msec to the post-injection value of 570 msec was observed. Due to the 























T1 value remained at low values of about 650 msec for the rest of the duration of the 
experiment. While we did not attempt to measure the blood half life (t1/2) in this study, 
we have shown that liposomes of similar size and lipid composition as the Gd-
nanocarrier have a t1/2 of about 18 h in Fisher rats (McNeeley et al., 2007). In a previous 
study (Ayyagari et al., 2006), we observed that the post-injection T1 values were about 
180 msec measured at 0.47 T upon administration of the Gd-nanocarrier at a dose similar 
to the one used in the current study. This difference is expected since higher resonance 
frequencies (or magnetic strength such as that used in the current study) produce longer 
T1 values. Following administration of (non-liposomal) gadodiamide, the plasma T1 value 
decreased to about 450 msec at 5 min post-injection. The rapid clearance of the agent 
from blood circulation resulted in a rapid increase of the T1 value reaching the pre-
injection value within 2 h after administration. Similarly, administration of the Gd-
nanocarrier resulted in a rapid drop of the plasma T2 value from the pre-injected value of 
113 msec to the post-injection value of about 16 msec which remained at these low 
values for the rest of the duration of the experiment (Figure 2.b). Such low plasma T2 
values suggest that the gadolinium-based contrast agent being packaged in the 
nanocarrier displays improved magnetic properties when used as a T2-shortening agent at 
the high magnetic field of 9.4 T. Upon injection of (non-liposomal) gadodiamide, the 
plasma T2 value dropped to 59 msec at 5 min post-injection and then rapidly returned to 




Figure A.2. Plasma relaxation time (a) T1 and (b) T2 measured ex vivo on 9.4 T after administration 
of the liposomal Gd-nanocarrier (n=3) and gadodiamide (n=3) at a dose of 0.25 mmol Gd/kg. The * 
indicates significant statistical difference (p<0.05) between the Gd- nanocarrier and gadodiamide. 
A.3.3. MR Angiograms 
Figure 3 shows high resolution coronal T2*-weighted images obtained using the 
9.4 T MRI before and after administration of the Gd-nanocarrier. It should be noted that 
the scanning parameters in the pre-and post-contrast images were identical. In the pre-
contrast image (Figure 3.a), few blood vessels (appear as black dots) of the vasculature of 
the cerebral cortex can be seen in the healthy tissue or in the cancerous lesion located  in 
the front of the right hemisphere (as indicated by the arrow). The prolonged blood 
circulation of the Gd-nanocarrier allowed negatively enhanced signal for long time 
increasing scanning times and the time window for image acquisition (subsequently 
lowering the signal to noise ratio). Administration of the nanoscale agent allowed clear 
visualization of the cerebral vasculature (Figure 3.b). Importantly, details of the glioma 












































Figure A.3. High resolution (78 μm in-plane resolution) coronal T2*-weighted images of rat brain on 
a 9.4 T MRI. (a) In the pre-contrast image, minor vasculature enhancement was seen in the normal 
cerebral tissue and tumor (arrow). (b) Administration of 0.25 mmol Gd/kg of the nanocarrier 
allowed clear visualization of the vasculature of the normal cerebral tissue. The post-contrast image 
revealed a spherical part of the tumor lesion with highly vascularized rim and a less vascularized 
inner core and a very well-vascularized envelope-shaped part of the lesion (scale bar is 0.5 cm). 
 
consisted of a spherical and an envelope-shaped part (as indicated in Figure 3.b). The 
sphere part (where originally inoculation of the cancer cells occurred) was characterized 
by a highly vascularized peripheral rim which is usually associated with high levels of 
angiogenic and permeability factors resulting in neoangiogenesis (Damert et al., 1997; 
Takano et al., 1996) and an inner core with less vascularization. The entire envelope (the 
other portion of the tumor) appeared highly vascularized. In previous studies (McNeeley 
et al., 2007), we have observed in many cases a similar pattern where the glioma grows 
initially as a sphere and then grows towards the front of the lobe most likely due to less 
restriction (e.g. pressure).  
A.3.4. Intratumoral Visualization of the Nanocarrier 
The Gd-nanocarrier was tested in adult male rats using an orthotopic brain tumor model 
developed by inoculation of 9L glioma cells. By utilizing a fast imaging protocol (with a 
duration of 13 min), we were able to obtain images of the brain with a spatial resolution 







of 156 x 117 x 234 μm. Figure 4 shows brain images of the same animal before and 5 
min, 1 day and 3 
 
Figure A.4. Coronal T2*-weighted images of rat brain with spatial resolution of 156 x 117 x 234 μm obtained 
before and 5 min, 1 day and 3 days after administration of the Gd-nanocarrier at a dose of 0.25 mmol Gd/kg 
on a 9.4 T MRI.  
days after injection of the Gd- nanocarrier. High density vasculature in normal and tumor 
tissue can be visualized immediately after injection. Over the time course of three days, 
the tumor exhibited increasing negative enhancement whereas the negative enhancement 
of the blood vessels in normal tissue was disappearing. This is consistent with clearance 
of the nanocarrier from circulation while accumulation of the agent within the 
int  tumo  l ext  v  cul    p ce vi  ext  v   tion th ough the tumo ‘  le ky v  cul tu e 
was increasing. It should be noted that the vasculature of normal brain with intact BBB is 
impermeable to the nanocarrier. In previous reports from our lab (McNeeley et al., 2007), 
we have shown that the half life (t1/2) of liposomes in rat blood circulation is about 18 h 
and that less than 10% of the nanocarrier remained in circulation at three days post-
injection. To verify the low levels of the nanocarrier in blood, a blood sample was 
obtained and measured ex vivo using the 9.4 T MRI (similar to the measurements in 
section 3.2). The plasma T2 value at 3 days post-contrast was 108 msec which is close to 
the pre-contrast values. A comparison of the enhancement of normal brain vasculature in 
the pre-contrast and in the 3-day post-contrast image (Figure 4) also supports the fact that 








low levels of the nanocarrier remained in circulation 3 days after administration. This 
allowed clear visualization of the extravascular accumulation of the nanocarrier since 
minor interfering signal was obtained from the blood side. The time course of the 
increase of tumor enhancement is consistent with previous reports in which 
biodistribution studies showed that the liposome intratumoral accumulation in rat brain 
tumors (McNeeley et al., 2007) and mouse breast tumors (Kirpotin et al., 2006) peaks at 
24-48 h after injection.  
Gadodiamide chelates have been extensively employed to perform dynamic 
contrast-enhanced MRI to evaluate tumor vasculature leakiness in animals and patients 
(Brix et al., 2004; Furman-Haran and Degani, 2002; Leach, 2001; Oshida et al., 2005; 
Sardanelli et al., 2005); (Teifke et al., 2006). These studies show that the temporal 
intratumoral uptake of the contrast agent displays a fast wash-in-wash-out profile 
indicating that the agent leaks out of the blood vessel into the tumor extravascular space 
and returns back to the blood in short times. This is not surprising since the transport of 
molecules (such as gadodiamide) is governed by passive diffusion, whereas extravasation 
of nanoparticles is governed by convective terms and therefore once a liposome 
extravasates it is generally difficult to return back to blood stream (Jain, 1999). While it‘  
difficult to directly determine whether the Gd chelate was intra-liposomal when the 
nanocarrier was deposited in the tumor extravascular space, it is reasonable to assume 
that the chelate would quickly return to the blood if it were not encapsulated within the 
liposome.  
To better realize the intratumoral accumulation of the nanocarrier, we performed 
T2* mapping and subsequently quantified the T2* values of the normal and the tumor 
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tissue. Figure 5 summarizes these findings. Even before administration of the nanocarrier, 
the tumor tissue displayed significantly lower T2* values than normal brain consistent 
with cancer-related neovascularization resulting in higher density of vasculature in the 
tumor comparing to normal brain. Immediately after administration of the nanocarrier, 
the T2* values of both normal and tumor tissue dropped significantly. While the values of 
normal brain reached its pre-contrast values in 3 days after injection, the T2* values 
remained low displaying a statistically significant difference when compared to the pre-
contrast values of the tumor tissue (p<0.001). This suggests that the nanocarrier was 
cleared from blood circulation while accumulated in the extravascular space of the tumor.  
 
Figure A.5. Comparison of T2* values of normal brain and tumor obtained via T2*-weighted 2D 
maps over the period of 3 days before and after administration of 0.25 mmol Gd/kg of the 
nanocarrier in rats (n=3).  
In the past, nanoscale liposomal contrast agents encapsulating Gd with prolonged 








































al., 2008; Erdogan et al., 2006; Torchilin, 1994; Krauze et al., 2006; Weissing et al., 
2000) but not for detecting extravascular deposition in tumors. Other macromolecular 
gadolinium-based agents (Daldrup et al., 1998) and iron oxide nanoparticles (USIOP) 
(Turetschek et al., 2001b; Turetschek et al., 2001a) have been employed to evaluate 
tumor vascular permeability. These agents and method of use however, failed to 
transparently characterize the tumor vascular permeability to nanoparticles due to 
persistent intravascular signal and/or inadequate extravascular signal. The primary 
explanation for these results is that the short duration of the imaging sessions (less than 1 
hr) used in those studies did not allow enough time for extravasation of large quantities of 
the nanoscale contrast agents to yield adequate signal. Indeed it has been established that 
the intratumoral, extravascular accumulation of long-circulating nanoscale agents peaks 
at about 48 h (Kirpotin et al., 2006). Though a liposomal based nanocarrier enabled 
evaluation of vascular permeability in this study, we hypothesize that such evaluation 
would be possible with other long-circulating nanoscale contrast agents as well. 
However, liposomal nanocarriers can serve as multifunctional agents since they can carry 
combinations of drugs and contrast agents and can conveniently be modified for active 
targeting (Zalipsky, 1993).  
A.3.5. Histological Analysis 
Histological analysis of tumors was performed on animals euthanized 3 days after 
administration of the rhodamine-tagged Gd- nanocarrier (immediately after completion of 
the last imaging session). Fluorescent microscopy of brain tissue section verified the 
intratumoral extravascular deposition of the nanocarrier. The tumor was characterized by 
a highly vascularized peripheral rim and an internal core with a lower vascularization 
181 
 
(Figure 6.a), consistent with earlier reports (Marzola et al., 2005; McNeeley et al., 2007). 
In the same histolological slice (Figure 6.b) the extravasated nanocarrier was observed to 
localize within the lesion (not in normal brain) exhibiting a patchy distribution. The 
typical intratumoral microdistribution of PEGylated liposomes is predominantly at the 
tumor (Kirpotin et al., 2006; Huang et al., 1992; Yuan et al., 1994), which is usually 
associated with high levels of angiogenic and permeability factors resulting in 
neoangiogenesis (Damert et al., 1997; Takano et al., 1996). This is consistent with our 
histological observations. 
 
Figure A.6. Microdistribution of the nanocarrier in the brain tumor lesion (the MR images of the 
same animal are shown in Fig. A.4) 72 h after IV injection of rhodamine-tagged Gd-nanocarrier 
using fluorescent microscopy at 20x magnification. (a) Immuhistochemical microvascular staining 
was achieved by staining with RECA-1, a cell surface antigen which is expressed by all rat 
endothelial cells (appeared as green) revealing a highly vascularized peripheral rim and a less 
vascularized inner core (DAPI was used as a nuclear stain; appeared as blue); (b) In the same 
histological slice, the liposomes (appeared as red) displayed a patchy distribution (scale bar is 0.5 
mm).  
A.4. Conclusions 
In this work, we demonstrated the ability to track non-invasively the fate of a 
systemically-administered nanocarrier. The nanocarrier consists of a 100nm-scale long-





size as the clinically used liposomal chemotherapy (Lasic and Papahadjopoulos, 1995). 
While gadolinium is traditionally used as a T1-shortening contrast agent under the 
currently used magnetic fields in the clinic (1.5-3 Tesla), the Gd-containing nanocarrier 
behaved as a potent T2-shortening agent on a 9.4 T MRI system. The significant T2 
shortening effect of the nanocarrier and the method of use allowed detection of the 
intratumoral, extravascular accumulation of the nanocarrier in a rat brain tumor model 
using a 9.4 T MRI system. It would be expected that a long-circulating agent would 
produce undistinguishable extravascular and intravascular signal making determination of 
the degree of vascular permeability unfeasible. This is the case for the first 24 h after 
injection since the intravascular levels of the agent are still high. As the concentration of 
the nanocarrier in the blood decreased, its extravascular accumulation in the tumor 
increased resulting in adequate negative enhancement without interference from the 
blood for detection. This allowed the evaluation of the nanocarrier uptake by a brain 
tumor 3 days post-injection. The visualization of the extravascular accumulation of the 
nanocarrier and at the same time invisibility of the vasculature makes MR imaging an 
attractive non-invasive method. Such an a priori determination of the extent of tumor 
susceptibility to nanocarrier-based chemotherapy would therefore facilitate personalized 
therapy, and spare potential non-responders from the rigors of a chemotherapy regimen. 
However, human cancer as a disease is much more heterogeneous than experimental 
tumor models in terms of both tumors and hosts. The current study demonstrated the 
feasibility of tracking the intratumoral deposition of the Gd-loaded nanocarrier on a 
single tumor model, and further testing of imaging followed by treatment in more tumor 
models is required to fully assess the clinical value of this approach. Recently, we have 
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fabricated a liposomal nanocarrier co-encapsulating Gd and doxorubicin (data not 
shown). Future studies will be performed with the nanocarrier co-encapsulating the 
contrast agent and the drug, and determine that indeed a rationally determined treatment 
regime would significantly enhance therapeutic efficacy of the chemotherapeutic 
nanocarriers. In addition, surgical units are increasingly co-locating MRI units to assist in 
surgical planning.  Imaging of tumor border and location using MRI could also serve as a 
useful surgical planning tool for tumor border mapping and resection. 
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